[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 334
1. Stoner J, Martin G, O'Mara K, Ehlers J, Tomlanovich M: Amiodarone and bretylium in the treatment of hypothermic ventricular fibrillation in a canine model. Acad Emerg Med; 2003 Mar;10(3):187-91
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amiodarone and bretylium in the treatment of hypothermic ventricular fibrillation in a canine model.
  • Despite mixed experimental data, some authors view bretylium as the drug of choice in hypothermic VF.
  • OBJECTIVES: To compare defibrillation rates from hypothermic VF after drug therapy with amiodarone, bretylium, and placebo.
  • Thirty anesthetized dogs were mechanically ventilated and instrumented to monitor coronary perfusion pressure (CPP), rectal core temperature, and electrocardiogram (ECG).
  • Ventricular fibrillation was induced as needed with a transthoracic AC current.
  • Return of spontaneous circulation (ROSC) was defined as a sustainable ECG rhythm generating a corresponding arterial pressure tracing lasting a minimum of 15 minutes.
  • RESULTS: CPR was adequate based on CPP > 15 mm Hg in all animals.
  • Mean (+/-SD) CPP was 35.3 +/- 18.8 mm Hg with an overall lower trend in the amiodarone group (p = 0.06).
  • [MeSH-major] Amiodarone / therapeutic use. Anti-Arrhythmia Agents / therapeutic use. Bretylium Compounds / therapeutic use. Ventricular Fibrillation / drug therapy
  • [MeSH-minor] Animals. Disease Models, Animal. Dogs. Hypothermia, Induced. Random Allocation

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12615580.001).
  • [ISSN] 1069-6563
  • [Journal-full-title] Academic emergency medicine : official journal of the Society for Academic Emergency Medicine
  • [ISO-abbreviation] Acad Emerg Med
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Arrhythmia Agents; 0 / Bretylium Compounds; N3RQ532IUT / Amiodarone; RZR75EQ2KJ / bretylium
  •  go-up   go-down


2. Takahashi M, Yamamoto J, Aoyama Y, Soejima Y, Akiba D, Nishizawa S: Efficacy of multi-staged surgery and adjuvant chemotherapy for successful treatment of atypical choroid plexus papilloma in an infant: case report. Neurol Med Chir (Tokyo); 2009 Oct;49(10):484-7
Genetic Alliance. consumer health - Choroid Plexus Papilloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of multi-staged surgery and adjuvant chemotherapy for successful treatment of atypical choroid plexus papilloma in an infant: case report.
  • A 12-month-old girl presented with a rare atypical choroid plexus papilloma manifesting as conscious disturbance and vomiting.
  • Only partial removal of the tumor was performed because of excessive intraoperative hemorrhage at the first surgery.
  • The histological diagnosis was atypical choroid plexus papilloma.
  • To control the intraoperative hemorrhage, embolization of the feeding artery was performed before the second surgery, and the tumor was macroscopically totally removed.
  • MR imaging disclosed a small residual tumor which showed relatively rapid growth.
  • Two months later, MR imaging showed a cystic lesion with a small nodule adjacent to the midbrain, indicating dissemination of the tumor.
  • The lesion was successfully treated with chemotherapy.
  • Atypical choroid plexus papilloma was recently defined in the classification of the World Health Organization, so clinical data based on these criteria are lacking to establish the therapeutic strategy.
  • Total resection of atypical choroid plexus papilloma is the most reliable treatment at present.
  • However, postoperative chemotherapy should be considered for recurrence or dissemination.
  • [MeSH-major] Brain / surgery. Lateral Ventricles / surgery. Papilloma, Choroid Plexus / drug therapy. Papilloma, Choroid Plexus / surgery
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cerebral Arteries / pathology. Cerebral Arteries / physiopathology. Craniotomy. Embolization, Therapeutic. Female. Humans. Infant. Intraoperative Complications / etiology. Intraoperative Complications / physiopathology. Intraoperative Complications / therapy. Lethargy / etiology. Magnetic Resonance Imaging. Neoplasm Metastasis / drug therapy. Neoplasm Metastasis / pathology. Neurosurgical Procedures. Postoperative Hemorrhage / etiology. Postoperative Hemorrhage / physiopathology. Postoperative Hemorrhage / therapy. Reoperation. Tomography, X-Ray Computed. Treatment Outcome. Ventriculostomy. Vomiting / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19855149.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


3. Wrede B, Hasselblatt M, Peters O, Thall PF, Kutluk T, Moghrabi A, Mahajan A, Rutkowski S, Diez B, Wang X, Pietsch T, Kortmann RD, Paulus W, Jeibmann A, Wolff JEA: Atypical choroid plexus papilloma: clinical experience in the CPT-SIOP-2000 study. J Neurooncol; 2009 Dec;95(3):383-392
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical choroid plexus papilloma: clinical experience in the CPT-SIOP-2000 study.
  • Atypical choroid plexus papilloma (APP) represents a novel intermediate-grade subtype of choroid plexus tumor (CPT), the clinical outcome of which has not been described yet.
  • A worldwide registration and a randomized trial for those patients who require chemotherapy started in 2000.
  • After surgery, patients who had undergone complete resection were observed, whereas patients with incompletely resected or metastasized APP were treated with six chemotherapy courses (etoposide and vincristine, combined with either carboplatin or cyclophosphamide).
  • Of the 106 patients with a centrally confirmed CPT histology, 30 had APP, 42 CPP and 34 CPC.
  • APP patients were significantly younger (median = 0.7 years) than patients with CPP or CPC (both medians = 2.3 years).
  • Complete resection was achieved in 68 (64%) patients (79% in CPP, 63% in APP, and 47% in CPC).
  • Metastases were present at diagnosis in 17% of APP patients, 5% of CPP patients, and 21% of CPC patients.
  • All nine APP patients who received postoperative chemotherapy showed an early response after two cycles: two had complete remission, four had partial response, and three had stable disease.
  • In the treatment group, one patient with a metastasized tumor and incompletely resected APP died.
  • While APP was defined histologically, median percentages of both the Ki-67/MIB-1 proliferation marker and the p53 tumor suppressor protein increased across the three histological subtypes (from CPP to APP and then CPC), suggesting that the subtypes comprise an ordinal categorization of increasingly severe CPT tumors.
  • This ordering was reiterated by clinical outcome in the 92 patients treated per the study protocol, with 5-year EFS rates of 92% in 39 CPP patients, 83% in 24 APP patients, and 28% in 29 CPC patients.
  • APP responded favorably to chemotherapy.
  • The intermediate position of APP between CPP and CPC was supported by the clinical data.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Choroid Plexus Neoplasms / drug therapy. Choroid Plexus Neoplasms / mortality. Papilloma, Choroid Plexus / drug therapy. Papilloma, Choroid Plexus / mortality
  • [MeSH-minor] Adolescent. Adult. Carboplatin / administration & dosage. Child, Preschool. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Etoposide / administration & dosage. Female. Gadolinium. Humans. Infant. Kaplan-Meier Estimate. Magnetic Resonance Imaging. Male. Middle Aged. Registries. Vincristine / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - Choroid Plexus Papilloma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Neurosurg. 1999 Sep;31(3):127-30 [10708353.001]
  • [Cites] J Neurooncol. 2000 Sep;49(3):263-8 [11212906.001]
  • [Cites] J Neurooncol. 2007 Dec;85(3):345-51 [17576522.001]
  • [Cites] Med Pediatr Oncol. 1993;21(7):480-7 [8341215.001]
  • [Cites] J Neurosurg. 2007 Sep;107(3 Suppl):199-202 [17918524.001]
  • [Cites] Lancet. 1999 Jun 19;353(9170):2126 [10382700.001]
  • [Cites] J Neurooncol. 2002 Feb;56(3):241-6 [12061730.001]
  • [Cites] Cancer. 1992 Jan 15;69(2):580-5 [1728390.001]
  • [Cites] J Neurosurg. 1998 Apr;88(4):757-60 [9525724.001]
  • [Cites] J Neurooncol. 1985;3(3):259-62 [2414413.001]
  • [Cites] J Neurooncol. 2004 May;68(1):49-55 [15174521.001]
  • [Cites] Surg Neurol. 1991 Jul;36(1):54-8 [2053075.001]
  • [Cites] Pediatr Neurosci. 1989;15(4):195-206 [2485914.001]
  • [Cites] Pediatr Neurosurg. 1991-1992;17(5):225-33 [1822687.001]
  • [Cites] J Neurooncol. 2007 Mar;82(1):69-74 [16955222.001]
  • [Cites] Anticancer Res. 2005 Nov-Dec;25(6C):4429-33 [16334121.001]
  • [Cites] Indian Pediatr. 1993 Oct;30(10):1217-8 [8077013.001]
  • [Cites] Acta Neurochir (Wien). 1979;50(1-2):79-90 [316268.001]
  • [Cites] Neuropathology. 2008 Apr;28(2):160-4 [18366349.001]
  • [Cites] Acta Neurochir (Wien). 1996;138(7):802-10 [8869707.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Microsc Res Tech. 2001 Jan 1;52(1):104-11 [11135453.001]
  • [Cites] Neuropathology. 2009 Jun;29(3):293-8 [18627486.001]
  • [Cites] Neurol Med Chir (Tokyo). 1995 Oct;35(10):742-4 [8532130.001]
  • [Cites] Acta Neuropathol. 2002 Jan;103(1):1-10 [11837741.001]
  • [Cites] J Neurosurg Spine. 2006 Jun;4(6):494-6 [16776361.001]
  • [Cites] Pediatr Neurosurg. 1995;22(4):189-96 [7619719.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Nov;65(11):1069-73 [17086103.001]
  • [Cites] Neurosurgery. 1998 Mar;42(3):470-5 [9526979.001]
  • [Cites] J Neurosurg. 2004 Jun;100(6):1076-8 [15200124.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Pediatr Neurosurg. 2000 Apr;32(4):192-9 [10940770.001]
  • [Cites] J Neurosurg. 1980 Feb;52(2):251-5 [7351566.001]
  • [Cites] J Neurosurg. 1988 Dec;69(6):843-9 [3193190.001]
  • [Cites] Br J Cancer. 2002 Nov 4;87(10):1086-91 [12402146.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 May;56(5):551-6 [9143268.001]
  • [Cites] Neuropathol Appl Neurobiol. 2004 Jun;30(3):304-7 [15175083.001]
  • [Cites] Med Pediatr Oncol. 1995 Feb;24(2):104-8 [7990757.001]
  • [Cites] Neurosurgery. 1989 Sep;25(3):327-35 [2771002.001]
  • [Cites] Acta Neurochir (Wien). 2007 Dec;149(12):1229-36; discussion 1236-7 [17924056.001]
  • [Cites] Am J Surg Pathol. 2006 Jan;30(1):66-74 [16330944.001]
  • [Cites] Histopathology. 1996 Aug;29(2):147-51 [8872148.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 May;64(5):391-7 [15892296.001]
  • [Cites] J Neurosurg. 1998 Mar;88(3):521-8 [9488307.001]
  • [Cites] Childs Nerv Syst. 1989 Oct;5(5):288-98 [2804999.001]
  • (PMID = 19543851.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00500890
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / R01 CA083932
  • [Publication-type] Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; AU0V1LM3JT / Gadolinium; BG3F62OND5 / Carboplatin
  •  go-up   go-down


Advertisement
4. Ortega-Martínez M, Cabezudo-Artero JM, Fernández-Portales I, Pimentel JJ, Gómez de Tejada R: Diffuse leptomeningeal seeding from benign choroid plexus papilloma. Acta Neurochir (Wien); 2007 Dec;149(12):1229-36; discussion 1236-7
Genetic Alliance. consumer health - Choroid Plexus Papilloma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse leptomeningeal seeding from benign choroid plexus papilloma.
  • Choroid plexus papillomas (CPP) are rare intracranial tumours with a favourable long-term outcome after surgical excision.
  • Although they are histologically benign, local recurrences may occasionally occur, but leptomeningeal dissemination is exceptional.
  • We report an unusual example of a fourth ventricle choroid plexus papilloma with diffuse leptomeningeal seeding.
  • Treatment with systemic and intrathecal chemotherapy was ineffective in this patient.
  • We review the literature concerning leptomeningeal dissemination of benign choroid plexus papillomas.
  • [MeSH-major] Cerebral Ventricle Neoplasms / surgery. Fourth Ventricle / surgery. Meningeal Neoplasms / secondary. Neoplasm Seeding. Papilloma, Choroid Plexus / surgery
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Biopsy. Disease Progression. Fatal Outcome. Female. Humans. Ki-67 Antigen / analysis. Laminectomy. Magnetic Resonance Imaging. Meninges / pathology. Reoperation. S100 Proteins / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17924056.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / S100 Proteins
  •  go-up   go-down


5. Serrano-Fabiá A, Albert-Marí A, Almenar-Cubells D, Jiménez-Torres NV: Multidisciplinary system for detecting medication errors in antineoplastic chemotherapy. J Oncol Pharm Pract; 2010 Jun;16(2):105-12
MedlinePlus Health Information. consumer health - Medication Errors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multidisciplinary system for detecting medication errors in antineoplastic chemotherapy.
  • OBJECTIVE: To analyze medication errors (MEs) in a multidisciplinary system with a Computerized Pharmacotherapy Process (CPP) in cancer patients.
  • DESIGN: A longitudinal, prospective 2-year (January 2003 -to December 2004) cohort study was made in adult patients administered antineoplastic treatment in Services of Oncology and Haematology.
  • MEs were identified by double cross-validation of each stage of the pharmacotherapeutic process (prescription, preparation, dispensing, administration, and follow-up) carried out by the multidisciplinary team (physician, pharmacist, nurse) with CPP assistance.
  • VARIABLES: Number of MEs per 1000 patient-days, percentage according to the stage of the pharmacotherapeutic process and the severity of intercepted ME (scored from 1 = no damage to the patient, to 5 = patient death).
  • RESULTS: A total of 1311 patients were receiving treatment, and MEs were identified in 225.
  • The detected ME distribution according to pharmacotherapeutic stage was: prescription 75.7%, preparation 21.0%, dispensing 1.8%, administration 1.1%, and follow-up 0.4%.
  • The system intercepted 98.9% of all MEs with severity >or=3 (MEs with a potential for causing patient damage).
  • CONCLUSIONS: The multidisciplinary system with a well-established CPP detects 20.9 MEs per 1000 patient-days and intercepts 98.8% of all MEs with a potential for causing patient damage.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Hospitals, University / standards. Interprofessional Relations. Medication Errors / prevention & control. Medication Systems, Hospital / standards

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19617304.001).
  • [ISSN] 1477-092X
  • [Journal-full-title] Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
  • [ISO-abbreviation] J Oncol Pharm Pract
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Validation Studies
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


6. Vercellini P, Viganò P, Somigliana E, Abbiati A, Barbara G, Fedele L: Medical, surgical and alternative treatments for chronic pelvic pain in women: a descriptive review. Gynecol Endocrinol; 2009 Apr;25(4):208-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medical, surgical and alternative treatments for chronic pelvic pain in women: a descriptive review.
  • Several causes of chronic pelvic pain (CPP) are recognised, but in many women a definite diagnosis cannot be made.
  • Few randomised controlled trials on treatment of CPP have been conducted.
  • The aim of this descriptive review is to describe the management of CPP, which can focus on treating the pain itself, the underlying cause, or both.
  • Combination drug therapy with medications with different mechanisms of action may improve therapeutic results.
  • Several alternative non-invasive treatments have been proposed including exercise programmes, cognitive and behavioural medicine, physical therapy, dietary modification, massage and acupuncture.
  • Treatment of CPP, generally, requires acceptance of the concept of managing rather than curing symptoms.
  • [MeSH-major] Complementary Therapies. Pelvic Pain / drug therapy. Pelvic Pain / surgery
  • [MeSH-minor] Chronic Disease. Female. Humans

  • MedlinePlus Health Information. consumer health - Complementary and Integrative Medicine.
  • MedlinePlus Health Information. consumer health - Pelvic Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19296329.001).
  • [ISSN] 1473-0766
  • [Journal-full-title] Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • [ISO-abbreviation] Gynecol. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 98
  •  go-up   go-down


7. Meltzer-Brody SE, Zolnoun D, Steege JF, Rinaldi KL, Leserman J: Open-label trial of lamotrigine focusing on efficacy in vulvodynia. J Reprod Med; 2009 Mar;54(3):171-8
Hazardous Substances Data Bank. LAMOTRIGINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Chronic pelvic pain (CPP) affects 15% of women and has a high rate of psychiatric comorbidity.
  • Vulvodynia, a vulvar pain syndrome that includes vulvar vestibulitis, is the most common subtype of CPP.
  • This study examined the efficacy of lamotrigine for the treatment of CPP using an open-label design.
  • STUDY DESIGN: Forty-three women with CPP were recruited from a specialty pelvic pain clinic.
  • Of these, 31 completed 8 weeks of active treatment.
  • In particular, women with vulvodynia-type CPP (N = 17) had robust reductions in pain and mood symptoms.
  • CONCLUSION: CPP is a heterogeneous disorder, with psychiatric comorbidity and poor treatment response.
  • This open-label study suggests that treatment with lamotrigine in women with the vulvodynia subtype of CPP may be helpful in addressing both the pain and mood symptoms associated with this disorder.
  • [MeSH-major] Analgesics / therapeutic use. Pelvic Pain / drug therapy. Pelvic Pain / psychology. Triazines / therapeutic use. Vulvar Diseases / drug therapy. Vulvar Diseases / psychology
  • [MeSH-minor] Adult. Aged. Anxiety / drug therapy. Anxiety / epidemiology. Comorbidity. Depression / drug therapy. Depression / epidemiology. Dose-Response Relationship, Drug. Female. Humans. Middle Aged. Pain Measurement / drug effects. Pain Measurement / psychology. Psychiatric Status Rating Scales. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Pelvic Pain.
  • MedlinePlus Health Information. consumer health - Vulvar Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19370903.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Grant] United States / NICHD NIH HHS / HD / K23 HD053631
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics; 0 / Triazines; U3H27498KS / lamotrigine
  • [Other-IDs] NLM/ NIHMS580758; NLM/ PMC4676413
  •  go-up   go-down


8. Bertelloni S, Mul D: Treatment of central precocious puberty by GnRH analogs: long-term outcome in men. Asian J Androl; 2008 Jul;10(4):525-34
SciCrunch. KEGG: Data: Disease Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of central precocious puberty by GnRH analogs: long-term outcome in men.
  • In boys, central precocious puberty (CPP) is the appearance of secondary sex characteristics driven by pituitary gonadotropin secretion before the age of 9 years.
  • In the last years, relevant improvements in the treatment of CPP have been achieved.
  • Because CPP is rare in boys, the majority of papers on this issue focus on girls and do not address specific features of male patients regarding end results and safety.
  • In the present paper, recent advances of CPP management with GnRH analogs in men are summarized.
  • End results in untreated and treated patients are also reviewed by an analysis of the recently published literature on treatment of CPP in men.
  • The available data indicate that therapy with GnRH analogs can improve final height into the range of target height without significant adverse short-term and long-term effects, but longer follow-up of larger series of patients is still required to draw definitive conclusions.
  • [MeSH-major] Gonadotropin-Releasing Hormone / analogs & derivatives. Gonadotropin-Releasing Hormone / therapeutic use. Puberty, Precocious / drug therapy
  • [MeSH-minor] Adolescent. Adult. Body Height / drug effects. Body Height / physiology. Child. Dose-Response Relationship, Drug. Humans. Male. Sex Characteristics. Treatment Outcome


9. Wrede B, Liu P, Wolff JE: Chemotherapy improves the survival of patients with choroid plexus carcinoma: a meta-analysis of individual cases with choroid plexus tumors. J Neurooncol; 2007 Dec;85(3):345-51
MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy improves the survival of patients with choroid plexus carcinoma: a meta-analysis of individual cases with choroid plexus tumors.
  • BACKGROUND: Choroid plexus carcinomas (CPC) are rare brain tumors with a dismal prognosis.
  • Although the role of surgery has been well established, the question of whether chemotherapy improves the prognosis is still under discussion.
  • METHODS: We created a database of all cases of choroid plexus tumors (CPT) reported in the literature up to the year 2004 to determine prognostic factors and different therapeutic modalities.
  • RESULTS: Of 857 documented cases of CPT (median patient age at diagnosis, 3 years), 347 were CPC, 15 atypical choroid plexus papilloma (APP), and 495 choroid plexus papilloma (CPP).
  • The 104 CPC patients who received chemotherapy had a statistically better survival than those without chemotherapy (P = .0004).
  • When subgroups were defined by radiation treatment, chemotherapy remained beneficial in the subgroup of nonirradiated tumors (P = .0001).
  • The benefit of chemotherapy was also significant when the analysis was restricted to the subgroup of patients with less than completely resected CPC (2-year overall survival (OS) 54.8 +/- 7% (standard deviation (SD) vs. 24.4 +/- 7%, P < .0001) and when this subgroup was further divided into smaller subgroups.
  • Likewise, in a multivariate analysis, chemotherapy was highly significantly linked to better prognosis (P = .0001).
  • CONCLUSION: Patients with less than completely resected CPC should receive chemotherapy.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma / drug therapy. Choroid Plexus Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Child. Child, Preschool. Combined Modality Therapy. Databases, Bibliographic. Databases, Factual. Female. Humans. Infant. Infant, Newborn. Male. Middle Aged. Prognosis. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Choroid Plexus Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2002 Apr;57(2):123-6 [12125972.001]
  • [Cites] Pediatr Neurosurg. 1999 Sep;31(3):127-30 [10708353.001]
  • [Cites] Med Pediatr Oncol. 1993;21(7):480-7 [8341215.001]
  • [Cites] Lancet. 1999 Jun 19;353(9170):2126 [10382700.001]
  • [Cites] Eur J Pediatr. 1983 Mar;140(1):51-6 [6873113.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 May 1;44(2):249-54 [10760416.001]
  • [Cites] Cancer. 1992 Jan 15;69(2):580-5 [1728390.001]
  • [Cites] Brain Pathol. 2003 Jul;13(3):409-14 [12946029.001]
  • [Cites] Am J Hum Genet. 1999 Nov;65(5):1342-8 [10521299.001]
  • [Cites] Med Pediatr Oncol. 1994;22(4):274-8 [8107660.001]
  • [Cites] Pediatr Neurosci. 1989;15(4):195-206 [2485914.001]
  • [Cites] Pediatr Neurosurg. 1991-1992;17(5):225-33 [1822687.001]
  • [Cites] J Neurosurg. 1987 Jun;66(6):800-5 [3572508.001]
  • [Cites] Anticancer Res. 2005 Nov-Dec;25(6C):4429-33 [16334121.001]
  • [Cites] Histopathology. 1995 Feb;26(2):137-43 [7737660.001]
  • [Cites] Indian Pediatr. 1993 Oct;30(10):1217-8 [8077013.001]
  • [Cites] J Neurosurg. 1983 Sep;59(3):369-83 [6886750.001]
  • [Cites] Acta Neurochir (Wien). 1979;50(1-2):79-90 [316268.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(6):557-63 [9755322.001]
  • [Cites] Noshuyo Byori. 1996 Nov;13(2):99-105 [8958514.001]
  • [Cites] Neuropediatrics. 1996 Jun;27(3):143-8 [8837074.001]
  • [Cites] Neurol Med Chir (Tokyo). 1995 Oct;35(10):742-4 [8532130.001]
  • [Cites] Pediatr Neurosurg. 1995;22(4):189-96 [7619719.001]
  • [Cites] Acta Oncol. 1990;29(2):241-3 [2185805.001]
  • [Cites] Neurosurgery. 1998 Mar;42(3):470-5 [9526979.001]
  • [Cites] J Neurosurg. 1980 Feb;52(2):251-5 [7351566.001]
  • [Cites] J Neurosurg. 1988 Dec;69(6):843-9 [3193190.001]
  • [Cites] Br J Cancer. 2002 Nov 4;87(10):1086-91 [12402146.001]
  • [Cites] Neoplasma. 2004;51(4):306-12 [15254663.001]
  • [Cites] Childs Brain. 1975;1(2-3):81-115 [1081032.001]
  • [Cites] Childs Nerv Syst. 1999 Oct;15(10):571-7 [10550588.001]
  • [Cites] Neurosurgery. 1980 Apr;6(4):380-4 [7393420.001]
  • [Cites] Neurosurgery. 1989 Sep;25(3):327-35 [2771002.001]
  • [Cites] Neurol Med Chir (Tokyo). 1996 Mar;36(3):179-84 [8869156.001]
  • [Cites] J Neurooncol. 1992 Jan;12 (1):69-74 [1541980.001]
  • [Cites] Am J Surg Pathol. 2006 Jan;30(1):66-74 [16330944.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 May;64(5):391-7 [15892296.001]
  • [Cites] J Neurosurg. 1998 Mar;88(3):521-8 [9488307.001]
  • [Cites] Pediatr Neurosci. 1988;14(3):134-9 [3075286.001]
  • (PMID = 17576522.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


10. Valencak J, Dietrich W, Raderer M, Dieckmann K, Prayer D, Hainfellner JA, Marosi C: Evidence of therapeutic efficacy of CCNU in recurrent choroid plexus papilloma. J Neurooncol; 2000 Sep;49(3):263-8
Hazardous Substances Data Bank. LOMUSTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence of therapeutic efficacy of CCNU in recurrent choroid plexus papilloma.
  • A pregnant 33-year old woman developed nystagmus and cerebellar ataxia.
  • A tumor in the roof of the fourth ventricle was diagnosed.
  • The tumor was subtotally removed using microneurosurgical techniques.
  • The histopathological diagnosis was choroid plexus papilloma (CPP).
  • Twenty-one months later, the tumor recurred and was reoperated.
  • Histologically the tumor displayed now increased mitotic activity and pleomorphism.
  • Radiation therapy of the neuroaxis was performed.
  • Within 59 months, the CPP recurred 3 more times with neuroradiological evidence of extensive spinal seeding.
  • After several palliative irradiations, including 2 gamma-knife boosts, the patient was referred to chemotherapy.
  • The course of disease in our patient provides evidence for therapeutic efficacy of CCNU in recurrent CPP.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Choroid Plexus Neoplasms / drug therapy. Lomustine / therapeutic use. Papilloma / drug therapy. Pregnancy Complications, Neoplastic / drug therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Magnetic Resonance Imaging. Neoplasm Recurrence, Local. Neoplasm Seeding. Pregnancy. Reoperation

  • Genetic Alliance. consumer health - Choroid Plexus Papilloma.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int Rev Cytol. 1980;65:117-91 [6248480.001]
  • [Cites] J Comput Assist Tomogr. 1979 Aug;3(4):530-2 [457968.001]
  • [Cites] Lancet. 1999 Jun 19;353(9170):2126 [10382700.001]
  • [Cites] J Neurosurg. 1982 May;56(5):722-7 [7069487.001]
  • [Cites] J Neurooncol. 1985;3(3):259-62 [2414413.001]
  • [Cites] J Clin Oncol. 1987 Aug;5(8):1221-31 [3040919.001]
  • [Cites] Surg Neurol. 1991 Jul;36(1):54-8 [2053075.001]
  • [Cites] J Neurosurg. 1987 Jun;66(6):800-5 [3572508.001]
  • [Cites] Surg Neurol. 1984 Nov;22(5):472-6 [6495155.001]
  • [Cites] Acta Neurochir (Wien). 1996;138(7):802-10 [8869707.001]
  • [Cites] J Neurosurg. 1977 Sep;47(3):442-50 [894346.001]
  • [Cites] Klin Padiatr. 1995 Mar-Apr;207(2):52-8 [7752600.001]
  • [Cites] J Neurosurg. 1960 Nov;17:1002-27 [13768200.001]
  • [Cites] Brain. 1967 Mar;90(1):177-86 [6023072.001]
  • [Cites] Cancer. 1983 Feb 1;51(3):470-5 [6821827.001]
  • [Cites] J Neurosurg. 1980 Feb;52(2):251-5 [7351566.001]
  • [Cites] J Neurosurg. 1988 Dec;69(6):843-9 [3193190.001]
  • [Cites] Acta Cytol. 1985 Sep-Oct;29(5):846-9 [3863432.001]
  • [Cites] J Neurooncol. 1992 Jan;12 (1):69-74 [1541980.001]
  • [Cites] Zentralbl Allg Pathol. 1959 Nov 30;100:136-42 [13818457.001]
  • [Cites] Histopathology. 1996 Aug;29(2):147-51 [8872148.001]
  • [Cites] Pediatr Neurosci. 1988;14(3):134-9 [3075286.001]
  • (PMID = 11212906.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7BRF0Z81KG / Lomustine
  • [Number-of-references] 30
  •  go-up   go-down


11. Huang SJ, Hong WC, Han YY, Chen YS, Wen CS, Tsai YS, Tu YK: Clinical outcome of severe head injury using three different ICP and CPP protocol-driven therapies. J Clin Neurosci; 2006 Oct;13(8):818-22
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical outcome of severe head injury using three different ICP and CPP protocol-driven therapies.
  • In the past 5 years, cerebral perfusion pressure (CPP) management has become the standard in the treatment of severe head injuries.
  • Guidelines published in 2000 suggest that CPP should be at least 70 mmHg; however, there is still debate about the optimal CPP.
  • The purpose of the present study was to evaluate the effectiveness of these three widely used therapies: (i) intracranial pressure (ICP) targeted;.
  • (ii) CPP-targeted with CPP >70 mmHg; and (iii) modified CPP-targeted (mCPP) therapy with CPP >60 mmHg.
  • Data, including patient age, sex, initial Glasgow Coma Scale, ICP, CPP, fluid status, amount of mannitol and vasopressor used, daily fluid intake and output, complications and clinical results, were collected from 213 patients with severe head injuries over a 12-year period.
  • Patients were categorized into three groups (ICP, CPP, mCPP) according to the treatment protocol used.
  • The mortality rate was 28.6%, 14.3% and 13.5% in the ICP, CPP, and mCPP groups, respectively.
  • Highest intake/output ratio, amount of vasopressor used and pulmonary complications were seen in the CPP patients.
  • Although CPP-targeted therapy is the most recommended therapeutic protocol, our data show that patients treated with modified CPP-target therapy with CPP >60 mmHg have better clinical outcomes and fewer complications.
  • [MeSH-major] Brain / blood supply. Cerebrovascular Circulation. Craniocerebral Trauma / therapy. Intracranial Hypertension / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Barbiturates / therapeutic use. Female. Humans. Hyperventilation. Intracranial Pressure / drug effects. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head Injuries.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16908157.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Barbiturates; WQ92Y2793G / barbituric acid
  •  go-up   go-down


12. Chen JH, Liang J, Wang GB, Han JS, Cui CL: Repeated 2 Hz peripheral electrical stimulations suppress morphine-induced CPP and improve spatial memory ability in rats. Exp Neurol; 2005 Aug;194(2):550-6
Hazardous Substances Data Bank. MORPHINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Repeated 2 Hz peripheral electrical stimulations suppress morphine-induced CPP and improve spatial memory ability in rats.
  • Our previous studies have shown that 2 Hz peripheral electrical stimulation (PES) can suppress morphine-induced conditioned place preference (CPP) in the rat, although the mechanisms remain unclear.
  • Since CPP involves the mechanism of learning and memory, it is rational to ask whether the suppressive effect of repeated 2 Hz PES on morphine-induced CPP is due to an impairment of the function of spatial learning and memory.
  • Rats were trained with 4 mg/kg morphine, i.p. for 4 days to establish the CPP.
  • Twenty-four hours after the CPP testing, they were given PES at 2 Hz once a day for 1, 3 or 5 days, followed by another CPP testing.
  • The results showed that (1) the morphine-induced CPP was significantly inhibited by 3 or 5 consecutive sessions, but not by single session of 2 Hz PES. (2) A test of spatial leaning and memory ability using the Morris water maze task revealed that 2 Hz PES per se exhibited a promoting, rather than a deteriorating effect on the ability of spatial memory. (3) 2 Hz PES by itself produced a moderate yet significant CPP.
  • The results imply that (a) a low frequency PES can produce a rewarding effect as revealed by the CPP testing, which may account, at least in part, for its suppressive effect on morphine induced CPP, (b) the suppressive effect of PES on morphine induced CPP is not due to a deteriorating effect on the ability of spatial memory.
  • [MeSH-major] Conditioning (Psychology) / drug effects. Electroacupuncture. Maze Learning / drug effects. Memory Disorders / therapy. Morphine Dependence / therapy. Substance Withdrawal Syndrome / therapy
  • [MeSH-minor] Animals. Brain / drug effects. Brain / physiopathology. Disease Models, Animal. Male. Morphine / adverse effects. Narcotics / adverse effects. Rats. Rats, Sprague-Dawley. Recovery of Function / physiology. Reward. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Memory.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15890338.001).
  • [ISSN] 0014-4886
  • [Journal-full-title] Experimental neurology
  • [ISO-abbreviation] Exp. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Narcotics; 76I7G6D29C / Morphine
  •  go-up   go-down


13. Ratanalert S, Phuenpathom N, Saeheng S, Oearsakul T, Sripairojkul B, Hirunpat S: ICP threshold in CPP management of severe head injury patients. Surg Neurol; 2004 May;61(5):429-34; discussion 434-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ICP threshold in CPP management of severe head injury patients.
  • BACKGROUND: Elevated intracranial pressure (ICP) is significantly associated with high mortality rate in severe head injury (SHI) patients.
  • METHODS: Treatment protocol in this study consisted of therapeutic maneuvers designed to maximize cerebral profusion pressure (CPP) and control ICP.
  • Twenty-seven patients with severe head injury and intracranial hypertension (ICP >or=20 mm Hg) were enrolled and fourteen cases were allocated to the group of ICP threshold >or=25 mm Hg.
  • Logistic regression identified the presence of basal cisterns on the initial computed tomography (CT) scan as a significant predictor of good outcome.
  • [MeSH-major] Brain / blood supply. Craniocerebral Trauma / complications. Intracranial Hypertension / etiology. Intracranial Hypertension / therapy
  • [MeSH-minor] Adult. Algorithms. Cerebral Hemorrhage, Traumatic / diagnosis. Cerebral Hemorrhage, Traumatic / drug therapy. Cerebral Hemorrhage, Traumatic / etiology. Combined Modality Therapy. Diuretics, Osmotic / therapeutic use. Glasgow Coma Scale. Humans. Mannitol / therapeutic use. Oxygen / therapeutic use. Prospective Studies

  • MedlinePlus Health Information. consumer health - Head Injuries.
  • Hazardous Substances Data Bank. D-MANNITOL .
  • Hazardous Substances Data Bank. OXYGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15120212.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Diuretics, Osmotic; 3OWL53L36A / Mannitol; S88TT14065 / Oxygen
  •  go-up   go-down


14. Zheng PZ, Zhao CJ, Du YZ, Chen SJ, Chen Z, Zhang J, Zhang QH, Wang KK: [Establishment of CPP-SOM integrated cDNA microarray technology]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2004 Oct;21(5):422-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Establishment of CPP-SOM integrated cDNA microarray technology].
  • OBJECTIVE: To get an insight into the molecular mechanisms of diseases development and targeted therapy at the transcriptome level and search for potential therapeutic targets.
  • METHODS: The present researchers established a cDNA microarray platform and applied component plane presentation integrated self-organizing map (CPP-SOM) to the microarray data obtained from a differentiation model, all trans retinoic acid-induced differentiation in NB4 cells.
  • By CPP-SOM, the researchers were able to not only well classify the regulated genes into functionally distinct categories but also depict transcriptional changes throughout the process of the development of diseases or drug treatment.
  • CONCLUSION: The platform has proven to be steady and reliable, and the CPP-SOM could serve as an important and good tool for analysis of microarray data.
  • [MeSH-minor] Cell Line, Tumor. Humans. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15476161.001).
  • [ISSN] 1003-9406
  • [Journal-full-title] Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  • [ISO-abbreviation] Zhonghua Yi Xue Yi Chuan Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


15. Celik T, Kayir H, Ceyhan M, Demirtaş S, Coşar A, Uzbay IT: CPP and amlodipine alter the decrease in basal acetylcholine and choline release by audiogenic stimulus in hippocampus of ethanol-withdrawn rats in vivo. Brain Res Bull; 2004 Sep 30;64(3):243-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CPP and amlodipine alter the decrease in basal acetylcholine and choline release by audiogenic stimulus in hippocampus of ethanol-withdrawn rats in vivo.
  • Either an NMDA receptor antagonist (+/-)-3-(2-carboxypiperazin-4-yl)-propyl-1-phosphonic acid (CPP) or a calcium channel antagonist amlodipine was administered, and 15 min later, an audiogenic stimulus (100 dB, 1 min) was applied to rats.
  • CPP (15 mg/kg) and amlodipine (20 mg/kg) reversed the decrement in acetylcholine and increment in choline release in EW rats.
  • [MeSH-major] Acetylcholine / metabolism. Amlodipine / pharmacology. Ethanol / adverse effects. Hippocampus / drug effects. Piperazines / pharmacology. Substance Withdrawal Syndrome / metabolism
  • [MeSH-minor] Acoustic Stimulation / adverse effects. Alcohol-Induced Disorders, Nervous System / drug therapy. Alcohol-Induced Disorders, Nervous System / metabolism. Alcohol-Induced Disorders, Nervous System / physiopathology. Animals. Body Weight / drug effects. Calcium Channel Blockers / pharmacology. Choline / metabolism. Disease Models, Animal. Down-Regulation / drug effects. Down-Regulation / physiology. Drug Interactions / physiology. Epilepsy, Reflex / chemically induced. Epilepsy, Reflex / drug therapy. Epilepsy, Reflex / physiopathology. Excitatory Amino Acid Agonists / pharmacology. Glutamic Acid / metabolism. Male. Microdialysis. Neural Pathways / drug effects. Neural Pathways / metabolism. Neural Pathways / physiopathology. Rats. Rats, Wistar. Seizures / chemically induced. Seizures / drug therapy. Seizures / physiopathology. Synaptic Transmission / drug effects. Synaptic Transmission / physiology

  • Hazardous Substances Data Bank. GLUTAMIC ACID HYDROCHLORIDE .
  • Hazardous Substances Data Bank. ETHANOL .
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • Hazardous Substances Data Bank. AMLODIPINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15464861.001).
  • [ISSN] 0361-9230
  • [Journal-full-title] Brain research bulletin
  • [ISO-abbreviation] Brain Res. Bull.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calcium Channel Blockers; 0 / Excitatory Amino Acid Agonists; 0 / Piperazines; 100828-16-8 / 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid; 1J444QC288 / Amlodipine; 3K9958V90M / Ethanol; 3KX376GY7L / Glutamic Acid; N91BDP6H0X / Choline; N9YNS0M02X / Acetylcholine
  •  go-up   go-down


16. Takamatsu Y, Yamamoto H, Ogai Y, Hagino Y, Markou A, Ikeda K: Fluoxetine as a potential pharmacotherapy for methamphetamine dependence: studies in mice. Ann N Y Acad Sci; 2006 Aug;1074:295-302
Hazardous Substances Data Bank. d-METHAMPHETAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluoxetine as a potential pharmacotherapy for methamphetamine dependence: studies in mice.
  • The monoamine transporters are the main targets of psychostimulant drugs, including methamphetamine (METH) and cocaine.
  • Interestingly, the rewarding effects of cocaine are retained in dopamine transporter (DAT) knockout (KO) mice, while serotonin transporter (SERT) and DAT double KO mice do not exhibit conditioned place preference (CPP) to cocaine.
  • ) CPP and locomotor sensitization to 1 mg/kg METH (i.p.) in C57BL/6J mice.
  • Fluoxetine treatment before both the conditioning and preference tests abolished METH CPP.
  • A two-way analysis of variance (ANOVA) revealed that METH CPP tended to be lower in mice pretreated with fluoxetine before the preference test than in control mice pretreated with saline before the preference test.
  • These results suggest that fluoxetine, a widely used medication for depression, may be also a useful tool for treating METH dependence.
  • [MeSH-major] Amphetamine-Related Disorders / drug therapy. Dopamine Agents / toxicity. Fluoxetine / therapeutic use. Methamphetamine / toxicity. Motor Activity / drug effects. Serotonin Uptake Inhibitors / therapeutic use

  • MedlinePlus Health Information. consumer health - Methamphetamine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17105925.001).
  • [ISSN] 0077-8923
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] eng
  • [Grant] United States / NIDA NIH HHS / DA / R01 DA11946
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Dopamine Agents; 0 / Serotonin Uptake Inhibitors; 01K63SUP8D / Fluoxetine; 44RAL3456C / Methamphetamine
  •  go-up   go-down


17. Karim A, Fowler M, McLaren B, Cardenas R, Patwardhan R, Nanda A: Concomitant choroid plexus papillomas involving the third and fourth ventricles: A case report and review of the literature. Clin Neurol Neurosurg; 2006 Sep;108(6):586-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Concomitant choroid plexus papillomas involving the third and fourth ventricles: A case report and review of the literature.
  • Choroid plexus papillomas (CPP) are histopathologically benign and rare central nervous system (CNS) neoplasms arising from the epithelium of the choroid plexus.
  • Third ventricular CPP are uncommon.
  • Pathology from the biopsy and both resections was benign CPP.
  • Multifocal concomitant CPP is rare.
  • Concomitant CPPs may be secondary to mere coincidental tumor occurrence or to biologic seeding of cerebrospinal fluid (CSF) from a primary CPP despite otherwise benign histopathology.
  • The primary treatment for CPP is surgical resection.
  • Post-operative chemotherapy or radiation for CPP is of controversial benefit.
  • [MeSH-major] Fourth Ventricle. Papilloma, Choroid Plexus / pathology. Third Ventricle

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15963638.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 21
  •  go-up   go-down


18. Ramond A, Sartorius E, Mousseau M, Ribuot C, Joyeux-Faure M: Erythropoietin pretreatment protects against acute chemotherapy toxicity in isolated rat hearts. Exp Biol Med (Maywood); 2008 Jan;233(1):76-83
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Erythropoietin pretreatment protects against acute chemotherapy toxicity in isolated rat hearts.
  • The use of chemotherapeutic agents, such as anthracycline or trastuzumab, in oncology is limited by their cardiac toxicity.
  • Doxorubicin exposure decreased left ventricular developed pressure (LVDP; approximately -40% of baseline) and increased end diastolic pressure (EDP; approximately +390% of baseline) and coronary perfusion pressure (CPP; approximately +70% of baseline).
  • Trastuzumab exposure increased CPP and EDP (approximately +70% of baseline for the both) without affecting LVDP.
  • Prior rhEPO treatment significantly prevented doxorubicin-induced deleterious effects on LVDP, EDP, and VT/VF incidence. rhEPO administration also prevented trastuzumab-induced deleterious effects on CPP and EDP.
  • [MeSH-major] Antibodies, Monoclonal / toxicity. Antineoplastic Agents / toxicity. Doxorubicin / toxicity. Erythropoietin / therapeutic use. Heart / drug effects
  • [MeSH-minor] Animals. Antibodies, Monoclonal, Humanized. Blood Pressure / drug effects. In Vitro Techniques. Protective Agents / therapeutic use. Rats. Recombinant Proteins. Trastuzumab. Ventricular Fibrillation / chemically induced. Ventricular Fibrillation / prevention & control

  • Hazardous Substances Data Bank. Trastuzumab .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18156309.001).
  • [ISSN] 1535-3702
  • [Journal-full-title] Experimental biology and medicine (Maywood, N.J.)
  • [ISO-abbreviation] Exp. Biol. Med. (Maywood)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; 0 / Protective Agents; 0 / Recombinant Proteins; 11096-26-7 / Erythropoietin; 80168379AG / Doxorubicin; P188ANX8CK / Trastuzumab
  •  go-up   go-down


19. Levy ML, Goldfarb A, Hyder DJ, Gonzales-Gomez I, Nelson M, Gilles FH, McComb JG: Choroid plexus tumors in children: significance of stromal invasion. Neurosurgery; 2001 Feb;48(2):303-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Choroid plexus tumors in children: significance of stromal invasion.
  • OBJECTIVE: A group of choroid plexus tumors fit the cellular criteria for choroid plexus papilloma (CPP) except for invasion into the adjacent parenchyma, with associated loss of the normal villus architecture at the site of invasion.
  • These tumors retain a benign cellular appearance.
  • In the existing literature, it is unclear whether these tumors are classified as choroid plexus carcinomas or as CPPs.
  • In our experience, although evidence of invasion is present, these tumors tend to exhibit benign behavior.
  • We suggest that stromal invasion of this type remains consistent with a benign clinical course, although surgical results may demonstrate higher morbidity rates, given the invasive nature of the tumors.
  • After gross total tumor removal, none of the eight children with CPPs received adjuvant therapy at our institution; all are alive without evidence of tumor recurrence after surgical excision (mean, 108 mo).
  • The one patient who underwent subtotal resection received chemotherapy at another facility.
  • CONCLUSION: It is recommended that CPPs with a benign cellular appearance but with evidence of local parenchymal invasion and loss of the normal villus architecture at the site of invasion be classified as CPPs.
  • Patients with these tumors respond to surgical therapy alone, without the need for adjuvant treatment.
  • [MeSH-major] Choroid Plexus Neoplasms / pathology. Choroid Plexus Neoplasms / surgery. Papilloma / pathology. Papilloma / surgery
  • [MeSH-minor] Child. Child, Preschool. Humans. Infant. Neoplasm Invasiveness. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11220372.001).
  • [ISSN] 0148-396X
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


20. Utaisincharoen P, Tangthawornchaikul N, Ubol S, Chaisuriya P, Sirisinha S: TNF-alpha induces caspase 3 (CPP 32) dependent apoptosis in human cholangiocarcinoma cell line. Southeast Asian J Trop Med Public Health; 2000;31 Suppl 1:167-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TNF-alpha induces caspase 3 (CPP 32) dependent apoptosis in human cholangiocarcinoma cell line.
  • Cholangiocarcinoma (CCA), a malignant tumor derived from bile duct epithelium, occurs with a higher incidence in tropical countires especially in some areas of Southeast Asian countries such as Thailand.
  • This tumor is relatively resistant to chemotherapy.
  • In this study, molecular mechanism of killing of this tumor by TNF-alpha was investigated.
  • Human cholangiocarcinoma cell line (HuCCA-1) was developed and used as a model for treatment.
  • Activation of HuCCA-1 with TNF-alpha in the present of actinomycin D (1 microg/ml) caused death of the tumor cells.
  • Western blotting analysis of the cells extracted demonstrated the cleavage of poly (ADP-ribose) polymerase (PARP) within 6-8 hours following TNF-alpha treatment indicating apoptotic death.
  • These results indicate that apoptosis of human cholangiocarcinoma cell line as induced by TNF-alpha treatment is mediated through caspase 3.
  • [MeSH-major] Apoptosis / drug effects. Bile Duct Neoplasms / drug therapy. Caspases / drug effects. Cholangiocarcinoma / drug therapy. Tumor Cells, Cultured / drug effects. Tumor Necrosis Factor-alpha / therapeutic use

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11414450.001).
  • [ISSN] 0125-1562
  • [Journal-full-title] The Southeast Asian journal of tropical medicine and public health
  • [ISO-abbreviation] Southeast Asian J. Trop. Med. Public Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Tumor Necrosis Factor-alpha; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases
  •  go-up   go-down


21. Fabi A, Salesi N, Di Cocco B, Vidiri A, Visca P, Pace A, Carapella C, De Paula U, Mirri A, Cognetti F: Choroid plexus carcinoma in the adult: is there a role for chemotherapy? J Exp Clin Cancer Res; 2005 Sep;24(3):493-6
Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Choroid plexus carcinoma in the adult: is there a role for chemotherapy?
  • Choroid plexus carcinoma is a rare primary brain neoplasm arising from epithelial differentiated tissue, originating from the choroids plexus of the ventricles and, in 90% of the cases, in the lateral and fourth ventricles.
  • This neoplasm is seen mainly in children and reported infrequently in adults.
  • The treatment of choroid plexus carcinoma is based on scarce evidence in literature.
  • We report a rare case of an adult woman affected by a choroid plexus tumour and a discussion on the therapeutic management of this uncommon adult malignancy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Choroid Plexus Neoplasms / drug therapy. Papilloma / drug therapy

  • Genetic Alliance. consumer health - Choroid Plexus Carcinoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16270538.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Contrast Media; BG3F62OND5 / Carboplatin; K2I13DR72L / Gadolinium DTPA; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


22. Houchi H, Warnault V, Barbier E, Dubois C, Pierrefiche O, Ledent C, Daoust M, Naassila M: Involvement of A2A receptors in anxiolytic, locomotor and motivational properties of ethanol in mice. Genes Brain Behav; 2008 Nov;7(8):887-98
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We aimed to investigate if the increased propensity of A2A(-/-) mice to consume ethanol is associated with an altered sensitivity in the motivational properties of ethanol in the conditioned place preference (CPP) and conditioned taste aversion (CTA) paradigms and with an altered development of sensitization to the locomotor effects of ethanol.
  • Our results show that A2A(-/-) mice produced on a CD1 background displayed a reduced ethanol-induced CPP and an increased sensitivity to the anxiolytic and locomotorstimulant effects of ethanol, but they did not show alteration in ethanol-induced CTA and locomotor sensitization.
  • Ethanol-induced CPP, ethanol consumption and the locomotor effects of ethanol were also tested in A2A(-/-) mice produced on a C57BL/6J background.
  • Our results emphasized the importance of the genetic background because alteration in ethanol consumption and preference, ethanol-induced CPP and locomotor-stimulant effects were not found in knockout mice produced on the alcohol-preferring C57BL/6J genetic background.
  • In conclusion, A2AR deficiency in mice generated on a CD1 background leads to high ethanol consumption that is associated with an increased sensitivity to the locomotor-stimulant/anxiolytic effects of ethanol and a decrease in ethanol-induced CPP.
  • [MeSH-major] Adenosine / metabolism. Alcohol-Induced Disorders, Nervous System / genetics. Brain / drug effects. Ethanol / pharmacology. Receptor, Adenosine A2A / drug effects
  • [MeSH-minor] Animals. Anti-Anxiety Agents / pharmacology. Anxiety / drug therapy. Anxiety / genetics. Anxiety / metabolism. Behavior, Animal / drug effects. Behavior, Animal / physiology. Central Nervous System Depressants / pharmacology. Conditioning (Psychology) / drug effects. Conditioning (Psychology) / physiology. Disease Models, Animal. Drug Resistance / drug effects. Drug Resistance / genetics. Genotype. Male. Mice. Mice, Inbred C57BL. Mice, Knockout. Motivation. Motor Activity / drug effects. Motor Activity / physiology. Species Specificity

  • Hazardous Substances Data Bank. Adenosine .
  • Hazardous Substances Data Bank. ETHANOL .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19097273.001).
  • [ISSN] 1601-183X
  • [Journal-full-title] Genes, brain, and behavior
  • [ISO-abbreviation] Genes Brain Behav.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Anxiety Agents; 0 / Central Nervous System Depressants; 0 / Receptor, Adenosine A2A; 3K9958V90M / Ethanol; K72T3FS567 / Adenosine
  •  go-up   go-down


23. Hashemi N, Mohammadirad A, Bayrami Z, Khorasani R, Vosough S, Aliahmadi A, Nikfar S, Sharifzadeh M, Kebriaeezadeh A, Abdollahi M: Restoration of morphine-induced alterations in rat submandibular gland function by N-methyl-D-aspartate agonist. Acta Biol Hung; 2006 Sep;57(3):283-94
Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The effects of morphine, 1-aminocyclobutane-cis-1,3-dicarboxylic (ACBD; NMDA agonist) and 3-((R)2-carboxypiperazin-4-yl)-propyl-l-phosphoric acid (CPP; NMDA antagonist) and their concurrent therapy on rat submandibular secretory function were studied.
  • Administration of ACBD (10 mg/kg) and CPP (10 mg/kg) alone did not influence secretion of submandibular glands.
  • In combination therapy, coadministration of CPP with morphine did not influence morphine-induced changes in salivary function while ABCD could restore all morphine-induced changes.
  • In combination treatment, ACBD prevented morphine-induced reduction of flow rate, total protein, calcium, and TGF-beta1 and reached control levels.
  • [MeSH-major] Morphine / adverse effects. N-Methylaspartate / agonists. Submandibular Gland / drug effects

  • Hazardous Substances Data Bank. MORPHINE .
  • Hazardous Substances Data Bank. POTASSIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. SODIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17048692.001).
  • [ISSN] 0236-5383
  • [Journal-full-title] Acta biologica Hungarica
  • [ISO-abbreviation] Acta. Biol. Hung.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 0 / Excitatory Amino Acid Antagonists; 0 / Glutamates; 0 / Piperazines; 100828-16-8 / 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid; 117488-23-0 / 2,4-methanoglutamate; 6384-92-5 / N-Methylaspartate; 76I7G6D29C / Morphine; 9NEZ333N27 / Sodium; RWP5GA015D / Potassium; SY7Q814VUP / Calcium
  •  go-up   go-down


24. McCall T, Binning M, Blumenthal DT, Jensen RL: Variations of disseminated choroid plexus papilloma: 2 case reports and a review of the literature. Surg Neurol; 2006 Jul;66(1):62-7; discussion 67-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Variations of disseminated choroid plexus papilloma: 2 case reports and a review of the literature.
  • BACKGROUND: Choroid plexus papillomas are typically considered benign lesions, but histology is not always predictive of their behavior.
  • We present 2 cases that illustrate the wide diversity with which choroid plexus papillomas can disseminate.
  • CASE DESCRIPTIONS: The patient described in case 1 had a primary fourth ventricular choroid plexus papilloma that produced diffuse cystic subarachnoid and leptomeningeal lesions.
  • Patient 2 also had a primary fourth ventricular tumor but with subsequent suprasellar and spinal drop metastases.
  • Patient 2 has been treated with several modalities, including radiation therapy and chemotherapy, with slowing of symptom progression.
  • CONCLUSIONS: Variations of choroid plexus papilloma dissemination include intraventricular, subarachnoid, and leptomeningeal nodules or cystic lesions, and intraparenchymal locations.
  • There is no consensus on the most effective treatment for choroid plexus papilloma metastases; surgical resection, chemotherapy, and radiation therapy may all yield benefits.
  • The prognosis for patients with disseminated choroid plexus papilloma can range from prolonged stable disease and symptoms to death within months.
  • [MeSH-major] Choroid Plexus / pathology. Choroid Plexus / surgery. Meningeal Neoplasms / diagnosis. Meningeal Neoplasms / therapy. Papilloma, Choroid Plexus / diagnosis. Papilloma, Choroid Plexus / therapy
  • [MeSH-minor] Adult. Antineoplastic Agents / therapeutic use. Arachnoid / pathology. Arachnoid / physiopathology. Arachnoid / surgery. Disease Progression. Female. Humans. Pia Mater / pathology. Pia Mater / physiopathology. Pia Mater / surgery. Subarachnoid Space / pathology. Subarachnoid Space / physiopathology. Subarachnoid Space / surgery. Treatment Outcome

  • Genetic Alliance. consumer health - Choroid Plexus Papilloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16793445.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 34
  •  go-up   go-down


25. Zhao RJ, Woo RS, Jeong MS, Shin BS, Kim DG, Kim KW: Orphanin FQ/nociceptin blocks methamphetamine place preference in rats. Neuroreport; 2003 Dec 19;14(18):2383-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Orphanin FQ/nociceptin (NOC) has been reported to regulate dopaminergic neurotransmission in rewarding pathway, and to suppress the development of conditioned place preference (CPP) induced by certain addictive drugs.
  • In this study, we investigated the effect of NOC on CPP induced by repeated administration of methamphetamine (MAP) in rats.
  • Repeated administration of MAP (1 mg/kg, i.p.) induced substantial CPP.
  • MAP-induced CPP was completely suppressed by NOC (10 nmol, i.c.v.).
  • ), an antagonist of the NOC receptor, antagonized the suppressive effect of NOC on MAP-induced CPP.
  • These results suggest that NOC blocks MAP-induced CPP by activation of the NOC receptor.
  • [MeSH-major] Conditioning (Psychology) / drug effects. Methamphetamine / antagonists & inhibitors. Methamphetamine / pharmacology. Opioid Peptides / pharmacology
  • [MeSH-minor] Animals. Behavior, Addictive / drug therapy. Behavior, Addictive / psychology. Male. Rats. Rats, Sprague-Dawley

  • MedlinePlus Health Information. consumer health - Methamphetamine.
  • Hazardous Substances Data Bank. d-METHAMPHETAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14663196.001).
  • [ISSN] 0959-4965
  • [Journal-full-title] Neuroreport
  • [ISO-abbreviation] Neuroreport
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Opioid Peptides; 0 / nociceptin; 44RAL3456C / Methamphetamine
  •  go-up   go-down


26. Fishbain DA, Cutler RB, Cole B, Lewis J, Rosomoff RS, Rosomoff HL: Medico-legal rounds: medico-legal issues and alleged breaches of "standards of medical care" in opioid rotation to methadone: a case report. Pain Med; 2003 Jun;4(2):195-201
Hazardous Substances Data Bank. METHADONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 1) To present an example of a medico-legal problem that developed as a result of a decision to rotate a chronic pain patient (CPP) to methadone in order to taper the CPP from oxycodone;.
  • METHODS: This is a case report of a CPP treated at a regional hospital pain clinic.
  • Methadone rotation was used in order to taper the CPP from oxycodone because of addictive disease.
  • RESULTS: During the rotation process, the CPP expired.
  • [MeSH-major] Analgesics, Opioid / adverse effects. Medication Errors / legislation & jurisprudence. Methadone / adverse effects. Opioid-Related Disorders. Pain / drug therapy. Pain Clinics / standards. Quality of Health Care / legislation & jurisprudence. Quality of Health Care / standards
  • [MeSH-minor] Adult. Autopsy. Chronic Disease. Decision Making. Expert Testimony. Florida. Humans. Male. Malpractice / legislation & jurisprudence. Oxycodone / adverse effects. Oxycodone / therapeutic use. Psychiatry

  • MedlinePlus Health Information. consumer health - Medication Errors.
  • MedlinePlus Health Information. consumer health - Pain.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. OXYCODONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Pain Med. 2004 Mar;5(1):109-10 [14996244.001]
  • [CommentIn] Pain Med. 2003 Jun;4(2):202-5 [12873270.001]
  • (PMID = 12873269.001).
  • [ISSN] 1526-2375
  • [Journal-full-title] Pain medicine (Malden, Mass.)
  • [ISO-abbreviation] Pain Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Legal Cases
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics, Opioid; CD35PMG570 / Oxycodone; UC6VBE7V1Z / Methadone
  •  go-up   go-down


27. Stergiou GS, Efstathiou SP, Argyraki CK, Gantzarou AP, Roussias LG, Mountokalakis TD: Clinic, home and ambulatory pulse pressure: comparison and reproducibility. J Hypertens; 2002 Oct;20(10):1987-93
MedlinePlus Health Information. consumer health - Home Care Services.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The objective of this study was to compare mean values and reproducibility of PP obtained in the clinic (CPP), at home (HPP) and with ambulatory monitoring (APP) and to evaluate potential implications for trials aiming to assess drug effects on PP.
  • METHODS: A total of 393 hypertensive subjects [mean age 51.5 +/- 11.5 (SD) years, 59% men, 35% treated] measured CPP (two visits), HPP (6 days) and APP (24 h).
  • The reproducibility of PP was assessed using the SD of differences (SDD) between measurements in 133 untreated subjects who had repeated CPP (five visits), HPP (6 days) and APP measurements (two occasions).
  • RESULTS: There was no difference between mean CPP (51.0 +/- 13.3 mmHg) and HPP (50.2 +/- 11.0) whereas APP (48.8 +/- 8.4) was lower than both CPP [mean difference 2.3 +/- 10.3 mmHg; 95% confidence interval (CI), 1.2, 3.3; P < 0.01] and HPP (1.5 +/- 7.8; 95% CI, 0.7, 2.3; P < 0.01).
  • The SDD between repeated measurements was about 10 mmHg for CPP (one visit), 5.2 mmHg for HPP (2 days) and 4 mmHg for APP (24-h).
  • For a parallel comparative trial aiming to detect a difference of 3 mmHg PP in the effect of two drugs, 415 subjects would be required when using CPP, compared to 127 using HPP and 63 using APP.
  • CONCLUSIONS: These data suggest that although differences among mean values of CPP, HPP and APP are small, differences in their reproducibility are important and should be taken into account in the design of trials assessing drug effects on PP.
  • [MeSH-minor] Adult. Age Factors. Aged. Antihypertensive Agents / therapeutic use. Circadian Rhythm / drug effects. Circadian Rhythm / physiology. Female. Humans. Hypertension / diagnosis. Hypertension / drug therapy. Hypertension / physiopathology. Male. Middle Aged. Pulse. Reproducibility of Results. Statistics as Topic. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12359977.001).
  • [ISSN] 0263-6352
  • [Journal-full-title] Journal of hypertension
  • [ISO-abbreviation] J. Hypertens.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antihypertensive Agents
  •  go-up   go-down


28. Benturquia N, Le Marec T, Scherrmann JM, Noble F: Effects of nitrous oxide on dopamine release in the rat nucleus accumbens and expectation of reward. Neuroscience; 2008 Aug 13;155(2):341-4
Hazardous Substances Data Bank. MORPHINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently we have shown that nitrous oxide (N2O) was able to block the expression of morphine-induced conditioned place preference (CPP) in mice.
  • Because dopamine (DA) has also been associated with the positive place conditioning we hypothesize that exposure to N2O would be significantly associated with a modification of extracellular level of DA.
  • Levels of DA, in the nucleus accumbens (Nac), in awake and freely moving rats during positive place conditioning after morphine chronic treatment has been measured by microdialysis.
  • Expression of morphine-induced CPP was totally abolished in mice and rats exposed to N2O.
  • In conclusion we showed the capacity of N2O to block the expression of morphine-induced CPP in mice and in rats.
  • [MeSH-major] Dopamine / metabolism. Morphine Dependence / drug therapy. Nitrous Oxide / pharmacology. Nucleus Accumbens / drug effects. Reward
  • [MeSH-minor] Analgesics, Opioid / pharmacology. Animals. Conditioning (Psychology) / drug effects. Conditioning (Psychology) / physiology. Drug Interactions. Male. Mice. Mice, Inbred Strains. Microdialysis. Morphine / pharmacology. Rats. Rats, Sprague-Dawley. Spatial Behavior / drug effects

  • HAL archives ouvertes. Full text from .
  • Hazardous Substances Data Bank. Nitrous oxide .
  • Hazardous Substances Data Bank. DOPAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18571333.001).
  • [ISSN] 0306-4522
  • [Journal-full-title] Neuroscience
  • [ISO-abbreviation] Neuroscience
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 76I7G6D29C / Morphine; K50XQU1029 / Nitrous Oxide; VTD58H1Z2X / Dopamine
  •  go-up   go-down


29. Esmaeili B, Basseda Z, Dehpour AR: Antagonism of muscarinic M1 receptors by dicyclomine inhibits the consolidation of morphine-associated contextual memory. Brain Res Bull; 2008 Jul 1;76(4):380-7
Hazardous Substances Data Bank. DICYCLOMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • M1 muscarinic receptor has been shown to be involved in cognitive functions of the brain.
  • Conditioned place preference (CPP) paradigm involves memory for the association between environmental stimuli and the rewarding properties produced by a treatment.
  • Using a balanced CPP design, we studied the possible involvement of M1 muscarinic receptors on the acquisition, expression and consolidation of morphine place conditioning in male mice.
  • Subcutaneous administration of morphine sulphate-induced CPP in a dose-dependent manner.
  • Using a 6-day schedule of conditioning, it was found that dicyclomine, an M1 muscarinic antagonist, significantly reduced the time spent by mice in the morphine compartment when given immediately, but not 6h, after each conditioning session (consolidation).
  • It had no effect when administered 30 min before each conditioning session during CPP training period (acquisition) or 30 min before testing for place preference in the absence of morphine (expression).
  • It is concluded that M1 muscarinic receptors may play a time-dependent role in the consolidation of reward-related memory of morphine.
  • [MeSH-major] Dicyclomine / pharmacology. Learning / drug effects. Memory / drug effects. Morphine / pharmacology. Receptor, Muscarinic M1 / antagonists & inhibitors
  • [MeSH-minor] Animals. Brain / drug effects. Brain / metabolism. Conditioning (Psychology) / drug effects. Conditioning (Psychology) / physiology. Dose-Response Relationship, Drug. Drug Interactions / physiology. Male. Mice. Morphine Dependence / drug therapy. Morphine Dependence / metabolism. Muscarinic Antagonists / pharmacology. Narcotics / pharmacology. Reward. Time Factors

  • MedlinePlus Health Information. consumer health - Memory.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MORPHINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18502314.001).
  • [ISSN] 1873-2747
  • [Journal-full-title] Brain research bulletin
  • [ISO-abbreviation] Brain Res. Bull.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Muscarinic Antagonists; 0 / Narcotics; 0 / Receptor, Muscarinic M1; 4KV4X8IF6V / Dicyclomine; 76I7G6D29C / Morphine
  •  go-up   go-down


30. Sadler R, Herzig V, Schmidt WJ: Repeated treatment with the NMDA antagonist MK-801 disrupts reconsolidation of memory for amphetamine-conditioned place preference. Behav Pharmacol; 2007 Nov;18(7):699-703
Hazardous Substances Data Bank. DIZOCILPINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Repeated treatment with the NMDA antagonist MK-801 disrupts reconsolidation of memory for amphetamine-conditioned place preference.
  • Long-lasting drug-associated memories can contribute to relapse; therefore these memories must be inactivated to enable sustainable success in addiction therapy.
  • As drug associations are usually acquired over several conditioning events, we assume that an effective treatment should be repeatedly applied to achieve persistent effects.
  • In this study, we examine whether 10 repeated memory reactivation tests followed by systemic N-methyl-D-aspartate receptor antagonist MK-801 (0.1 mg/kg) administrations can disrupt memory reconsolidation in rats, leading to a reduction of well-established amphetamine-conditioned place preference (CPP).
  • We found that immediate (but not 60-min delayed) administration of MK-801 after the tests reduced amphetamine-CPP expression after at least four treatments.
  • These effects were specific to CPP expression as no MK-801-induced change in locomotion was observed during all tests.
  • We discuss these results as being caused by MK-801 disrupting memory reconsolidation and we propose the applied repeated-treatment regimen as a new therapeutic research strategy to persistently disrupt drug-associated memories.
  • [MeSH-major] Amphetamine / pharmacology. Central Nervous System Stimulants / pharmacology. Conditioning, Operant / drug effects. Dizocilpine Maleate / pharmacology. Memory / drug effects. Receptors, N-Methyl-D-Aspartate / antagonists & inhibitors
  • [MeSH-minor] Animals. Behavior, Animal / drug effects. Male. Motor Activity / drug effects. Rats. Rats, Sprague-Dawley

  • MedlinePlus Health Information. consumer health - Memory.
  • Hazardous Substances Data Bank. AMPHETAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17912055.001).
  • [ISSN] 0955-8810
  • [Journal-full-title] Behavioural pharmacology
  • [ISO-abbreviation] Behav Pharmacol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Central Nervous System Stimulants; 0 / Receptors, N-Methyl-D-Aspartate; 6LR8C1B66Q / Dizocilpine Maleate; CK833KGX7E / Amphetamine
  •  go-up   go-down


31. Toumba M, Bacopoulou I, Savva SC, Skordis N: Efficacy of combined treatment with growth hormone and gonadotropin releasing hormone analogue in children with poor prognosis of adult height. Indian Pediatr; 2007 Jul;44(7):497-502
MedlinePlus Health Information. consumer health - Growth Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of combined treatment with growth hormone and gonadotropin releasing hormone analogue in children with poor prognosis of adult height.
  • OBJECTIVE: This study was conducted to study the role of combination therapy of growth hormone and Gonadotropin-releasing hormone (GnRH) analogues in girls with idiopathic central precocious puberty (CPP) or idiopathic short stature (ISS).
  • METHODS: Five girls with CPP (median age 9.1 y, pubertal stage 2-3) (3 of them previously treated with GnRH analogue (GnRHa) for 16.2 +/- 0.3 months) and 8 girls with ISS (median age 11.4 y, pubertal stage 2-3) (previously treated with GH for 10.95 +/- 1.42 months), were treated with recombinant human GH (0.33 mg/kg/week) and GnRHa (3.75 mg/28 days) for 22 months.
  • RESULTS: Height of girls with CPP improved from - 1.3 to - 0.2 SDS and height for BA from - 2.1 to - 0.6 SDS (P = 0.042).
  • CONCLUSION: Combined treatment improves height and PAH in CPP.
  • [MeSH-major] Body Height / drug effects. Gonadotropin-Releasing Hormone / analogs & derivatives. Growth Disorders / drug therapy. Growth Hormone / therapeutic use. Puberty, Precocious / drug therapy
  • [MeSH-minor] Algorithms. Bone Development / drug effects. Child. Drug Therapy, Combination. Female. Humans. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17684302.001).
  • [ISSN] 0019-6061
  • [Journal-full-title] Indian pediatrics
  • [ISO-abbreviation] Indian Pediatr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 33515-09-2 / Gonadotropin-Releasing Hormone; 9002-72-6 / Growth Hormone
  •  go-up   go-down


32. Chiu WT, Lin TJ, Lin JW, Huang SJ, Chang CK, Chen HY: Multicenter evaluation of propofol for head-injured patients in Taiwan. Surg Neurol; 2006;66 Suppl 2:S37-42
Hazardous Substances Data Bank. PROPOFOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The present study was a multicenter, retrospective study which aimed to evaluate the efficacy of propofol, a new choice of pharmacotherapy in head-injured patients.
  • Data on patients' demographics, laboratory data, GCS score, ICP, CPP, concurrent medications, and therapeutic outcomes were collected.
  • Mean CPP for the first 5 days in the ICU was 71.10 +/- 15.32 mm Hg in the propofol group and 43.20 +/- 29.92 mm Hg in the nonpropofol group (P<.001).
  • [MeSH-major] Brain Injuries / drug therapy. Brain Injuries / mortality. Hypnotics and Sedatives / therapeutic use. Propofol / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Glasgow Coma Scale. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate. Taiwan / epidemiology. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17071254.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hypnotics and Sedatives; YI7VU623SF / Propofol
  •  go-up   go-down


33. Herzig V, Schmidt WJ: Repeated-testing of place preference expression for evaluation of anti-craving-drug effects. Amino Acids; 2005 May;28(3):309-17
Hazardous Substances Data Bank. ACAMPROSATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Repeated-testing of place preference expression for evaluation of anti-craving-drug effects.
  • In addiction research, the conditioned place preference (CPP) paradigm is a widely used animal model of conditioned reward.
  • Usually, CPP development is studied, while only few studies examine CPP expression.
  • In the present study, the suitability of a schedule allowing repeated testing of CPP expression was evaluated.
  • This schedule consisted of four repeated applications of a sequence of drug- (i.e. cocaine or morphine), saline- and anti-craving-drug- (i.e. acamprosate, naloxone, their joint administration or saline as internal control) tests.
  • Methodologically, the repeated-testing-schedule produced stable CPP expression in both groups over 12 subsequent tests.
  • In conclusion, it is suggested as a useful method to study effects of anti-craving-drugs on CPP expression, thereby reducing the overall number of experimental animals.
  • The evaluation of the anti-craving-drug effects revealed that neither acamprosate and naloxone given separately nor their combined administration significantly reduced cocaine- or morphine-CPP expression.
  • Thus, we suggest that these anti-craving-drugs are unlikely to be effective for relapse prevention in cocaine- or morphine-addicts.
  • [MeSH-major] Behavior, Animal / drug effects. Conditioning (Psychology) / drug effects. Naloxone / administration & dosage. Narcotic Antagonists / administration & dosage. Opioid-Related Disorders / drug therapy
  • [MeSH-minor] Alcohol Deterrents. Analgesics, Opioid / administration & dosage. Analgesics, Opioid / adverse effects. Anesthetics, Local / administration & dosage. Anesthetics, Local / adverse effects. Animals. Cocaine / administration & dosage. Cocaine / adverse effects. Drug Evaluation, Preclinical. Male. Morphine / administration & dosage. Morphine / adverse effects. Rats. Rats, Sprague-Dawley. Taurine / analogs & derivatives

  • Hazardous Substances Data Bank. Taurine .
  • Hazardous Substances Data Bank. NALOXONE .
  • Hazardous Substances Data Bank. COCAINE .
  • Hazardous Substances Data Bank. MORPHINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15791393.001).
  • [ISSN] 0939-4451
  • [Journal-full-title] Amino acids
  • [ISO-abbreviation] Amino Acids
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Alcohol Deterrents; 0 / Analgesics, Opioid; 0 / Anesthetics, Local; 0 / Narcotic Antagonists; 1EQV5MLY3D / Taurine; 36B82AMQ7N / Naloxone; 76I7G6D29C / Morphine; I5Y540LHVR / Cocaine; N4K14YGM3J / acamprosate
  •  go-up   go-down


34. Russo SJ, Festa ED, Fabian SJ, Gazi FM, Kraish M, Jenab S, Quiñones-Jenab V: Gonadal hormones differentially modulate cocaine-induced conditioned place preference in male and female rats. Neuroscience; 2003;120(2):523-33
Hazardous Substances Data Bank. PROGESTERONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present study, conditioned place preference (CPP), a measure of non-contingent reward, was used to determine the effects of endogenous gonadal hormones and of estrogen and progesterone replacement on cocaine reward.
  • Although both intact and gonadectomized male and female rats showed a significant CPP for cocaine, ovariectomy attenuated the magnitude of CPP.
  • These alterations coincided with a decrease in serum levels of corticosterone.
  • In ovariectomized rats, pretreatment with progesterone inhibited cocaine CPP while estrogen plus progesterone potentiated the magnitude of CPP.
  • [MeSH-major] Cocaine / pharmacology. Conditioning (Psychology) / drug effects. Estrogens / pharmacology. Progesterone / pharmacology. Sex Characteristics
  • [MeSH-minor] Analysis of Variance. Anesthetics, Local / pharmacology. Animals. Behavior, Animal. Biogenic Monoamines / metabolism. Cesarean Section / methods. Chromatography, High Pressure Liquid / instrumentation. Chromatography, High Pressure Liquid / methods. Corticosterone / blood. Drug Interactions. Exploratory Behavior / drug effects. Exploratory Behavior / physiology. Female. Hormone Replacement Therapy / methods. Male. Motor Activity / drug effects. Motor Activity / physiology. Nucleus Accumbens / drug effects. Nucleus Accumbens / metabolism. Radioimmunoassay / methods. Rats. Rats, Inbred F344. Reaction Time. Reward. Time Factors. Ventral Tegmental Area / drug effects. Ventral Tegmental Area / metabolism

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. COCAINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12890521.001).
  • [ISSN] 0306-4522
  • [Journal-full-title] Neuroscience
  • [ISO-abbreviation] Neuroscience
  • [Language] eng
  • [Grant] United States / NIDA NIH HHS / DA / DA12136; United States / NIGMS NIH HHS / GM / GM60654; United States / NINDS NIH HHS / NS / NS-41073; United States / NCRR NIH HHS / RR / RR-03037
  • [Publication-type] Comparative Study; Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anesthetics, Local; 0 / Biogenic Monoamines; 0 / Estrogens; 4G7DS2Q64Y / Progesterone; I5Y540LHVR / Cocaine; W980KJ009P / Corticosterone
  •  go-up   go-down


35. Pollack AE, Haisley EC: NMDA glutamate receptor stimulation is required for the expression of D2 dopamine mediated responses in apomorphine primed 6-hydroxydopamine lesioned rats. Brain Res; 2001 Apr 6;897(1-2):213-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pretreatment with NMDA glutamate antagonists MK-801 or CPP dose-dependently attenuates these quinpirole-mediated responses.
  • [MeSH-minor] Animals. Behavior, Animal / drug effects. Brain Chemistry / drug effects. Denervation. Dizocilpine Maleate / pharmacology. Excitatory Amino Acid Antagonists / pharmacology. Male. Oxidopamine. Parkinson Disease / drug therapy. Parkinson Disease / metabolism. Piperazines / pharmacology. Proto-Oncogene Proteins c-fos / metabolism. Rats. Rats, Sprague-Dawley. Sympatholytics

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. APOMORPHINE .
  • Hazardous Substances Data Bank. DIZOCILPINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11282380.001).
  • [ISSN] 0006-8993
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Dopamine Agonists; 0 / Excitatory Amino Acid Antagonists; 0 / Piperazines; 0 / Proto-Oncogene Proteins c-fos; 0 / Receptors, Dopamine D2; 0 / Receptors, N-Methyl-D-Aspartate; 0 / Sympatholytics; 100828-16-8 / 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid; 6LR8C1B66Q / Dizocilpine Maleate; 8HW4YBZ748 / Oxidopamine; N21FAR7B4S / Apomorphine
  •  go-up   go-down


36. Wang R, Zhang Y, Qing H, Liu M, Yang P: The extinction of morphine-induced conditioned place preference by histone deacetylase inhibition. Neurosci Lett; 2010 Oct 11;483(2):137-42
Hazardous Substances Data Bank. MORPHINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we will examine the effect of histone deacetylase (HDAC) inhibitors on extinction of morphine-induced conditioned place preference (CPP).
  • To exclude the effect of repeated NaBut injections themselves on morphine-CPP in the absence of extinction session, rats received injection of either NaBut or vehicle for 8 days.
  • We found that HDAC inhibition during nonconfined extinction or confined extinction consolidation can facilitate extinction of morphine-induced CPP.
  • We also showed that the extinction of drug seeking via HDAC inhibition modulates extinction learning such that reinstatement behavior is significantly attenuated.
  • There is no effect of repeated NaBut injections themselves on morphine-CPP in the absence of extinction session.
  • In conclusion, our results extend earlier reports on the ability of HDACi to modify the behavioral effects of drugs of abuse.
  • Our increasing understanding of these epigenetic mechanisms will provide key answers to basic processes in drug addiction and hopefully provide insight into designing improved treatments for drug addiction.
  • [MeSH-major] Conditioning (Psychology) / drug effects. Conditioning (Psychology) / physiology. Enzyme Inhibitors / pharmacology. Extinction, Psychological / drug effects. Histone Deacetylase 1 / antagonists & inhibitors. Morphine Dependence / drug therapy. Protein Processing, Post-Translational / genetics
  • [MeSH-minor] Analgesics, Opioid / pharmacology. Animals. Behavior, Animal / drug effects. Behavior, Animal / physiology. Disease Models, Animal. Male. Morphine / pharmacology. Rats. Rats, Sprague-Dawley

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20691756.001).
  • [ISSN] 1872-7972
  • [Journal-full-title] Neuroscience letters
  • [ISO-abbreviation] Neurosci. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 0 / Enzyme Inhibitors; 76I7G6D29C / Morphine; EC 3.5.1.98 / Hdac1 protein, rat; EC 3.5.1.98 / Histone Deacetylase 1
  •  go-up   go-down


37. Braun K, Ehemann V, Wiessler M, Pipkorn R, Didinger B, Mueller G, Waldeck W: High-resolution flow cytometry: a suitable tool for monitoring aneuploid prostate cancer cells after TMZ and TMZ-BioShuttle treatment. Int J Med Sci; 2009;6(6):338-47
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-resolution flow cytometry: a suitable tool for monitoring aneuploid prostate cancer cells after TMZ and TMZ-BioShuttle treatment.
  • If metastatic prostate cancer gets resistant to antiandrogen therapy, there are few treatment options, because prostate cancer is not very sensitive to cytostatic agents.
  • Temozolomide (TMZ) as an orally applicable chemotherapeutic substance has been proven to be effective and well tolerated with occasional moderate toxicity especially for brain tumors and an application to prostate cancer cells seemed to be promising.
  • Unfortunately, TMZ was inefficient in the treatment of symptomatic progressive hormone-refractory prostate cancer (HRPC).
  • The reasons could be a low sensitivity against TMZ the short plasma half-life of TMZ, non-adapted application regimens and additionally, the aneuploid DNA content of prostate cancer cells suggesting different sensitivity against therapeutical interventions e.g. radiation therapy or chemotherapy.
  • The modular-composed carrier consists of a transmembrane transporter (CPP), connected to a nuclear localization sequence (NLS) cleavably-bound, which in turn was coupled with TMZ.
  • The NLS-sequence allows an active delivery of the TMZ into the cell nucleus after transmembrane passage of the TMZ-BioShuttle and intra-cytoplasm enzymatic cleavage and separation from the CPP.
  • This TMZ-BioShuttle could contribute to improve therapeutic options exemplified by the hormone refractory prostate cancer.
  • The high-resolution flow cytometric analysis showed to be an appropriate system for a better detection and distinction of several cell populations dependent on their different DNA-indices as well as changes in proliferation of cell populations after chemotherapeutical treatment.
  • [MeSH-major] Aneuploidy. Antineoplastic Agents, Alkylating / administration & dosage. Dacarbazine / analogs & derivatives. Drug Monitoring / methods. Drug Resistance, Neoplasm. Flow Cytometry / methods. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Cell Line, Tumor. DNA, Neoplasm / analysis. Drug Delivery Systems. Humans. Male

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Chemother Pharmacol. 2000;45(6):509-12 [10854140.001]
  • [Cites] Med Res Rev. 2010 Jan;30(1):23-66 [19536866.001]
  • [Cites] Nature. 2001 May 17;411(6835):366-74 [11357144.001]
  • [Cites] J Mol Biol. 2002 Apr 26;318(2):237-43 [12051833.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):427-35 [12243818.001]
  • [Cites] Biochem Soc Trans. 2002 Nov;30(Pt 6):952-8 [12440953.001]
  • [Cites] Anticancer Res. 2002 Nov-Dec;22(6C):4147-50 [12553046.001]
  • [Cites] Urol Int. 2003;70(1):1-14 [12566808.001]
  • [Cites] Cancer Lett. 2003 May 8;194(1):125-31 [12706866.001]
  • [Cites] Cell Cycle. 2004 Jan;3(1):46-50 [14657665.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jul 15;59(4):928-42 [15234026.001]
  • [Cites] Chembiochem. 2004 Oct 4;5(10):1432-47 [15457527.001]
  • [Cites] Int J Cancer. 1978 Mar 15;21(3):274-81 [631930.001]
  • [Cites] Biochem Pharmacol. 1987 Feb 15;36(4):457-62 [3470008.001]
  • [Cites] Adv Cancer Res. 1991;57:1-46 [1950701.001]
  • [Cites] Biochem Int. 1992 Aug;27(4):567-77 [1417893.001]
  • [Cites] J Histochem Cytochem. 1994 Jun;42(6):697-704 [8189032.001]
  • [Cites] Curr Opin Immunol. 1994 Apr;6(2):279-89 [8011211.001]
  • [Cites] J Urol. 1994 Nov;152(5 Pt 2):1816 [7933240.001]
  • [Cites] J Urol. 1994 Nov;152(5 Pt 2):1837-42 [7523731.001]
  • [Cites] Cancer Res. 1995 Jul 15;55(14):2959-62 [7606709.001]
  • [Cites] Antimicrob Agents Chemother. 1995 Dec;39(12):2620-4 [8592990.001]
  • [Cites] J Clin Oncol. 1996 May;14(5):1617-25 [8622080.001]
  • [Cites] Cancer Res. 1997 Feb 1;57(3):524-31 [9012485.001]
  • [Cites] Int J Cancer. 1997 May 16;71(4):698-704 [9178829.001]
  • [Cites] J Clin Oncol. 1998 Jun;16(6):2272-9 [9626231.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1998 Jun 1;41(3):491-500 [9635694.001]
  • [Cites] Semin Nephrol. 1998 Sep;18(5):505-18 [9754603.001]
  • [Cites] Oncogene. 1998 Dec 24;17(25):3225-36 [9916985.001]
  • [Cites] Cancer Lett. 1999 Apr 26;138(1-2):101-6 [10378780.001]
  • [Cites] J Natl Cancer Inst. 1999 Sep 15;91(18):1574-80 [10491435.001]
  • [Cites] Ann Oncol. 2004 Nov;15(11):1613-21 [15520061.001]
  • [Cites] Radiother Oncol. 2004 Dec;73 Suppl 2:S119-22 [15971325.001]
  • [Cites] JAMA. 2005 Jul 13;294(2):238-44 [16014598.001]
  • [Cites] In Vivo. 2006 Jan-Feb;20(1):17-23 [16433023.001]
  • [Cites] Ann Oncol. 2006 Jun;17(6):952-6 [16565212.001]
  • [Cites] Hinyokika Kiyo. 2006 Jul;52(7):515-21 [16910582.001]
  • [Cites] Cochrane Database Syst Rev. 2006;(4):CD005247 [17054249.001]
  • [Cites] J Mol Histol. 2006 Sep;37(5-7):253-60 [16841236.001]
  • [Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]
  • [Cites] Urology. 2007 Feb;69(2):347-51 [17320676.001]
  • [Cites] BJU Int. 2007 Mar;99(3):497-501 [17092283.001]
  • [Cites] Amino Acids. 2007;32(3):373-9 [17077962.001]
  • [Cites] Drug Resist Updat. 2007 Feb-Apr;10(1-2):51-8 [17387035.001]
  • [Cites] Clin Genitourin Cancer. 2007 Mar;5(4):278-83 [17553208.001]
  • [Cites] Pathol Oncol Res. 2007;13(2):84-90 [17607368.001]
  • [Cites] J Clin Oncol. 2007 Sep 1;25(25):3965-70 [17761981.001]
  • [Cites] Cancer Treat Rev. 2007 Oct;33(6):521-7 [17658220.001]
  • [Cites] Hepatology. 2007 Sep;46(3):759-68 [17663418.001]
  • [Cites] Int J Oncol. 2008 Feb;32(2):341-7 [18202756.001]
  • [Cites] Biochim Biophys Acta. 2008 Jan;1779(1):3-16 [18078840.001]
  • [Cites] Biostatistics. 2008 Apr;9(2):333-54 [17873151.001]
  • [Cites] Int J Med Sci. 2008;5(5):273-84 [18797509.001]
  • [Cites] J Pept Sci. 2009 Mar;15(3):235-41 [19177421.001]
  • [Cites] Br J Cancer. 2008 Sep 16;99(6):900-10 [19238631.001]
  • [Cites] Biomaterials. 2009 Jul;30(20):3466-75 [19304320.001]
  • [Cites] Oncol Rep. 2009 Aug;22(2):345-8 [19578775.001]
  • [Cites] BMC Cancer. 2009;9:210 [19563641.001]
  • [Cites] DNA Repair (Amst). 2009 Sep 2;8(9):1153-65 [19501553.001]
  • [Cites] Int J Cancer. 2009 Dec 15;125(12):2978-90 [19422046.001]
  • [Cites] Nature. 2001 May 17;411(6835):342-8 [11357141.001]
  • (PMID = 19946604.001).
  • [ISSN] 1449-1907
  • [Journal-full-title] International journal of medical sciences
  • [ISO-abbreviation] Int J Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / DNA, Neoplasm; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide
  • [Other-IDs] NLM/ PMC2781174
  • [Keywords] NOTNLM ; Flow Cytometry / Prostate Cancer Cells / TMZ-BioShuttle
  •  go-up   go-down


38. Kang L, Wang D, Li B, Hu M, Zhang P, Li J: Mirtazapine, a noradrenergic and specific serotonergic antidepressant, attenuates morphine dependence and withdrawal in Sprague-Dawley rats. Am J Drug Alcohol Abuse; 2008;34(5):541-52
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The effects of mirtazapine, a noradrenergic and specific serotonergic antidepressant, on morphine withdrawal and morphine conditioned place preference (CPP) were investigated in rats.
  • The expression of morphine-induced CPP was significantly blocked by mirtazapine (10 or 30 mg/kg, i.p.
  • ), while chronic treatment with mirtazapine (1 or 10 mg/kg, i.p. once, daily, for six consecutive days) significantly attenuated the acquisition of morphine CPP.
  • Our results demonstrated that mirtazapine attenuates morphine withdrawal and morphine-induced CPP in rats and suggest that mirtazapine may have therapeutic potential in the treatment of opiate dependence.
  • [MeSH-major] Antidepressive Agents, Tricyclic / pharmacology. Mianserin / analogs & derivatives. Morphine Dependence / drug therapy. Substance Withdrawal Syndrome / drug therapy
  • [MeSH-minor] Animals. Conditioning, Operant / drug effects. Dose-Response Relationship, Drug. Drug Administration Schedule. Male. Morphine / adverse effects. Rats. Rats, Sprague-Dawley. Serotonin Receptor Agonists / administration & dosage. Serotonin Receptor Agonists / pharmacology

  • Hazardous Substances Data Bank. MIANSERIN .
  • Hazardous Substances Data Bank. MORPHINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18618337.001).
  • [ISSN] 1097-9891
  • [Journal-full-title] The American journal of drug and alcohol abuse
  • [ISO-abbreviation] Am J Drug Alcohol Abuse
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antidepressive Agents, Tricyclic; 0 / Serotonin Receptor Agonists; 250PJI13LM / Mianserin; 76I7G6D29C / Morphine; A051Q2099Q / mirtazapine
  •  go-up   go-down


39. Herzig V, Schmidt WJ: Anti-craving drugs acamprosate and naloxone do not reduce expression of morphine conditioned place preference in isolated and group-housed rats. Neurosci Lett; 2005 Feb 10;374(2):119-23
Hazardous Substances Data Bank. ACAMPROSATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-craving drugs acamprosate and naloxone do not reduce expression of morphine conditioned place preference in isolated and group-housed rats.
  • Relapse prevention in clean addicts is a great challenge for addiction-therapy.
  • As strong cravings often precede relapse, anti-craving drugs seem to be a promising way for addicts to stay clean.
  • Naloxone and acamprosate are two candidates for anti-craving drugs that are already used for relapse prevention in alcoholic patients.
  • However, it has to be figured out if both drugs are also effective in opiate-addicts.
  • In order to evaluate their effectiveness, a conditioned place preference (CPP) paradigm was used in rats conditioned to 10 mg/kg, i.p., morphine.
  • As acamprosate and naloxone have been suggested to selectively affect different types of craving (withdrawal-craving versus reward-craving), we have tried to modulate craving-behaviour by maintaining two groups of rats under different conditions (isolated versus group-housed).
  • Thereafter, the effectiveness of acamprosate (200 mg/kg, i.p.) and naloxone (2 mg/kg, i.p.) in reducing morphine-CPP expression was evaluated.
  • As a result, isolation produced a weak reduction in morphine-CPP development.
  • Furthermore, acamprosate and naloxone had no effect on morphine-CPP expression.
  • Based on the present results, we assume that the anti-craving drugs acamprosate and naloxone may not be effective for relapse prevention in opiate-addicts.
  • [MeSH-major] Alcohol Deterrents / pharmacology. Conditioning, Operant / drug effects. Morphine / pharmacology. Naloxone / pharmacology. Narcotic Antagonists / pharmacology. Narcotics / pharmacology. Taurine / analogs & derivatives. Taurine / pharmacology
  • [MeSH-minor] Analysis of Variance. Animals. Behavior, Animal. Drug Interactions. Locomotion / drug effects. Male. Rats. Rats, Sprague-Dawley. Social Isolation. Spatial Behavior / drug effects

  • MedlinePlus Health Information. consumer health - Opioid Abuse and Addiction.
  • Hazardous Substances Data Bank. Taurine .
  • Hazardous Substances Data Bank. NALOXONE .
  • Hazardous Substances Data Bank. MORPHINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15644276.001).
  • [ISSN] 0304-3940
  • [Journal-full-title] Neuroscience letters
  • [ISO-abbreviation] Neurosci. Lett.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Alcohol Deterrents; 0 / Narcotic Antagonists; 0 / Narcotics; 1EQV5MLY3D / Taurine; 36B82AMQ7N / Naloxone; 76I7G6D29C / Morphine; N4K14YGM3J / acamprosate
  •  go-up   go-down


40. Wolff JE, Sajedi M, Brant R, Coppes MJ, Egeler RM: Choroid plexus tumours. Br J Cancer; 2002 Nov 4;87(10):1086-91

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Choroid plexus tumours.
  • Choroid plexus tumours are rare epithelial brain tumours and limited information is available regarding their biology and the best treatment.
  • A meta-analysis was done to determine prognostic factors and the influence of various treatment modalities.
  • A thorough review of the medical literature (1966-1998) revealed 566 well-documented choroid plexus tumours.
  • These were entered into a database, which was analysed to determine prognostic factors and treatment modalities.
  • Most patients with a supratentorial tumour were children, while the most common sites in adults were the fourth ventricle and the cerebellar pontine angle.
  • Cerebellar pontine angle tumours were more frequently benign.
  • Histology was the most important prognostic factor, as one, five, and 10-year projected survival rates were 90, 81, and 77% in choroid plexus-papilloma (n=353) compared to only 71, 41, and 35% in choroid plexus-carcinoma respectively (P<0.0005).
  • Surgery was prognostically relevant for both choroid plexus-papilloma (P=0.0005) and choroid plexus-carcinoma (P=0.0001).
  • Radiotherapy was associated with significantly better survival in choroid plexus-carcinomas.
  • Eight of 22 documented choroid plexus-carcinomas responded to chemotherapy.
  • Relapse after primary treatment was a poor prognostic factor in choroid plexus-carcinoma patients but not in choroid plexus-papilloma patients.
  • Treatment of choroid plexus tumours should start with radical surgical resection.
  • This should be followed by adjuvant treatment in case of choroid plexus-carcinoma, and a "wait and see" approach in choroid plexus-papilloma.
  • [MeSH-major] Choroid Plexus Neoplasms / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 Cancer Research UK
  • [Cites] Zentralbl Allg Pathol. 1989;135(3):235-40 [2773602.001]
  • [Cites] Childs Nerv Syst. 1997 May;13(5):244-9 [9224912.001]
  • [Cites] Acta Oncol. 1990;29(2):241-3 [2185805.001]
  • [Cites] AJNR Am J Neuroradiol. 1990 Jul-Aug;11(4):793-9 [2114770.001]
  • [Cites] Childs Nerv Syst. 1990 Sep;6(6):331-4 [2257546.001]
  • [Cites] Acta Neuropathol. 1990;80(6):635-41 [1703384.001]
  • [Cites] Surg Neurol. 1991 Jul;36(1):54-8 [2053075.001]
  • [Cites] Med Pediatr Oncol. 2001 Feb;36(2):323-5 [11452945.001]
  • [Cites] Childs Brain. 1975;1(2-3):81-115 [1081032.001]
  • [Cites] Childs Brain. 1977;3(1):12-24 [844343.001]
  • [Cites] Int J Cancer. 1978 Jan 15;21(1):12-7 [203540.001]
  • [Cites] Acta Neurochir (Wien). 1978;43(3-4):239-49 [212932.001]
  • [Cites] No Shinkei Geka. 1979 Aug;7(8):815-8 [492463.001]
  • [Cites] J Neurosurg. 1980 Feb;52(2):251-5 [7351566.001]
  • [Cites] J Neurosurg. 1981 Feb;54(2):245-7 [6969788.001]
  • [Cites] Acta Neuropathol. 1981;53(1):29-33 [7010876.001]
  • [Cites] Neurosurg Rev. 1981;4(3):129-37 [7301142.001]
  • [Cites] Neurochirurgie. 1986;32(3):258-61 [3762840.001]
  • [Cites] Acta Cytol. 1988 Mar-Apr;32(2):263-6 [2450440.001]
  • [Cites] Arch Geschwulstforsch. 1988;58(1):51-5 [3369921.001]
  • [Cites] J Neurosurg. 1988 Dec;69(6):843-9 [3193190.001]
  • [Cites] Pediatr Neurosci. 1988;14(1):23-30 [3217283.001]
  • [Cites] Neurosurgery. 1988 Sep;23(3):384-9 [3226520.001]
  • [Cites] Pediatr Neurosci. 1988;14(3):134-9 [3075286.001]
  • [Cites] AJNR Am J Neuroradiol. 1991 May-Jun;12(3):564-5 [2058519.001]
  • [Cites] Cancer. 1992 Jan 15;69(2):580-5 [1728390.001]
  • [Cites] J Neurooncol. 1992 Jan;12(1):69-74 [1541980.001]
  • [Cites] N Engl J Med. 1992 Apr 9;326(15):988-93 [1312224.001]
  • [Cites] Brain Dev. 1991 Nov;13(6):438-41 [1667249.001]
  • [Cites] Neurosurgery. 1992 Sep;31(3):563-6 [1383866.001]
  • [Cites] Cancer. 1993 Feb 1;71(3):855-8 [8431869.001]
  • [Cites] Hum Genet. 1993 Feb;90(6):611-3 [8444466.001]
  • [Cites] Hum Genet. 1994 Feb;93(2):227 [8112757.001]
  • [Cites] Neurosurgery. 1994 May;34(5):910-2; discussion 912 [8052392.001]
  • [Cites] Br J Neurosurg. 1994;8(2):169-77 [7917088.001]
  • [Cites] Pediatr Neurosurg. 1995;22(4):189-96 [7619719.001]
  • [Cites] Brain Dev. 1995 Jul-Aug;17(4):283-5 [7503393.001]
  • [Cites] Neurol Med Chir (Tokyo). 1995 Oct;35(10):742-4 [8532130.001]
  • [Cites] Med Pediatr Oncol. 1997 Oct;29(4):293-5 [9251736.001]
  • [Cites] Neurosurgery. 1998 Mar;42(3):470-5 [9526979.001]
  • [Cites] Lancet. 1999 Jun 19;353(9170):2126 [10382700.001]
  • [Cites] Virology. 1995 Oct 1;212(2):710-7 [7571441.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 May;17(5):939-42 [8733971.001]
  • [Cites] Neuropediatrics. 1996 Jun;27(3):143-8 [8837074.001]
  • [Cites] Cancer Res. 1996 Oct 15;56(20):4820-5 [8841004.001]
  • [Cites] Acta Neurochir (Wien). 1996;138(7):802-10 [8869707.001]
  • [Cites] Histopathology. 1996 Aug;29(2):147-51 [8872148.001]
  • [Cites] Pathol Res Pract. 1996 Aug;192(8):840-4 [8897520.001]
  • [Cites] Am J Pathol. 1997 Jan;150(1):1-13 [9006316.001]
  • [Cites] J Korean Med Sci. 1997 Apr;12(2):162-7 [9170025.001]
  • [Cites] Neurosurgery. 1997 Jun;40(6):1279-82 [9179902.001]
  • [Cites] Eur J Hum Genet. 1997 Mar-Apr;5(2):61-8 [9195154.001]
  • [Cites] Tumori. 1989 Oct 31;75(5):463-9 [2690434.001]
  • (PMID = 12402146.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis
  • [Publication-country] Scotland
  • [Other-IDs] NLM/ PMC2376189
  •  go-up   go-down


41. Manoharan C, Singh J: Evaluation of polyanhydride microspheres for basal insulin delivery: Effect of copolymer composition and zinc salt on encapsulation, in vitro release, stability, in vivo absorption and bioactivity in diabetic rats. J Pharm Sci; 2009 Nov;98(11):4237-50
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The potential of poly 1,3-bis-(p-carboxyphenoxy) propane-co-sebacic acid (p(CPP:SA)) microspheres was investigated for controlled delivery of basal insulin.
  • CPP:SA copolymers with molar compositions of 20:80, 40:60, and 50:50 were synthesized, characterized, and used in the fabrication of microspheres by water-in-oil-in-water double emulsion solvent evaporation technique.
  • Insulin encapsulation efficiency (EE) and in vitro release kinetics were influenced by the molar ratios of CPP:SA copolymer.
  • Increasing CPP content and addition of zinc oxide increased EE, reduced burst release, and prolonged insulin in vitro release over a month.
  • Dimer aggregates were observed for insulin encapsulated in CPP:SA 50:50 microspheres and addition of zinc oxide prevented dimer formation.
  • Subcutaneous administration of CPP:SA 50:50 microspheres in diabetic rats controlled insulin release over a month, and the released insulin was bioactive as determined by lowering blood glucose levels.
  • The results indicate that CPP:SA microspheres controlled insulin release in vitro and in vivo over a month and the released insulin was conformationally and chemically stable, and bioactive.
  • [MeSH-minor] Absorption. Animals. Blood Glucose / metabolism. Chemistry, Pharmaceutical. Diabetes Mellitus, Experimental / drug therapy. Drug Carriers / chemistry. Drug Compounding. Drug Delivery Systems. Drug Stability. Insulin, Long-Acting. Kinetics. Male. Microscopy, Electron, Scanning. Molecular Structure. Molecular Weight. Particle Size. Polymers / chemical synthesis. Polymers / chemistry. Rats. Rats, Sprague-Dawley. Technology, Pharmaceutical / methods

  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • Hazardous Substances Data Bank. ZINC COMPOUNDS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc. and the American Pharmacists Association
  • (PMID = 19472196.001).
  • [ISSN] 1520-6017
  • [Journal-full-title] Journal of pharmaceutical sciences
  • [ISO-abbreviation] J Pharm Sci
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Drug Carriers; 0 / Hypoglycemic Agents; 0 / Insulin; 0 / Insulin, Long-Acting; 0 / Polyanhydrides; 0 / Polymers; 0 / Zinc Compounds
  •  go-up   go-down


42. Yu LL, Wang XY, Zhao M, Liu Y, Li YQ, Li FQ, Wang X, Xue YX, Lu L: Effects of cannabinoid CB1 receptor antagonist rimonabant in consolidation and reconsolidation of methamphetamine reward memory in mice. Psychopharmacology (Berl); 2009 Jun;204(2):203-11
Hazardous Substances Data Bank. d-METHAMPHETAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: The purpose of this study was to examine whether rimonabant, a cannabinoid CB1 receptor antagonist, would disrupt the consolidation and reconsolidation of methamphetamine-related reward memory, using conditioned place preference paradigm (CPP).
  • MATERIALS AND METHODS: Separate groups of male Kunming mice were trained to acquire methamphetamine CPP.
  • Vehicle or rimonabant (1 mg/kg or 3 mg/kg, i.p.) was given at different time points: immediately after each CPP training session (consolidation), 30 min before the reactivation of CPP (retrieval), or immediately after the reactivation of CPP (reconsolidation).
  • Methamphetamine CPP was retested 24 h and 1 and 2 weeks after rimonabant administration.
  • RESULTS: Rimonabant at doses of 1 and 3 mg/kg significantly inhibited the consolidation of methamphetamine CPP.
  • Only high-dose rimonabant (3 mg/kg) disrupted the retrieval and reconsolidation of methamphetamine CPP.
  • Rimonabant had no effect on methamphetamine CPP in the absence of methamphetamine CPP reactivation.
  • CONCLUSIONS: Our findings suggest that cannabinoid CB1 receptors play a major role in methamphetamine reward memory, and cannabinoid CB1 receptor antagonists may be a potential pharmacotherapy to manage relapse associated with drug-reward-related memory.
  • [MeSH-major] Central Nervous System Stimulants / pharmacology. Memory / drug effects. Methamphetamine / pharmacology. Piperidines / pharmacology. Pyrazoles / pharmacology. Receptor, Cannabinoid, CB1 / antagonists & inhibitors
  • [MeSH-minor] Animals. Dose-Response Relationship, Drug. Male. Mice. Reward

  • MedlinePlus Health Information. consumer health - Memory.
  • MedlinePlus Health Information. consumer health - Methamphetamine.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurobiol Learn Mem. 2008 Jul;90(1):1-9 [18342551.001]
  • [Cites] Drug Alcohol Rev. 2008 May;27(3):236-42 [18368604.001]
  • [Cites] Addiction. 1996 Jul;91(7):921-49; discussion 951-65 [8688822.001]
  • [Cites] Learn Mem. 2006 May-Jun;13(3):316-21 [16705137.001]
  • [Cites] Eur J Neurosci. 2007 Apr;25(7):2191-200 [17419755.001]
  • [Cites] Annu Rev Neurosci. 2007;30:123-52 [17417939.001]
  • [Cites] Neuropharmacology. 2002 Oct;43(5):857-67 [12384171.001]
  • [Cites] Eur J Neurosci. 2004 Oct;20(7):1849-57 [15380006.001]
  • [Cites] Acta Pharmacol Sin. 2007 Oct;28(10):1505-18 [17883935.001]
  • [Cites] Nat Med. 2001 Oct;7(10 ):1151-4 [11590440.001]
  • [Cites] J Neurosci. 2008 May 21;28(21):5602-10 [18495894.001]
  • [Cites] Nature. 1993 Sep 2;365(6441):61-5 [7689702.001]
  • [Cites] Drug Alcohol Rev. 2008 May;27(3):253-62 [18368606.001]
  • [Cites] Neuroscience. 1998 Mar;83(2):393-411 [9460749.001]
  • [Cites] Psychopharmacology (Berl). 2006 Mar;185(1):19-28 [16374599.001]
  • [Cites] Dialogues Clin Neurosci. 2007;9(4):389-97 [18286799.001]
  • [Cites] Science. 2002 Apr 26;296(5568):678-82 [11976437.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2932-7 [16473939.001]
  • [Cites] Am J Addict. 2001 Summer;10(3):201-17 [11579619.001]
  • [Cites] J Neurosci. 2008 Dec 3;28(49):13248-57 [19052216.001]
  • [Cites] Brain Res. 2006 Feb 23;1075(1):60-7 [16464439.001]
  • [Cites] Trends Neurosci. 2003 Feb;26(2):65-72 [12536129.001]
  • [Cites] Ann N Y Acad Sci. 2004 Oct;1025:515-27 [15542757.001]
  • [Cites] Neurosci Lett. 2005 Jun 3;380(3):270-5 [15862900.001]
  • [Cites] J Psychopharmacol. 2002 Jun;16(2):139-43 [12095072.001]
  • [Cites] Drug Alcohol Rev. 2008 May;27(3):243-52 [18368605.001]
  • [Cites] Neuropsychopharmacology. 2004 Aug;29(8):1470-8 [15085091.001]
  • [Cites] Behav Brain Res. 2007 Mar 12;178(1):146-53 [17239969.001]
  • [Cites] Neurobiol Learn Mem. 2007 Jan;87(1):93-100 [16905344.001]
  • [Cites] Learn Mem. 2008 May 05;15(5):304-14 [18463174.001]
  • [Cites] J Neurochem. 2007 Dec;103(6):2505-17 [17953657.001]
  • [Cites] Nature. 2005 Sep 22;437(7058):556-9 [16100511.001]
  • [Cites] Drug Alcohol Rev. 2008 May;27(3):229-35 [18368603.001]
  • [Cites] Psychopharmacology (Berl). 2007 Apr;191(2):223-31 [17211653.001]
  • [Cites] Neuroreport. 2007 Jul 16;18(11):1153-6 [17589317.001]
  • [Cites] Hippocampus. 2001;11(1):8-17 [11261775.001]
  • [Cites] Learn Mem. 2006 Jul-Aug;13(4):426-30 [16882859.001]
  • [Cites] Eur J Pharmacol. 2008 Jul 28;589(1-3):122-6 [18534572.001]
  • [Cites] Alcohol Clin Exp Res. 2007 Dec;31(12):2001-5 [17949470.001]
  • [Cites] Am J Psychiatry. 2005 Aug;162(8):1414-22 [16055762.001]
  • [Cites] Drug Alcohol Rev. 2008 Mar;27(2):185-9 [18264880.001]
  • [Cites] Behav Pharmacol. 2005 Sep;16(5-6):395-404 [16148444.001]
  • [Cites] Eur J Pharmacol. 2003 Sep 23;477(3):213-7 [14522359.001]
  • [Cites] J Neurosci. 2001 Dec 1;21(23 ):9506-18 [11717385.001]
  • [Cites] Prog Neurobiol. 1999 Jul;58(4):315-48 [10368032.001]
  • [Cites] Neurobiol Learn Mem. 2005 Mar;83(2):119-24 [15721795.001]
  • [Cites] Pharmacol Biochem Behav. 2005 Jun;81(2):396-406 [15925401.001]
  • [Cites] J Pharmacol Exp Ther. 2005 Mar;312(3):875-83 [15525797.001]
  • [Cites] Alcohol Alcohol. 2005 Jan-Feb;40(1):46-53 [15582988.001]
  • [Cites] Neurosci Biobehav Rev. 2004 Jan;27(8):827-39 [15019432.001]
  • [Cites] Trends Pharmacol Sci. 1994 Oct;15(10):374-9 [7809953.001]
  • [Cites] Trends Pharmacol Sci. 2005 Aug;26(8):420-6 [15992935.001]
  • [Cites] Jpn J Pharmacol. 2000 Nov;84(3):229-36 [11138722.001]
  • [Cites] Neuron. 2005 Sep 15;47(6):873-84 [16157281.001]
  • [Cites] Nat Rev Neurosci. 2008 Mar;9(3):182-94 [18270514.001]
  • [Cites] J Neurosci. 1995 Mar;15(3 Pt 2):2301-11 [7891168.001]
  • [Cites] J Physiol Biochem. 2000 Mar;56(1):17-24 [10879677.001]
  • [Cites] Neuroreport. 2006 Sep 18;17(13):1443-7 [16932155.001]
  • [Cites] Nature. 1990 Aug 9;346(6284):561-4 [2165569.001]
  • [Cites] J Neurosci. 2006 Aug 16;26(33):8531-6 [16914679.001]
  • [Cites] Eur J Neurosci. 2007 Jun;25(11):3417-21 [17553010.001]
  • [Cites] Acta Pharmacol Sin. 2006 Feb;27(2):140-4 [16412261.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jul 10;104(28):11580-4 [17592122.001]
  • [Cites] Eur J Pharmacol. 2004 Sep 13;498(1-3):119-23 [15363985.001]
  • [Cites] Psychopharmacology (Berl). 2007 Dec;195(2):193-201 [17661018.001]
  • [Cites] Pharmacol Biochem Behav. 2005 Jun;81(2):387-95 [15935455.001]
  • [Cites] Neuropharmacology. 2004;47 Suppl 1:33-46 [15464124.001]
  • [Cites] Annu Rev Neurosci. 2006;29:565-98 [16776597.001]
  • [Cites] Neurocase. 2001;7(5):357-82 [11744778.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):1393-8 [12538878.001]
  • [Cites] Neurobiol Learn Mem. 2008 Sep;90(2):374-81 [18524639.001]
  • [Cites] Trends Neurosci. 2006 Dec;29(12):695-703 [17084911.001]
  • [Cites] Trends Neurosci. 1990 Oct;13(10):420-3 [1700516.001]
  • [Cites] Pharmacol Biochem Behav. 2005 Jun;81(2):263-84 [15936806.001]
  • (PMID = 19148622.001).
  • [ISSN] 1432-2072
  • [Journal-full-title] Psychopharmacology
  • [ISO-abbreviation] Psychopharmacology (Berl.)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Central Nervous System Stimulants; 0 / Piperidines; 0 / Pyrazoles; 0 / Receptor, Cannabinoid, CB1; 44RAL3456C / Methamphetamine; RML78EN3XE / rimonabant
  •  go-up   go-down


43. Pelissier T, Infante C, Constandil L, Espinosa J, Lapeyra CD, Hernández A: Antinociceptive effect and interaction of uncompetitive and competitive NMDA receptor antagonists upon capsaicin and paw pressure testing in normal and monoarthritic rats. Pain; 2008 Jan;134(1-2):113-27
Hazardous Substances Data Bank. CAPSAICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We assessed whether intrathecal administration of the uncompetitive and competitive NMDA receptor antagonists ketamine and (+/-)CPP, respectively, could produce differential modulation on chemical and mechanical nociception in normal and monoarthritic rats.
  • In addition, the antinociceptive interaction of ketamine and (+/-)CPP on monoarthritic pain was also studied using isobolographic analysis.
  • Four weeks later, the antinociceptive effect of intrathecal administration of the drugs alone or combined was evaluated by using the intraplantar capsaicin and the paw pressure tests.
  • Ketamine (0.1, 1, 10, 30, 100, 300 and 1000 microg i.t.) and (+/-)CPP (0.125, 2.5, 7.5, 12.5, 25 and 50 microg i.t.) produced significantly greater dose-dependent antinociception in the capsaicin than in the paw pressure test.
  • The efficacy of the drugs, alone or combined, is likely to depend on the differential sensitivity of tonic versus phasic pain and/or chemical versus mechanical pain to NMDA antagonists.
  • [MeSH-major] Analgesics / therapeutic use. Arthritis, Experimental / drug therapy. Excitatory Amino Acid Antagonists / therapeutic use. Pain / drug therapy. Receptors, N-Methyl-D-Aspartate / antagonists & inhibitors
  • [MeSH-minor] Animals. Binding, Competitive. Capsaicin / toxicity. Drug Interactions / physiology. Drug Therapy, Combination. Injections, Spinal. Pain Measurement / drug effects. Pain Measurement / methods. Physical Stimulation / methods. Pressure. Rats. Rats, Sprague-Dawley. Vocalization, Animal / drug effects. Vocalization, Animal / physiology

  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17517475.001).
  • [ISSN] 1872-6623
  • [Journal-full-title] Pain
  • [ISO-abbreviation] Pain
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Analgesics; 0 / Excitatory Amino Acid Antagonists; 0 / Receptors, N-Methyl-D-Aspartate; S07O44R1ZM / Capsaicin
  •  go-up   go-down


44. Eun JS, Bae K, Yun YP, Hong JT, Kwon HN, Oh KW: Inhibitory effects of paeonol on morphine-induced locomotor sensitization and conditioned place preference in mice. Arch Pharm Res; 2006 Oct;29(10):904-10
Hazardous Substances Data Bank. MORPHINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The inhibitory effects of paeonol, a major compound of Paeoniae radix, on the development of locomotor sensitization, conditioned place preference (CPP) and dopamine receptor supersensitivity induced by the repeated administration of morphine were investigated through behavioral experiments.
  • Repeated administration of morphine develops sensitization (reverse tolerance), a progressive enhancement of locomotion, which is used as a model for studying the drug-induced drug-seeking behaviors, and CPP, which is used as a model for studying drug reinforcement.
  • Paeonol inhibited morphine-induced hyperlocomotion, sensitization and CPP.
  • In addition, paeonol inhibited the development of postsynaptic dopamine receptors supersensitivity, which may be an underlying common mechanism that mediates the morphine-induced dopaminergic behaviors such as sensitization and CPP.
  • These results provide evidence that paeonol exerts anti-dopaminergic activity, and it is suggested that paeonol may be useful for the prevention and therapy of these adverse actions of morphine.
  • [MeSH-major] Acetophenones / pharmacology. Conditioning (Psychology) / drug effects. Morphine / antagonists & inhibitors. Motor Activity / drug effects. Spatial Behavior / drug effects
  • [MeSH-minor] Administration, Oral. Animals. Behavior, Animal / drug effects. Dopamine Antagonists / administration & dosage. Dopamine Antagonists / pharmacology. Dose-Response Relationship, Drug. Injections, Subcutaneous. Male. Mice. Mice, Inbred ICR. Paeonia / chemistry. Plant Roots / chemistry. Receptors, Dopamine / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17121187.001).
  • [ISSN] 0253-6269
  • [Journal-full-title] Archives of pharmacal research
  • [ISO-abbreviation] Arch. Pharm. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Acetophenones; 0 / Dopamine Antagonists; 0 / Receptors, Dopamine; 3R834EPI82 / paeonol; 76I7G6D29C / Morphine
  •  go-up   go-down


45. Heger S, Müller M, Ranke M, Schwarz HP, Waldhauser F, Partsch CJ, Sippell WG: Long-term GnRH agonist treatment for female central precocious puberty does not impair reproductive function. Mol Cell Endocrinol; 2006 Jul 25;254-255:217-20
Genetic Alliance. consumer health - Central precocious puberty.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term GnRH agonist treatment for female central precocious puberty does not impair reproductive function.
  • Depot gonadotropin releasing hormone (GnRH) agonist (GnRHa) therapy is the treatment of choice for patients with central precocious puberty (CPP).
  • The present study was performed on 46 women, former CPP patients, 12.5+/-3.7 years after the discontinuation of treatment with depot GnRHa.
  • In a structured interview, we assessed general health status, clinical signs possibly associated with hyperandrogenism, menstrual cycle, gynaecological diseases and reproductive function.
  • It appears that long-term treatment with depot GnRHa is safe and does not impair reproductive function.
  • The risk of former CPP patients to develop hirsutism and/or polycystic ovary syndrome does not seem to be increased compared to the normal population but this issue needs to be addressed in further long-term follow-up studies.
  • [MeSH-major] Gonadotropin-Releasing Hormone / agonists. Gonadotropin-Releasing Hormone / therapeutic use. Puberty, Precocious / drug therapy. Reproduction / drug effects
  • [MeSH-minor] Adult. Androgens / adverse effects. Body Height / drug effects. Body Mass Index. Body Weight / drug effects. Delayed-Action Preparations / administration & dosage. Drug Administration Routes. Female. Fertility / drug effects. Follow-Up Studies. Genital Diseases, Female / etiology. Health Status. Humans. Hyperandrogenism / diagnosis. Interviews as Topic. Long-Term Care. Menstrual Cycle / drug effects. Triptorelin Pamoate / therapeutic use

  • Genetic Alliance. consumer health - Precocious puberty.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16757104.001).
  • [ISSN] 0303-7207
  • [Journal-full-title] Molecular and cellular endocrinology
  • [ISO-abbreviation] Mol. Cell. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Androgens; 0 / Delayed-Action Preparations; 33515-09-2 / Gonadotropin-Releasing Hormone; 57773-63-4 / Triptorelin Pamoate
  •  go-up   go-down


46. Tao PL, Liang KW, Sung WY, Wu YT, Huang EY: Nalbuphine is effective in decreasing the rewarding effect induced by morphine in rats. Drug Alcohol Depend; 2006 Sep 15;84(2):175-81
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using the conditioned place preference (CPP) paradigm in rats, we demonstrated that co-administration of nalbuphine (1mg/kg, i.p.) with morphine (5mg/kg, i.p.) during conditioning could completely block the CPP induced by morphine.
  • All of these results suggest nalbuphine could have a great potential as a pharmacotherapy for opiate abuse.
  • [MeSH-major] Behavior, Animal / drug effects. Morphine / antagonists & inhibitors. Nalbuphine / pharmacology. Narcotic Antagonists / pharmacology. Reward
  • [MeSH-minor] 3,4-Dihydroxyphenylacetic Acid / metabolism. Animals. Chromatography, High Pressure Liquid. Conditioning (Psychology). Drug Tolerance. Homovanillic Acid / metabolism. Locomotion / drug effects. Male. Narcotics / administration & dosage. Narcotics / pharmacokinetics. Nucleus Accumbens / drug effects. Nucleus Accumbens / metabolism. Rats. Rats, Sprague-Dawley

  • Hazardous Substances Data Bank. MORPHINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16517095.001).
  • [ISSN] 0376-8716
  • [Journal-full-title] Drug and alcohol dependence
  • [ISO-abbreviation] Drug Alcohol Depend
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Narcotic Antagonists; 0 / Narcotics; 102-32-9 / 3,4-Dihydroxyphenylacetic Acid; 76I7G6D29C / Morphine; L2T84IQI2K / Nalbuphine; X77S6GMS36 / Homovanillic Acid
  •  go-up   go-down


47. Strojan P, Popović M, Surlan K, Jereb B: Choroid plexus tumors: a review of 28-year experience. Neoplasma; 2004;51(4):306-12

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Choroid plexus tumors: a review of 28-year experience.
  • The aims of the study were to review the patients with choroid plexus tumor (CPT) treated in Slovenia between 1972-1999, to calculate the incidence of CPTs, and to evaluate treatment results in respect to tumor histology and mode of therapy.
  • Twelve patients (7 females, 5 males), 0.8-43 years old (median 6.1 years; <15 years: 10/12,83%) with CPT, representing 0.36% of all intracranial tumors registered during the period under study, were identified.
  • There were eight papillomas (CPPs) and four carcinomas (CPCs) with no difference in age distribution between the groups.
  • Of seven patients with gross tumor resection in CPP group, one patient died of postoperative meningitis and one had local recurrence 1.6 years after surgery; the latter is disease-free 17.9 years after re-operation.
  • In the CPC-group, only the patient who received adjuvant BEP chemotherapy and craniospinal irradiation following incomplete surgery is alive with no signs of disease after 6.5 years.
  • Ten-year disease-specific survival for all CPTs and for CPP subgroup was 73% and 100%, respectively.
  • In Slovenia, CPTs represent 0.36% of intracranial tumors.
  • In CPPs, the treatment of choice is surgery alone.
  • For CPCs, adjuvant multiagent chemotherapy and craniospinal radiotherapy following surgery should be considered.
  • [MeSH-major] Choroid Plexus Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Brain Neoplasms / diagnosis. Brain Neoplasms / epidemiology. Brain Neoplasms / therapy. Carcinoma / diagnosis. Carcinoma / epidemiology. Carcinoma / therapy. Child. Child, Preschool. Female. Humans. Infant. Magnetic Resonance Imaging. Male. Papilloma, Choroid Plexus / diagnosis. Papilloma, Choroid Plexus / epidemiology. Papilloma, Choroid Plexus / therapy. Recurrence. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15254663.001).
  • [ISSN] 0028-2685
  • [Journal-full-title] Neoplasma
  • [ISO-abbreviation] Neoplasma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Slovakia
  •  go-up   go-down


48. Mascia L, Andrews PJ, McKeating EG, Souter MJ, Merrick MV, Piper IR: Cerebral blood flow and metabolism in severe brain injury: the role of pressure autoregulation during cerebral perfusion pressure management. Intensive Care Med; 2000 Feb;26(2):202-5
Hazardous Substances Data Bank. OXYGEN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebral blood flow and metabolism in severe brain injury: the role of pressure autoregulation during cerebral perfusion pressure management.
  • OBJECTIVE: To ascertain if norepinephrine can be used as part of the cerebral perfusion pressure (CPP) management to increase arterial blood pressure (MAP) without causing cerebral hyperemia after severe head injury (HI).
  • INTERVENTIONS: CPP management ( = 70 mmHg).
  • Pressure autoregulation (assessed by norepinephrine infusion) was defined intact if % CPP/%CVR < or = 2.
  • Norepinephrine increased CPP by 33 % (+/- 4).
  • CONCLUSIONS: During CPP management norepinephrine can be used to increase MAP without potentiating hyperemia if pressure autoregulation is preserved.
  • The assessment of pressure autoregulation should be considered as a guide for arterial pressure-oriented therapy after HI.
  • [MeSH-major] Brain Injuries / drug therapy. Brain Injuries / physiopathology. Cerebrovascular Circulation. Intracranial Pressure / drug effects. Norepinephrine / therapeutic use. Vasoconstrictor Agents / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Analysis of Variance. Blood Flow Velocity / drug effects. Blood Flow Velocity / physiology. Blood Pressure / drug effects. Blood Pressure / physiology. Female. Glasgow Coma Scale. Humans. Infusions, Intravenous. Intensive Care Units. Male. Middle Aged. Oxygen / metabolism. Prospective Studies. Ultrasonography, Doppler, Transcranial

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Norepinephrine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10784309.001).
  • [ISSN] 0342-4642
  • [Journal-full-title] Intensive care medicine
  • [ISO-abbreviation] Intensive Care Med
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Vasoconstrictor Agents; S88TT14065 / Oxygen; X4W3ENH1CV / Norepinephrine
  •  go-up   go-down


49. El-Gaidi MA, Eissa EM: Infantile intracranial neoplasms: characteristics and surgical outcomes of a contemporary series of 21 cases in an Egyptian referral center. Pediatr Neurosurg; 2010;46(4):272-82
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Infantile intracranial neoplasms: characteristics and surgical outcomes of a contemporary series of 21 cases in an Egyptian referral center.
  • OBJECTIVE: To investigate the demographic, clinical, radiological, pathological and surgical features and outcomes of infantile intracranial neoplasms, the second most common neoplasm in infants.
  • RESULTS: Out of 451 patients with primary intracranial neoplasms (age 0-14 years), 21 infants (<1 year) underwent surgery, representing 4.7% of total cases.
  • The most common tumor was choroid plexus papilloma (23.8%), followed by teratoma (19%) then astrocytoma and ependymoma (14.3% each).
  • Three patients received chemotherapy, but none received radiotherapy.
  • The statistically significant predictors of prognosis were the extent of resection and tumor grade.
  • CONCLUSION: Although the prognosis for infantile intracranial neoplasms is worse than for older children, an overall promising outcome with low operative morbidity and mortality was achieved using gross total excision and appropriate adjuvant chemotherapy as part of a multidisciplinary approach.
  • [MeSH-major] Brain Neoplasms / mortality. Brain Neoplasms / surgery. Papilloma, Choroid Plexus / mortality. Papilloma, Choroid Plexus / surgery
  • [MeSH-minor] Adolescent. Astrocytoma / drug therapy. Astrocytoma / mortality. Astrocytoma / surgery. Chemotherapy, Adjuvant. Child. Child, Preschool. Combined Modality Therapy. Egypt / epidemiology. Ependymoma / drug therapy. Ependymoma / mortality. Ependymoma / surgery. Female. Humans. Infant. Infant, Newborn. Male. Medulloblastoma / drug therapy. Medulloblastoma / mortality. Medulloblastoma / surgery. Morbidity. Neurilemmoma / drug therapy. Neurilemmoma / mortality. Neurilemmoma / surgery. Prognosis. Quality of Life. Referral and Consultation / statistics & numerical data. Retrospective Studies. Teratoma / drug therapy. Teratoma / mortality. Teratoma / surgery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 S. Karger AG, Basel.
  • (PMID = 21160236.001).
  • [ISSN] 1423-0305
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


50. Udy A, Boots R, Senthuran S, Stuart J, Deans R, Lassig-Smith M, Lipman J: Augmented creatinine clearance in traumatic brain injury. Anesth Analg; 2010 Dec;111(6):1505-10
Hazardous Substances Data Bank. Norepinephrine .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Augmented creatinine clearance in traumatic brain injury.
  • BACKGROUND: Hypertonic saline and/or norepinephrine infusion are routinely used to achieve a desired cerebral perfusion pressure (CPP) in the management of traumatic brain injury (TBI).
  • METHODS: This was an observational cohort study in TBI patients older than 16 years with normal serum creatinine concentrations, requiring maintenance of CPP.
  • Demographic data, use of vasoactive medications, fluid balance, feeding regimen, and hemodynamic variables were recorded throughout the study period.
  • The mean maximum CrCl was 179 mL/min/1.73 m(2) while receiving CPP therapy (95% confidence interval [CI], 159-198), returning to a mean of 111 mL/min/1.73 m(2) (95% CI, 91-131; P < 0.001) when measured after discharge from the intensive care unit.
  • The mean CrCl in the intensive care unit while not receiving CPP therapy was 150 mL/min/1.73 m(2) (95% CI, 134-167; P = 0.03).
  • The mean time to reach peak CrCl while receiving active treatment was 4.7 days (95% CI, 3.0-6.4).
  • CONCLUSIONS: Augmented CrCls are common in TBI patients receiving active management of CPP and persist even after discontinuation of such therapy.
  • Further work is needed to clarify the impact of such clearances on renally excreted drugs in this setting.
  • [MeSH-major] Adrenergic alpha-Agonists / administration & dosage. Brain Injuries / therapy. Creatinine / urine. Fluid Therapy. Norepinephrine / administration & dosage
  • [MeSH-minor] Adult. Biomarkers / urine. Female. Humans. Intensive Care Units. Intracranial Pressure / drug effects. Male. Queensland. Time Factors. Treatment Outcome. Up-Regulation. Young Adult

  • MedlinePlus Health Information. consumer health - Creatinine.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21048095.001).
  • [ISSN] 1526-7598
  • [Journal-full-title] Anesthesia and analgesia
  • [ISO-abbreviation] Anesth. Analg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adrenergic alpha-Agonists; 0 / Biomarkers; AYI8EX34EU / Creatinine; X4W3ENH1CV / Norepinephrine
  •  go-up   go-down


51. Shahrokhi N, Khaksari M, Soltani Z, Mahmoodi M, Nakhaee N: Effect of sex steroid hormones on brain edema, intracranial pressure, and neurologic outcomes after traumatic brain injury. Can J Physiol Pharmacol; 2010 Apr;88(4):414-21
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of sex steroid hormones on brain edema, intracranial pressure, and neurologic outcomes after traumatic brain injury.
  • Recent studies have reported that estrogen and progesterone have a neuroprotective effect after traumatic brain injury (TBI); however, the mechanism(s) for this effect have not yet been elucidated.
  • The aim of the present study was to investigate the role of sex steroid hormones on changes in brain edema, intracranial pressure (ICP), and cerebral perfusion pressure (CPP) after TBI in ovariectomized (OVX) rats.
  • ICP was measured in the spinal cord, and CPP was calculated by subtracting the mean arterial pressure (MAP) from ICP.
  • The results revealed that brain water content after TBI was lower (p < 0.001) in the estrogen and progesterone groups than in the vehicle group.
  • The CPP in the estrogen and progesterone groups increased after 24 h compared with vehicle (p < 0.001).
  • In conclusion, pharmacological doses of estrogen and progesterone improved ICP, CPP, and neurological scores after TBI in OVX rats, which implies that these hormones play a neuroprotective role in TBI.
  • [MeSH-major] Brain Edema / drug therapy. Brain Injuries / drug therapy. Estrogens / therapeutic use. Intracranial Pressure / drug effects. Progesterone / therapeutic use
  • [MeSH-minor] Animals. Drug Evaluation, Preclinical. Female. Nervous System Diseases. Ovariectomy. Rats. Rats, Wistar. Treatment Outcome

  • Hazardous Substances Data Bank. PROGESTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20555409.001).
  • [ISSN] 1205-7541
  • [Journal-full-title] Canadian journal of physiology and pharmacology
  • [ISO-abbreviation] Can. J. Physiol. Pharmacol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Estrogens; 4G7DS2Q64Y / Progesterone
  •  go-up   go-down


52. Lewis KA, Eugster EA: Experience with the once-yearly histrelin (GnRHa) subcutaneous implant in the treatment of central precocious puberty. Drug Des Devel Ther; 2009;3:1-5
SciCrunch. DrugBank: Data: Chemical .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Experience with the once-yearly histrelin (GnRHa) subcutaneous implant in the treatment of central precocious puberty.
  • In 2007, a hydrogel histrelin implant was approved for the treatment of children with central precocious puberty (CPP).
  • Children with CPP commonly have reduced height potential due to premature closure of the epiphyseal growth plates from exposure to sex steroids.
  • Gonadotropin-releasing hormone analog (GnRHa) treatment halts puberty and allows for improvement of adult height.
  • A hydrogel implant delivery system utilizing the potent GnRHa, histrelin, was first developed for use in men with prostate cancer.
  • A once yearly histrelin subcutaneous implant was subsequently developed for the treatment of children with CPP.
  • Studies to date have demonstrated safety, tolerability, and effectiveness of this treatment option in patients treated up to 2 years.
  • Cost of this treatment seems comparable to somewhat higher than the commonly used GnRHa treatment option, depot leuprolide.
  • While long term studies are needed to establish continued efficacy and safety beyond 2 years of treatment, the histrelin implant appears to be an attractive option for GnRHa treatment in patients with CPP.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr. 1986 Jan;108(1):47-54 [3080571.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Jan;84(1):44-9 [9920060.001]
  • [Cites] J Urol. 2000 Mar;163(3):838-44 [10687989.001]
  • [Cites] Eur J Pediatr. 2000 May;159(5):369-74 [10834524.001]
  • [Cites] Urology. 2001 Oct;58(4):578-82 [11597543.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Oct;86(10):4711-6 [11600530.001]
  • [Cites] Asian J Androl. 2008 Jul;10(4):525-34 [18478155.001]
  • [Cites] Pediatrics. 2005 Dec;116(6):e798-802 [16322137.001]
  • [Cites] J Urol. 2006 Apr;175(4):1353-8 [16515997.001]
  • [Cites] Curr Probl Pediatr Adolesc Health Care. 2007 Feb;37(2):50-72 [17223057.001]
  • [Cites] J Clin Endocrinol Metab. 2007 May;92(5):1697-704 [17327379.001]
  • [Cites] J Pediatr Endocrinol Metab. 2007 Nov;20(11):1189-98 [18183790.001]
  • [Cites] J Clin Pharmacol. 2005 Nov;45(11):1245-9 [16239357.001]
  • (PMID = 19920916.001).
  • [ISSN] 1177-8881
  • [Journal-full-title] Drug design, development and therapy
  • [ISO-abbreviation] Drug Des Devel Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC2769233
  • [Keywords] NOTNLM ; central precocious puberty / gonadotropin-releasing-hormone analogs / histrelin / implant
  •  go-up   go-down


53. Nabhan ZM, Feezle LK, Kunselman AR, Johnson NB, Lee PA: Normal adult height among girls treated for central precocious puberty with gonadotropin-releasing hormone analog therapy. J Pediatr Endocrinol Metab; 2009 Apr;22(4):309-16
Genetic Alliance. consumer health - Central precocious puberty.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Normal adult height among girls treated for central precocious puberty with gonadotropin-releasing hormone analog therapy.
  • AIM: To evaluate adult height (AH) among girls with central precocious puberty (CPP) treated with gonadotropin releasing hormone analog (GnRHa) and to assess the impact of posttreatment growth on AH.
  • STUDY DESIGN: Medical records of girls with CPP were reviewed.
  • There was a significant difference between AH and predicted adult height (PAH) at the initiation of therapy (p = 0.005).
  • Using univariate analysis, the only factor associated with AH was total growth after discontinuation of therapy.
  • Growth after discontinuation of therapy was variable and often greater than expected.
  • Both age and skeletal age at the end of therapy had strong linear relationships with growth after therapy explaining 60% of this growth.
  • CONCLUSION: This report confirms that AH is normal among females with CPP treated in a timely fashion with GnRHa.
  • The lack of predictability of growth after discontinuation of therapy suggests that the decision to stop treatment should be individualized.
  • [MeSH-major] Gonadotropin-Releasing Hormone / analogs & derivatives. Gonadotropin-Releasing Hormone / therapeutic use. Puberty, Precocious / drug therapy

  • Genetic Alliance. consumer health - Precocious puberty.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19554804.001).
  • [ISSN] 0334-018X
  • [Journal-full-title] Journal of pediatric endocrinology & metabolism : JPEM
  • [ISO-abbreviation] J. Pediatr. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 33515-09-2 / Gonadotropin-Releasing Hormone
  •  go-up   go-down


54. Fenton BW, Palmieri PA, Durner C, Fanning J: Quantification of abdominal wall pain using pain pressure threshold algometry in patients with chronic pelvic pain. Clin J Pain; 2009 Jul-Aug;25(6):500-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Chronic pelvic pain (CPP) is a syndrome involving 1 or more pain generating organs in the pelvis, which includes pain from the lower anterior abdominal wall.
  • In this study, pain pressure threshold (PPT) testing of the lower anterior abdominal wall in CPP patients was performed to determine the range and distribution of values at each site, and the clinical utility of using PPT in a definition of MFPS.
  • METHODS: Fifty-six patients evaluated in a CPP specialty clinic underwent PPT algometry of 14 sites on the lower anterior abdominal wall.
  • These values were described and evaluated before and after treatment.
  • PPT values were also evaluated in patients found to be drug seeking.
  • After trigger point injection there was a 75% improvement in PPT, and response to medical therapy resulted in a 60% improvement.
  • A composite measure was able to distinguish drug-seeking patients with statistical accuracy.
  • DISCUSSION: PPT testing can be used to evaluate MFPS in CPP patients.
  • [MeSH-major] Abdominal Pain / diagnosis. Abdominal Pain / etiology. Abdominal Wall / physiopathology. Pain Threshold / physiology. Pelvic Pain / complications. Pressure
  • [MeSH-minor] Analysis of Variance. Chronic Disease. Humans. Pain Measurement / methods. ROC Curve. Sensation

  • MedlinePlus Health Information. consumer health - Abdominal Pain.
  • MedlinePlus Health Information. consumer health - Pelvic Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19542798.001).
  • [ISSN] 1536-5409
  • [Journal-full-title] The Clinical journal of pain
  • [ISO-abbreviation] Clin J Pain
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


55. Biala G, Budzynska B, Staniak N: Effects of rimonabant on the reinstatement of nicotine-conditioned place preference by drug priming in rats. Behav Brain Res; 2009 Sep 14;202(2):260-5
Hazardous Substances Data Bank. MORPHINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of rimonabant on the reinstatement of nicotine-conditioned place preference by drug priming in rats.
  • Drug addiction is a chronic disorder characterized by a relatively high rate of relapse even after long period of abstinence.
  • In the present study, we used the conditioned place preference (CPP) paradigm to investigate the establishment, extinction, reinstatement and cross-reinstatement of nicotine-induced place conditioning in rats.
  • Nicotine produced a place preference to the initially less-preferred compartment paired with its injections during conditioning (0.5mg/kg, i.p., three drug sessions).
  • Once established, nicotine CPP was extinguished by repeated testing.
  • Following this extinction phase, the reinstatement of CPP was investigated.
  • These priming injections of both drugs induced a marked preference for the compartment previously paired with nicotine.
  • Furthermore, the objective of the present study was to evaluate the efficacy of CB1 cannabinoid receptor antagonist rimonabant (0.5, 1 and 2mg/kg, i.p.) in blocking the reinstatement of nicotine-induced CPP provoked by nicotine and morphine.
  • It was shown that rimonabant attenuated the reinstatement of nicotine-conditioned response induced by both drugs.
  • The outcome of our studies may suggest that CB1 receptor antagonists may become a promising target for effective pharmacotherapy of tobacco addiction and polydrug abuse.
  • [MeSH-major] Central Nervous System Agents / administration & dosage. Conditioning, Classical / drug effects. Morphine / administration & dosage. Nicotine / administration & dosage. Nicotinic Agonists / administration & dosage. Piperidines / administration & dosage. Pyrazoles / administration & dosage
  • [MeSH-minor] Analysis of Variance. Animals. Extinction, Psychological. Male. Random Allocation. Rats. Rats, Wistar. Receptor, Cannabinoid, CB1 / antagonists & inhibitors. Spatial Behavior / drug effects

  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Hazardous Substances Data Bank. NICOTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19463710.001).
  • [ISSN] 1872-7549
  • [Journal-full-title] Behavioural brain research
  • [ISO-abbreviation] Behav. Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Central Nervous System Agents; 0 / Nicotinic Agonists; 0 / Piperidines; 0 / Pyrazoles; 0 / Receptor, Cannabinoid, CB1; 158681-13-1 / rimonabant; 6M3C89ZY6R / Nicotine; 76I7G6D29C / Morphine
  •  go-up   go-down


56. Kunz GJ, Sherman TI, Klein KO: Luteinizing hormone (LH) and estradiol suppression and growth in girls with central precocious puberty: is more suppression better? Are pre-injection LH levels useful in monitoring treatment? J Pediatr Endocrinol Metab; 2007 Nov;20(11):1189-98
Hazardous Substances Data Bank. LEUPROLIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Luteinizing hormone (LH) and estradiol suppression and growth in girls with central precocious puberty: is more suppression better? Are pre-injection LH levels useful in monitoring treatment?
  • CONTEXT: Girls with central precocious puberty (CPP) are treated with gonadotropin releasing hormone (GnRH) analogues to suppress puberty.
  • Gonadotropin levels are used to monitor treatment, since estradiol is difficult to measure at low levels.
  • OBJECTIVE: We hypothesized that in girls treated for CPP, estradiol levels (by ultrasensitive bioassay) would correlate with the rate of skeletal maturation and linear growth velocity.
  • We also compared pre- and post-injection LH levels for monitoring treatment.
  • DESIGN: Thirty girls with CPP were followed for up to 2 years during treatment with leuprolide acetate depot at a dose of 0.3 mg/kg/28 days.
  • RESULTS: Estradiol levels were suppressed to below the detection limit in three-quarters of the girls and did not correlate with the rate of skeletal maturation or linear growth.
  • CONCLUSIONS: Greater LH suppression may improve height outcome in girls treated for CPP with GnRH analogues.
  • Pre-injection LH levels may be useful for monitoring treatment.
  • Further investigation is needed, with longer treatment duration, a range of doses, and ultimately final height.
  • [MeSH-major] Drug Monitoring / methods. Estradiol / blood. Fertility Agents, Female / therapeutic use. Growth / drug effects. Leuprolide / therapeutic use. Luteinizing Hormone / blood. Puberty, Precocious / drug therapy
  • [MeSH-minor] Body Height / drug effects. Bone and Bones / metabolism. Bone and Bones / pathology. Bone and Bones / radiography. Child. Child, Preschool. Delayed-Action Preparations. Female. Humans. Treatment Outcome

  • Genetic Alliance. consumer health - Precocious puberty.
  • Genetic Alliance. consumer health - Central precocious puberty.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18183790.001).
  • [ISSN] 0334-018X
  • [Journal-full-title] Journal of pediatric endocrinology & metabolism : JPEM
  • [ISO-abbreviation] J. Pediatr. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Delayed-Action Preparations; 0 / Fertility Agents, Female; 4TI98Z838E / Estradiol; 9002-67-9 / Luteinizing Hormone; EFY6W0M8TG / Leuprolide
  •  go-up   go-down


57. Lottes AE, Rundell AE, Geddes LA, Kemeny AE, Otlewski MP, Babbs CF: Sustained abdominal compression during CPR raises coronary perfusion pressures as much as vasopressor drugs. Resuscitation; 2007 Dec;75(3):515-24
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sustained abdominal compression during CPR raises coronary perfusion pressures as much as vasopressor drugs.
  • OBJECTIVES: This study investigated sustained abdominal compression as a means to improve coronary perfusion pressure (CPP) during cardiopulmonary resuscitation (CPR) and compared the resulting CPP augmentation with that achieved using vasopressor drugs.
  • METHOD: During electrically induced ventricular fibrillation in anesthetized, 30kg juvenile pigs, Thumper CPR was supplemented at intervals either by constant abdominal compression at 100-500mmHg using an inflated contoured cuff or by the administration of vasopressor drugs (epinephrine, vasopressin, or glibenclamide).
  • CPP before and after cuff inflation or drug administration was the end point.
  • RESULTS: Sustained abdominal compression at >200mmHg increases CPP during VF and otherwise standard CPR by 8-18mmHg.
  • The effect persists over practical ranges of chest compression force and duty cycle and is similar to that achieved with vasopressor drugs.
  • Constant abdominal compression also augments CPP after prior administration of epinephrine or vasopressin.
  • CONCLUSIONS: During CPR noninvasive abdominal compression with the inflatable contoured cuff rapidly elevates the CPP, sustains the elevated CPP as long as the device is inflated, and is immediately and controllably reversible upon device deflation.
  • Physical control of peripheral vascular resistance during CPR by abdominal compression has some advantages over pharmacological manipulation and deserves serious reconsideration, now that the limitations of pressor drugs during CPR have become better understood, including post-resuscitation myocardial depression and the need for intravenous access.
  • [MeSH-major] Cardiopulmonary Resuscitation / methods. Coronary Circulation / drug effects. Coronary Circulation / physiology. Vascular Resistance / physiology. Vasoconstrictor Agents / pharmacology
  • [MeSH-minor] Abdomen. Animals. Disease Models, Animal. Pressure. Sus scrofa. Ventricular Fibrillation / therapy

  • MedlinePlus Health Information. consumer health - CPR.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17630090.001).
  • [ISSN] 0300-9572
  • [Journal-full-title] Resuscitation
  • [ISO-abbreviation] Resuscitation
  • [Language] eng
  • [Grant] United States / NIBIB NIH HHS / EB / NGAR21EB001540
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Vasoconstrictor Agents
  •  go-up   go-down


58. Fishbain DA, Lewis JE, Cole B, Rosomoff RS, Rosomoff HL: Medicolegal rounds: medicolegal issues and alleged breaches of standards of medical care in a patient motor vehicle accident allegedly related to chronic opioid analgesic therapy. J Opioid Manag; 2007 Jan-Feb;3(1):16-20
Hazardous Substances Data Bank. METHADONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Medicolegal rounds: medicolegal issues and alleged breaches of standards of medical care in a patient motor vehicle accident allegedly related to chronic opioid analgesic therapy.
  • The objective of this medicolegal case report is to present the details of the case of a chronic pain patient (CPP) who was placed on chronic opioid analgesic therapy (COAT) and was involved in a motor vehicle accident, alleged in litigation to be related to COAT.
  • We aim to present both the plaintiffs and defendant's expert witnesses' opinions on whether the defendant physician fell below the "standard" in allowing the CPP to drive.
  • [MeSH-major] Accidents, Traffic / legislation & jurisprudence. Analgesics, Opioid / administration & dosage. Automobile Driving / standards. Methadone / therapeutic use. Pain / drug therapy. Pain, Intractable / drug therapy. Quality of Health Care / standards
  • [MeSH-minor] Adult. Chronic Disease. Expert Testimony. Florida. Humans. Male. Malpractice / legislation & jurisprudence. Pain Clinics / standards

  • MedlinePlus Health Information. consumer health - Pain.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17367090.001).
  • [ISSN] 1551-7489
  • [Journal-full-title] Journal of opioid management
  • [ISO-abbreviation] J Opioid Manag
  • [Language] eng
  • [Publication-type] Journal Article; Legal Cases
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics, Opioid; UC6VBE7V1Z / Methadone
  •  go-up   go-down


59. Mori T, Sasaki J, Aoyama Y, Sera T: Regulation of cancer-related growth factor expression by artificial zinc-finger proteins. Nucleic Acids Symp Ser (Oxf); 2006;(50):291-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One attractive approach to anticancer therapy is repression of expression of vascular endothelial growth factor (VEGF) gene, which is a potent target for prevention of tumor growth.
  • We demonstrated ATFs fused to CPPs, designated CPP-ATFs or designed regulatory proteins (DRPs), could penetrate into mammalian cells and transiently repress expression of a reporter gene, which was under control of the VEGF promoter/5'-UTR.
  • We discuss gene-regulatory properties of CPP-ATFs in detail.
  • [MeSH-minor] Gene Expression / drug effects. Genes, Reporter. Humans. Neoplasms / blood supply. Zinc Fingers

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17150932.001).
  • [ISSN] 1746-8272
  • [Journal-full-title] Nucleic acids symposium series (2004)
  • [ISO-abbreviation] Nucleic Acids Symp Ser (Oxf)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Carrier Proteins; 0 / PTD4-ATF protein; 0 / Recombinant Fusion Proteins; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


60. Szendei G, Hernádi Z, Dévényi N, Csapó Z: Is there any correlation between stages of endometriosis and severity of chronic pelvic pain? Possibilities of treatment. Gynecol Endocrinol; 2005 Aug;21(2):93-100
MedlinePlus Health Information. consumer health - Pelvic Pain.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is there any correlation between stages of endometriosis and severity of chronic pelvic pain? Possibilities of treatment.
  • We report herein findings on 181 patients, suffering from pelvic endometriosis confirmed by histology, whose main symptom was chronic pelvic pain (CPP).
  • The short form of the McGill pain questionnaire was used for the evaluation of CPP.
  • After the first operative intervention, therapy with a gonadotropin-releasing hormone (GnRH) analog was given for 6 months.
  • Second-look laparoscopy was performed 8-10 weeks after the end of GnRH-analog treatment, which was followed by a non-conventionally administered, monophasic oral contraceptive (OC) treatment.
  • In the long term, 118 patients received the non-conventionally administered, monophasic OC treatment, which contained a third-generation progestogen, to be taken continuously for at least 6 months.
  • The other 63 patients who did not receive OC treatment for one reason or another were evaluated as a control group.
  • We analyzed data on CPP before the first surgical intervention, then following therapy with the GnRH analog at the second-look operation, and then after 6, 12, 18 and 24 months.
  • We also reviewed potential causes of CPP, especially focused on endometriosis.
  • No correlation was found between the stage of endometriosis according to R-AFS score and the severity of CPP.
  • At the 24-month follow-up after second-look laparoscopy, the non-conventionally administered monophasic OC treatment was found not only to significantly reduce pain scores, but also the required radical operative solution (hysterectomy plus bilateral adnexectomy) for CPP by OC users.
  • [MeSH-major] Contraceptives, Oral, Combined / therapeutic use. Endometriosis / drug therapy. Gonadotropin-Releasing Hormone / therapeutic use. Pelvic Pain / prevention & control
  • [MeSH-minor] Combined Modality Therapy. Drug Administration Schedule. Dysmenorrhea / drug therapy. Dyspareunia / drug therapy. Female. Humans. Laparoscopy. Pain Measurement. Secondary Prevention

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16109595.001).
  • [ISSN] 0951-3590
  • [Journal-full-title] Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • [ISO-abbreviation] Gynecol. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Contraceptives, Oral, Combined; 33515-09-2 / Gonadotropin-Releasing Hormone
  •  go-up   go-down


61. Pillai A, Rajeev K, Chandi S, Unnikrishnan M: Intrinsic brainstem choroid plexus papilloma. Case report. J Neurosurg; 2004 Jun;100(6):1076-8
Hazardous Substances Data Bank. LOMUSTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrinsic brainstem choroid plexus papilloma. Case report.
  • The authors report an intrinsic brainstem lesion that was diagnosed initially as a pontine cavernoma, which finally proved to be a choroid plexus papilloma.
  • Choroid plexus papillomas are rare tumors of the central nervous system and are usually intraventricular in location.
  • The occurrence of this tumor in an intraparenchymal location is extremely rare, and its occurrence within the brainstem is previously unreported.
  • The authors also report a trial of chemotherapy with lomustine in the management of the residual tumor.
  • [MeSH-major] Brain Stem Neoplasms / pathology. Choroid Plexus Neoplasms / pathology. Glioma / pathology
  • [MeSH-minor] Antineoplastic Agents, Alkylating / therapeutic use. Female. Humans. Lomustine / therapeutic use. Middle Aged

  • Genetic Alliance. consumer health - Choroid Plexus Papilloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15200124.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 7BRF0Z81KG / Lomustine
  •  go-up   go-down


62. Lang EW, Chesnut RM: A bedside method for investigating the integrity and critical thresholds of cerebral pressure autoregulation in severe traumatic brain injury patients. Br J Neurosurg; 2000 Apr;14(2):117-26
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A bedside method for investigating the integrity and critical thresholds of cerebral pressure autoregulation in severe traumatic brain injury patients.
  • To avoid ischaemic secondary insults after severe head injury (SHI) it would be helpful to know the relationship between cerebral perfusion pressure (CPP) and intracranial pressure (ICP).
  • Mean arterial pressure (MAP) was varied to detect changes in intracranial pressure (ICP) indicative of intact AR.
  • Three types of responses were observed:.
  • (3) MAP elevation lowers ICP; Changes between types 1/2 and type 3 suggests AR breakpoints.
  • Varying response types and breakpoints were observed between and within patients.
  • Lower AR breakpoints were seen from 60 to 80 mmHg CPP, upper breakpoints were as high as 112.
  • CPP monitoring achieves a twofold utility in targeted therapy:.
  • Although the precise relationship between pAR breakpoints and the adequacy of cerebral perfusion to meet metabolic needs remains unclear, a technique such as described here is simple and has much to offer in targeting therapy toward specific pathophysiological processes in traumatic brain injury.
  • [MeSH-major] Brain Injuries / physiopathology. Homeostasis / physiology. Intracranial Pressure / physiology. Point-of-Care Systems
  • [MeSH-minor] Adolescent. Adult. Blood Pressure / drug effects. Blood Pressure / physiology. Cerebrovascular Circulation / drug effects. Cerebrovascular Circulation / physiology. Glasgow Coma Scale. Humans. Male. Middle Aged. Phenylephrine / pharmacology. Vasoconstrictor Agents / pharmacology

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. PHENYLEPHRINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10889883.001).
  • [ISSN] 0268-8697
  • [Journal-full-title] British journal of neurosurgery
  • [ISO-abbreviation] Br J Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Vasoconstrictor Agents; 1WS297W6MV / Phenylephrine
  •  go-up   go-down


63. Turk DC, Swanson KS, Gatchel RJ: Predicting opioid misuse by chronic pain patients: a systematic review and literature synthesis. Clin J Pain; 2008 Jul-Aug;24(6):497-508
MedlinePlus Health Information. consumer health - Pain.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, a minority may develop aberrant drug behaviors.
  • OBJECTIVE: To synthesize the evidence of published strategies for identifying at-risk patients to guide clinicians' decisions and practices for prescribing opioid treatment for chronic pain patients (CPP).
  • Studies were limited to human studies in the English language related to screening for predictors of aberrant drug behaviors in CPP who were prescribed long-term opioids.
  • We included studies reviewing, developing measures, or investigating outcomes related to screening for aberrant opioid behaviors in CPP.
  • RESULTS: We identified 6 published articles addressing clinician-based predictors of substance misuse of opioids and 9 published studies evaluating the predictive ability of clinical interviews and self-report measures for aberrant opioid behaviors in CPP.
  • CONCLUSION: Review of the published studies reveals that no one procedure or set of predictor variables is sufficient to identify CPP at-risk for opioid misuse or abuse.
  • Strong predictors include a personal history of illicit drug and alcohol abuse.
  • Prospective studies, especially ones with CPP who have not already been started on chronic opioid therapy, are needed.
  • [MeSH-major] Analgesics, Opioid / adverse effects. Opioid-Related Disorders / etiology. Pain / drug therapy
  • [MeSH-minor] Chronic Disease. Humans. MEDLINE / statistics & numerical data. Predictive Value of Tests

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18574359.001).
  • [ISSN] 1536-5409
  • [Journal-full-title] The Clinical journal of pain
  • [ISO-abbreviation] Clin J Pain
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / 5K23GM071400-03
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics, Opioid
  • [Number-of-references] 64
  •  go-up   go-down


64. Pak AC, Ashby CR Jr, Heidbreder CA, Pilla M, Gilbert J, Xi ZX, Gardner EL: The selective dopamine D3 receptor antagonist SB-277011A reduces nicotine-enhanced brain reward and nicotine-paired environmental cue functions. Int J Neuropsychopharmacol; 2006 Oct;9(5):585-602
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The selective dopamine D3 receptor antagonist SB-277011A reduces nicotine-enhanced brain reward and nicotine-paired environmental cue functions.
  • Increasing evidence suggests that enhanced dopamine (DA) neurotransmission in the nucleus accumbens (NAc) may play a role in mediating the reward and reinforcement produced by addictive drugs and in the attentional processing of drug-associated environmental cues.
  • The meso-accumbens DA system is selectively enriched with DA D3 receptors, a DA receptor subtype increasingly implicated in reward-related brain and behavioural processes.
  • From a variety of evidence, it has been suggested that selective DA D3 receptor antagonism may be a useful pharmacotherapeutic approach for treating addiction.
  • The present experiments tested the efficacy of SB-277011A, a selective DA D3 receptor antagonist, in rat models of nicotine-enhanced electrical brain-stimulation reward (BSR), nicotine-induced conditioned locomotor activity (LMA), and nicotine-induced conditioned place preference (CPP).
  • SB-277011A, given intraperitoneally within the dose range of 1-12 mg/kg, dose-dependently reduced nicotine-enhanced BSR, nicotine-induced conditioned LMA, and nicotine-induced CPP.
  • The results suggest that selective D3 receptor antagonism constitutes a new and promising pharmacotherapeutic approach to the treatment of nicotine dependence.
  • [MeSH-major] Brain / drug effects. Conditioning, Operant / drug effects. Dopamine Antagonists / pharmacology. Nicotine / pharmacology. Nicotinic Agonists / pharmacology. Nitriles / pharmacology. Reward. Tetrahydroisoquinolines / pharmacology
  • [MeSH-minor] Analysis of Variance. Animals. Area Under Curve. Association Learning / drug effects. Behavior, Animal / drug effects. Cues. Dose-Response Relationship, Drug. Drug Interactions. Male. Motor Activity / drug effects. Rats. Rats, Long-Evans

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. NICOTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pharmacol Exp Ther. 2000 Sep;294(3):1154-65 [10945872.001]
  • [Cites] Synapse. 1998 May;29(1):72-9 [9552176.001]
  • [Cites] Neuropsychopharmacology. 2003 Feb;28(2):329-38 [12589386.001]
  • [Cites] Behav Brain Res. 1998 Nov;96(1-2):185-8 [9821554.001]
  • [Cites] Annu Rev Psychol. 1989;40:191-225 [2648975.001]
  • [Cites] Pharmacol Biochem Behav. 1993 Oct;46(2):453-7 [8265701.001]
  • [Cites] Psychopharmacology (Berl). 2003 Dec;170(4):409-22 [12955296.001]
  • [Cites] Neuropsychopharmacology. 2003 Jun;28(6):1150-9 [12700684.001]
  • [Cites] Behav Neurosci. 1987 Apr;101(2):209-14 [3580122.001]
  • [Cites] Prog Neurobiol. 1998 Dec;56(6):613-72 [9871940.001]
  • [Cites] Eur J Pharmacol. 2001 Aug 24;426(1-2):R1-2 [11525784.001]
  • [Cites] Life Sci. 1996;58(25):PL365-72 [8649214.001]
  • [Cites] Psychopharmacology (Berl). 1995 Jul;120(1):10-20 [7480530.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 1989 Jan-Feb;339(1-2):208-13 [2725697.001]
  • [Cites] Nature. 1996 Jul 18;382(6588):255-7 [8717040.001]
  • [Cites] Science. 1975 Feb 14;187(4176):547-9 [1114313.001]
  • [Cites] Synapse. 1995 Oct;21(2):140-8 [8584975.001]
  • [Cites] Behav Pharmacol. 1995 Jun;6(4):333-347 [11224342.001]
  • [Cites] Behav Brain Res. 2000 Aug;113(1-2):97-103 [10942036.001]
  • [Cites] Ciba Found Symp. 1990;152:153-62; discussion 162-8 [2209252.001]
  • [Cites] Exp Clin Psychopharmacol. 1999 Feb;7(1):72-8 [10036612.001]
  • [Cites] Neuropharmacology. 2004;47 Suppl 1:190-201 [15464137.001]
  • [Cites] Synapse. 2003 Mar;47(3):176-83 [12494400.001]
  • [Cites] Neuroreport. 2003 Jan 20;14(1):93-8 [12544838.001]
  • [Cites] Synapse. 2002 May;44(2):61-3 [11891877.001]
  • [Cites] Eur J Pharmacol. 2000 Oct 27;407(1-2):47-51 [11050289.001]
  • [Cites] Eur J Pharmacol. 1988 Jul 7;151(2):233-42 [2844553.001]
  • [Cites] Respiration. 2002;69(5):381-4 [12232442.001]
  • [Cites] Pharmacol Rev. 1997 Sep;49(3):231-52 [9311022.001]
  • [Cites] Eur J Pharmacol. 2000 Mar 30;393(1-3):295-314 [10771025.001]
  • [Cites] Brain Res Brain Res Rev. 2005 Jul;49(1):77-105 [15960988.001]
  • [Cites] Eur J Pharmacol. 1987 Sep 23;141(3):395-9 [3666033.001]
  • [Cites] J Med Chem. 2000 May 4;43(9):1878-85 [10794704.001]
  • [Cites] Psychopharmacology (Berl). 1996 Feb;123(3):280-8 [8833421.001]
  • [Cites] Psychiatr Med. 1985;3(4):445-60 [2893431.001]
  • [Cites] Recent Adv Biol Psychiatry. 1961;4:288-309 [13916635.001]
  • [Cites] Synapse. 2000 Feb;35(2):160-2 [10611642.001]
  • [Cites] Neuropsychopharmacology. 2003 May;28(5):839-49 [12637956.001]
  • [Cites] J Neurosci. 2002 Nov 1;22(21):9595-603 [12417684.001]
  • [Cites] Behav Brain Res. 2003 Jul 14;143(1):65-74 [12842297.001]
  • [Cites] Neurosci Biobehav Rev. 1989 Summer-Fall;13(2-3):123-8 [2530477.001]
  • [Cites] Synapse. 2003 Jun 1;48(3):154-6 [12645041.001]
  • [Cites] Neuropharmacology. 2005 Sep;49(4):525-41 [15963538.001]
  • [Cites] Am J Addict. 2000 Fall;9(4):285-313 [11155784.001]
  • [Cites] Nicotine Tob Res. 2002 Aug;4(3):259-66 [12215234.001]
  • [Cites] Behav Brain Res. 1987 Oct;26(1):57-62 [3675835.001]
  • [Cites] NIDA Res Monogr. 1994;145:191-206 [8742814.001]
  • [Cites] Neuropsychopharmacology. 2003 Jul;28(7):1272-80 [12700694.001]
  • [Cites] Neuropsychobiology. 2002;45(2):87-94 [11893865.001]
  • [Cites] Synapse. 1997 May;26(1):93-4 [9097409.001]
  • [Cites] Pharmacol Biochem Behav. 1999 Apr;62(4):659-72 [10208371.001]
  • [Cites] Pharmacol Biochem Behav. 2005 May;81(1):190-7 [15894078.001]
  • [Cites] Psychopharmacology (Berl). 1976 Aug 17;48(3):311-8 [823588.001]
  • [Cites] Mol Psychiatry. 2003 Feb;8(2):225-30 [12610655.001]
  • [Cites] Physiol Behav. 1985 Sep;35(3):395-403 [3840902.001]
  • [Cites] Ann N Y Acad Sci. 1992 Jun 28;654:192-8 [1632583.001]
  • [Cites] J Neurosci. 1997 Nov 1;17(21):8580-7 [9334429.001]
  • [Cites] Synapse. 1998 Oct;30(2):181-93 [9723788.001]
  • [Cites] Drug Discov Today. 2005 Jul 1;10(13):917-25 [15993811.001]
  • [Cites] Br J Pharmacol. 1989 Sep;98(1):135-40 [2804543.001]
  • [Cites] Synapse. 1999 Jan;31(1):76-86 [10025686.001]
  • [Cites] Synapse. 2005 Jul;57(1):17-28 [15858839.001]
  • [Cites] Psychopharmacology (Berl). 2002 Feb;160(1):56-66 [11862374.001]
  • [Cites] Science. 1993 Jun 18;260(5115):1814-6 [8099761.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1976-81 [11172061.001]
  • [Cites] Curr Opin Pharmacol. 2005 Feb;5(1):107-18 [15661634.001]
  • [Cites] Behav Pharmacol. 2003 May;14(3):191-8 [12799520.001]
  • [Cites] J Neurosci. 2001 Aug 1;21(15):5841-6 [11466456.001]
  • [Cites] Pharmacol Biochem Behav. 1991 Jun;39(2):465-8 [1682950.001]
  • [Cites] Eur J Neurosci. 2005 Jun;21(12):3427-38 [16026480.001]
  • [Cites] Psychopharmacologia. 1960 Feb 12;1:251-6 [13834123.001]
  • [Cites] Eur J Pharmacol. 2001 Jul 20;424(2):85-90 [11476753.001]
  • [Cites] Psychopharmacology (Berl). 2000 May;149(4):388-96 [10867966.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4321-6 [10760299.001]
  • [Cites] Eur J Pharmacol. 1986 Dec 16;132(2-3):337-8 [3816984.001]
  • [Cites] Drugs Today (Barc). 2004 Apr;40(4):355-65 [15190388.001]
  • [Cites] Psychopharmacology (Berl). 1982;78(3):204-9 [6296898.001]
  • [Cites] Pharmacol Biochem Behav. 2001 Jan;68(1):135-45 [11274718.001]
  • [Cites] Pharmacol Biochem Behav. 1992 Apr;41(4):755-9 [1594644.001]
  • [Cites] Nature. 1999 Jul 22;400(6742):371-5 [10432116.001]
  • [Cites] Addiction. 2000 Aug;95(8):1173-83 [11092065.001]
  • [Cites] J Med Chem. 2005 Jun 2;48(11):3663-79 [15916415.001]
  • [Cites] Pharmacol Biochem Behav. 1994 Aug;48(4):853-62 [7972288.001]
  • [Cites] Pharmacol Biochem Behav. 1997 Aug;57(4):915-21 [9259024.001]
  • [Cites] Neuropsychopharmacology. 2003 Nov;28(11):1903-15 [12915863.001]
  • [Cites] Nat Med. 2003 Jun;9(6):762-7 [12740572.001]
  • [Cites] Psychopharmacology (Berl). 2005 May;179(3):567-75 [15619116.001]
  • [Cites] Behav Neurosci. 1993 Feb;107(1):161-5 [8095392.001]
  • [Cites] Psychopharmacology (Berl). 2005 Apr;178(4):481-92 [15765262.001]
  • [Cites] Psychopharmacology (Berl). 2004 Oct;176(1):57-65 [15083257.001]
  • [Cites] Brain Res. 1994 Aug 8;653(1-2):278-84 [7982062.001]
  • [Cites] Neuroreport. 1997 Jul 7;8(9-10):2373-7 [9243643.001]
  • [Cites] Neuropsychopharmacology. 2005 Apr;30(4):720-30 [15562293.001]
  • [Cites] Psychopharmacology (Berl). 1992;107(2-3):285-9 [1615127.001]
  • [Cites] Trends Pharmacol Sci. 1991 Dec;12(12):467-73 [1792691.001]
  • [Cites] Psychopharmacology (Berl). 1997 Nov;134(2):187-92 [9399383.001]
  • [Cites] J Pharmacol Exp Ther. 1994 Oct;271(1):294-301 [7965727.001]
  • [Cites] Can J Psychol. 1977 Dec;31(4):195-203 [608135.001]
  • (PMID = 16942635.001).
  • [ISSN] 1461-1457
  • [Journal-full-title] The international journal of neuropsychopharmacology
  • [ISO-abbreviation] Int. J. Neuropsychopharmacol.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 DA999999
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Dopamine Antagonists; 0 / Nicotinic Agonists; 0 / Nitriles; 0 / SB 277011; 0 / Tetrahydroisoquinolines; 6M3C89ZY6R / Nicotine
  • [Other-IDs] NLM/ NIHMS493706; NLM/ PMC3732043
  •  go-up   go-down


65. Johnston AJ, Steiner LA, Chatfield DA, Coles JP, Hutchinson PJ, Al-Rawi PG, Menon DK, Gupta AK: Effect of cerebral perfusion pressure augmentation with dopamine and norepinephrine on global and focal brain oxygenation after traumatic brain injury. Intensive Care Med; 2004 May;30(5):791-7
Hazardous Substances Data Bank. DOPAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of cerebral perfusion pressure augmentation with dopamine and norepinephrine on global and focal brain oxygenation after traumatic brain injury.
  • OBJECTIVE: To compare the effects of a cerebral perfusion pressure (CPP) intervention achieved with dopamine and norepinephrine after severe head injury.
  • PATIENTS: Eleven patients with a head injury, requiring dopamine or norepinephrine infusions to support CPP.
  • INTERVENTION: Cerebral tissue gas measurements were recorded using a multimodal sensor, and regional chemistry was assessed using microdialysis.
  • Patients received in, randomised order, either dopamine or norepinephrine to achieve and maintain a CPP of 65 mmHg, and then, following a 30-min period of stable haemodynamics, a CPP of 85 mmHg.
  • MEASUREMENTS AND RESULTS: The CPP augmentation with norepinephrine, but not with dopamine, resulted in a significant reduction in arterial-venous oxygen difference (37+/-11 vs 33+/-12 ml/l) and a significant increase in brain tissue oxygen (2.6+/-1.1 vs 3.0+/-1.1 kPa).
  • The CPP intervention did not significantly affect intracranial pressure.
  • There were no significant differences between norepinephrine and dopamine on cerebral oxygenation or metabolism either at baseline or following a CPP intervention; however, the response to a CPP intervention with dopamine seemed to be more variable than the response achieved with norepinephrine.
  • CONCLUSIONS: If CPP is to be raised to a level higher than 65-70 mmHg, then it is important to recognise that the response to the intervention may be unpredictable and that the vasoactive agent used may be of importance.
  • [MeSH-major] Brain Injuries / drug therapy. Cardiotonic Agents / therapeutic use. Dopamine / therapeutic use. Intracranial Pressure / drug effects. Norepinephrine / therapeutic use. Sympathomimetics / therapeutic use

  • Hazardous Substances Data Bank. Norepinephrine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neurochir Suppl. 1998;71:19-21 [9779132.001]
  • [Cites] J Neurotrauma. 2000 Jun-Jul;17(6-7):507-11 [10937893.001]
  • [Cites] Intensive Care Med. 1994;20(4):260-7 [8046119.001]
  • [Cites] Br J Pharmacol. 1980 Aug;69(4):543-4 [7437640.001]
  • [Cites] Anesth Analg. 1999 Mar;88(3):549-53 [10072004.001]
  • [Cites] Br Med Bull. 1999;55(1):226-58 [10695089.001]
  • [Cites] Intensive Care Med. 2001 Jan;27(1):101-6 [11280619.001]
  • [Cites] Neurosurgery. 1996 Jan;38(1):21-31 [8747947.001]
  • [Cites] J Trauma. 1987 Sep;27(9):1007-13 [3656462.001]
  • [Cites] J Neurosurg Anesthesiol. 1999 Oct;11(4):240-51 [10527142.001]
  • [Cites] J Neurotrauma. 2002 Nov;19(11):1421-32 [12490007.001]
  • [Cites] Acta Neurochir Suppl. 1998;71:162-5 [9779173.001]
  • [Cites] Curr Opin Crit Care. 2002 Apr;8(2):115-20 [12386511.001]
  • [Cites] Am J Physiol. 1977 Oct;233(4):H458-65 [199075.001]
  • [Cites] Am J Physiol. 1986 Oct;251(4 Pt 2):H824-33 [3766759.001]
  • [Cites] Br J Neurosurg. 2000 Feb;14(1):46-8 [10884885.001]
  • [Cites] Int J Clin Monit Comput. 1994 Nov;11(4):223-32 [7738416.001]
  • [Cites] Intensive Care Med. 2002 May;28(5):547-53 [12029400.001]
  • [Cites] Acta Neurochir Suppl. 2002;81:225-7 [12168310.001]
  • [Cites] J Physiol. 1978 Jan;274:149-56 [624991.001]
  • [Cites] J Neurosurg. 1995 Dec;83(6):949-62 [7490638.001]
  • [Cites] Acta Anaesthesiol Scand. 2000 Aug;44(7):886-94 [10939705.001]
  • [Cites] Curr Opin Crit Care. 2002 Apr;8(2):121-7 [12386512.001]
  • [Cites] Crit Care Med. 1999 Oct;27(10):2086-95 [10548187.001]
  • [Cites] Intensive Care Med. 2001 Jul;27(7):1215-23 [11534571.001]
  • (PMID = 15048550.001).
  • [ISSN] 0342-4642
  • [Journal-full-title] Intensive care medicine
  • [ISO-abbreviation] Intensive Care Med
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G9439390
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cardiotonic Agents; 0 / Sympathomimetics; VTD58H1Z2X / Dopamine; X4W3ENH1CV / Norepinephrine
  •  go-up   go-down


66. Endoh T, Ohtsuki T: Cellular siRNA delivery using cell-penetrating peptides modified for endosomal escape. Adv Drug Deliv Rev; 2009 Jul 25;61(9):704-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RNAi-mediated silencing of specific genes is a promising strategy for gene therapy.
  • To utilize RNAi for therapy, an efficient and safe method for delivery of RNA into the cell cytosol is necessary.
  • This review focuses on CPP-based RNA delivery strategies.
  • In using CPP-based RNA delivery, most of the RNA internalized by the cell is entrapped in endosomes.
  • [MeSH-minor] Amino Acid Sequence. Animals. Drug Carriers. Fluorescent Dyes. Gene Silencing. Genetic Therapy. Humans. Molecular Sequence Data. Photosensitizing Agents / pharmacology. RNA Interference. RNA-Binding Proteins / chemistry. RNA-Binding Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19383521.001).
  • [ISSN] 1872-8294
  • [Journal-full-title] Advanced drug delivery reviews
  • [ISO-abbreviation] Adv. Drug Deliv. Rev.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Drug Carriers; 0 / Fluorescent Dyes; 0 / Peptides; 0 / Photosensitizing Agents; 0 / RNA, Small Interfering; 0 / RNA-Binding Proteins
  • [Number-of-references] 74
  •  go-up   go-down


67. Groblewski PA, Lattal KM, Cunningham CL: Effects of D-cycloserine on extinction and reconditioning of ethanol-seeking behavior in mice. Alcohol Clin Exp Res; 2009 May;33(5):772-82
Hazardous Substances Data Bank. CYCLOSERINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: D-cycloserine (DCS), a partial N-methyl-D-aspartate receptor agonist, has been shown to enhance the extinction of both cocaine and amphetamine-induced conditioned place preference (CPP).
  • Thus, the current experiments examined the effects of DCS on the extinction and subsequent reconditioning of ethanol-induced CPP in mice.
  • METHODS: Male DBA/2J mice received either 2 or 4 pairings of ethanol (2 g/kg) with a conditioned stimulus (CS+) floor cue (and an equal number of saline pairings with a CS- floor cue on alternate days) resulting in either a weak or strong ethanol CPP, respectively.
  • Following conditioning of a strong ethanol CPP mice received saline or 30 mg/kg DCS prior to each of the twelve 30-minute choice extinction trials administered at 48-hour intervals.
  • Mice that had received conditioning of a weak ethanol CPP received saline, 30 or 60 mg/kg DCS immediately before each of the six 30-minute choice extinction trials.
  • Following successful ethanol CPP extinction, mice received reconditioning trials similar to the initial conditioning trials.
  • A final experiment examined the effects 12 DCS pre-exposures (15, 30, and 60 mg/kg) on initial conditioning of ethanol CPP.
  • RESULTS: First, we showed that 2 doses of DCS (30 and 60 mg/kg) did not have aversive properties that could confound the effects on extinction of CPP (Experiment 1).
  • Second, we showed that DCS (30 and 60 mg/kg) had no effect on the rate of extinction of either strong (Experiment 2) or weak (Experiment 3) ethanol-induced CPP.
  • Interestingly, DCS administered during extinction interfered with reconditioning of ethanol-induced CPP--an effect specific to reconditioning, as DCS pre-exposure did not influence initial ethanol CPP conditioning (Experiment 4).
  • CONCLUSIONS: These experiments show that although DCS showed no effect on extinction behavior, when given during extinction it interfered with subsequent reconditioning of ethanol CPP.
  • The mechanisms of this effect were not, however, due to nonspecific interference with learning because repeated DCS pre-exposures did not impair initial conditioning of ethanol CPP.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Behav Neurosci. 2006 Oct;120(5):1159-62 [17014266.001]
  • [Cites] Biol Psychiatry. 2006 Aug 15;60(4):369-75 [16919524.001]
  • [Cites] J Psychiatr Res. 2007 Sep;41(6):466-71 [16828803.001]
  • [Cites] Psychopharmacology (Berl). 2007 Apr;191(2):195-202 [17216157.001]
  • [Cites] Neurobiol Learn Mem. 2007 May;87(4):476-82 [17275356.001]
  • [Cites] Neuroreport. 2007 May 28;18(8):777-80 [17471065.001]
  • [Cites] Nat Protoc. 2006;1(4):1662-70 [17487149.001]
  • [Cites] Neurosci Behav Physiol. 2007 Jun;37(5):509-15 [17505804.001]
  • [Cites] Int Clin Psychopharmacol. 2007 Jul;22(4):230-7 [17519647.001]
  • [Cites] Behav Neurosci. 2007 Jun;121(3):501-14 [17592941.001]
  • [Cites] Behav Pharmacol. 2007 Sep;18(5-6):497-506 [17762518.001]
  • [Cites] Biol Psychiatry. 2007 Oct 15;62(8):835-8 [17588545.001]
  • [Cites] Amino Acids. 2008 Apr;34(3):485-95 [17690951.001]
  • [Cites] Neurobiol Learn Mem. 2008 Oct;90(3):504-10 [18672079.001]
  • [Cites] Alcohol Alcohol. 2008 Nov-Dec;43(6):626-9 [18945754.001]
  • [Cites] Psychopharmacology (Berl). 2009 Jan;202(1-3):403-9 [18695929.001]
  • [Cites] Psychopharmacology (Berl). 2009 Jan;202(1-3):397-402 [18781295.001]
  • [Cites] Epilepsy Res. 2000 Jul;40(2-3):109-21 [10863138.001]
  • [Cites] J Neurosci. 2002 Mar 15;22(6):2343-51 [11896173.001]
  • [Cites] Psychopharmacology (Berl). 2002 Apr;160(4):414-24 [11919669.001]
  • [Cites] Behav Brain Res. 2003 Mar 18;140(1-2):1-47 [12644276.001]
  • [Cites] Psychopharmacology (Berl). 2003 Dec;170(4):409-22 [12955296.001]
  • [Cites] Behav Neurosci. 2004 Jun;118(3):505-13 [15174928.001]
  • [Cites] Behav Brain Res. 1986 Sep;21(3):189-94 [2876714.001]
  • [Cites] Nature. 1987 Feb 5-11;325(6104):529-31 [2433595.001]
  • [Cites] Eur J Pharmacol. 1992 Oct 20;221(2-3):249-54 [1330624.001]
  • [Cites] Eur J Pharmacol. 1994 May 12;257(1-2):7-12 [8082709.001]
  • [Cites] Mol Pharmacol. 1995 Oct;48(4):717-23 [7476899.001]
  • [Cites] Neurochem Int. 1996 Sep;29(3):255-61 [8885284.001]
  • [Cites] Alcohol Alcohol Suppl. 1994;2:199-204 [8974336.001]
  • [Cites] Pharmacol Biochem Behav. 1997 Dec;58(4):1059-64 [9408214.001]
  • [Cites] Arch Gen Psychiatry. 2004 Nov;61(11):1136-44 [15520361.001]
  • [Cites] Am Rev Tuberc. 1956 Nov;74(5):802-6 [13372966.001]
  • [Cites] Biol Psychiatry. 2005 Apr 15;57(8):841-7 [15820704.001]
  • [Cites] Neurobiol Learn Mem. 2005 May;83(3):224-31 [15820858.001]
  • [Cites] Arch Gen Psychiatry. 2006 Mar;63(3):298-304 [16520435.001]
  • [Cites] Behav Brain Res. 2006 Sep 15;172(1):173-8 [16769132.001]
  • [Cites] Neuroscience. 2006 Nov 3;142(4):979-90 [16934411.001]
  • (PMID = 19298331.001).
  • [ISSN] 1530-0277
  • [Journal-full-title] Alcoholism, clinical and experimental research
  • [ISO-abbreviation] Alcohol. Clin. Exp. Res.
  • [Language] ENG
  • [Grant] United States / NIAAA NIH HHS / AA / AA007702-22; United States / NIAAA NIH HHS / AA / AA 007702; United States / NIDA NIH HHS / DA / R01 DA025922-02; United States / NIAAA NIH HHS / AA / T32 AA007468-20; United States / NIDA NIH HHS / DA / DA025922-02; United States / NIMH NIH HHS / MH / R01 MH077111-04; United States / NIAAA NIH HHS / AA / R01 AA007702-22; United States / NIDA NIH HHS / DA / DA 025922; United States / NIAAA NIH HHS / AA / T32 AA007468; United States / NIDA NIH HHS / DA / R01 DA025922; United States / NIAAA NIH HHS / AA / R37 AA007702; United States / NIMH NIH HHS / MH / R01 MH077111; United States / NIAAA NIH HHS / AA / AA007468-20; United States / NIAAA NIH HHS / AA / AA 007468; United States / NIMH NIH HHS / MH / MH 077111; United States / NIAAA NIH HHS / AA / R01 AA007702
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 3K9958V90M / Ethanol; 95IK5KI84Z / Cycloserine
  • [Other-IDs] NLM/ NIHMS187094; NLM/ PMC2883465
  •  go-up   go-down


68. Leung JC, Ragland N, Marphis T, Silverstein DM: NMDA agonists and antagonists induce renal culture cell toxicity. Med Chem; 2008 Nov;4(6):565-71
Hazardous Substances Data Bank. DIZOCILPINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The NMDA receptor (NMDAR) is expressed in the renal proximal tubule.
  • We studied the effect of NMDAR agonists and antagonists on renal cell survival in renal culture cells: proximal tubule-like opossum kidney (OK) and distal-tubule-like madine darby canine kidney cells (MDCK) cells.
  • Exposure of cells to the non-competitive NMDAR blocker MK-801 or the competitive NMDAR antagonist CPP induced a time and dose-dependent increase in cell death and apoptosis.
  • The presence of fetal bovine serum in the pre-incubation media attenuated the toxicity caused by MK-801 and CPP.
  • Finally, pre-treatment of OK cells with the renal cytoprotective glycine completely blunted the affect of MK-801 on renal cell survival.
  • [MeSH-major] Excitatory Amino Acid Agonists / pharmacology. Excitatory Amino Acid Antagonists / pharmacology. Kidney / cytology. Kidney / drug effects. Receptors, N-Methyl-D-Aspartate / antagonists & inhibitors
  • [MeSH-minor] Animals. Apoptosis / drug effects. Cell Line. Cell Survival / drug effects. Cells, Cultured. Dizocilpine Maleate / pharmacology. Dogs. Glycine / pharmacology. L-Lactate Dehydrogenase / metabolism. Opossums. Piperazines / toxicity

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GLYCINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18991741.001).
  • [ISSN] 1573-4064
  • [Journal-full-title] Medicinal chemistry (Shāriqah (United Arab Emirates))
  • [ISO-abbreviation] Med Chem
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Excitatory Amino Acid Agonists; 0 / Excitatory Amino Acid Antagonists; 0 / Piperazines; 0 / Receptors, N-Methyl-D-Aspartate; 100828-16-8 / 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid; 6LR8C1B66Q / Dizocilpine Maleate; EC 1.1.1.27 / L-Lactate Dehydrogenase; TE7660XO1C / Glycine
  •  go-up   go-down


69. Maffeis C, Franceschi R, Moghetti P, Camilot M, Lauriola S, Tatò L: Circulating ghrelin levels in girls with central precocious puberty are reduced during treatment with LHRH analog. Eur J Endocrinol; 2007 Jan;156(1):99-103
Hazardous Substances Data Bank. ESTRADIOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Circulating ghrelin levels in girls with central precocious puberty are reduced during treatment with LHRH analog.
  • No data are available for girls with central precocious puberty (CPP).
  • AIMS: To explore ghrelin changes before, during, and after GnRH analog treatment in girls with CPP.
  • SUBJECTS AND METHODS: A sample of 20 Caucasian girls (8.08 +/- 0.65 years of age) with CPP was recruited.
  • Height and weight, bone age, LH, FSH, 17beta estradiol (E(2)), and ghrelin were measured before starting treatment with GnRH analog, 18 months after therapy began and again 6 months after therapy discontinuation.
  • RESULTS: LH and E(2) serum levels decreased significantly during treatment (2.45 +/- 2.03 vs 0.67 +/- 0.49 UI/l, P < 0.01 and 28.17 +/- 9.7 vs 15 pmol/l, P < 0.01 respectively), returning to baseline levels after the discontinuation of therapy (4.75 +/- 1.66 UI/l and 29.23 +/- 6.99 pmol/l respectively).
  • LH peaked following LHRH stimulation significantly (P < 0.01) decreased during treatment (24.45 +/- 14.17 vs 1.3 +/- 0.18 UI/l) and then increased after therapy discontinuation (12.58 +/- 6.09, P < 0.01).
  • Ghrelin decreased significantly (P < 0.05) during treatment (1849 +/- 322 vs 1207 +/- 637 pg/ml), and increased, though not significantly (P = 0.09) after therapy withdrawal (1567 +/- 629 pg/ml).
  • CONCLUSIONS: Contrary to what is expected in physiologic puberty, where ghrelin is progressively reduced, the prepubertal hormone milieau induced by GnRHa treatment in patients suffering from central precocious puberty (CPP) did not promote an increase in ghrelin circulating levels.
  • Therefore, in CPP, ghrelin secretion seems to be independent from pubertal development per se.
  • Concomitant estrogen suppression during treatment may play a potential role in the regulation of ghrelin secretion in these girls.

  • Genetic Alliance. consumer health - Precocious puberty.
  • Genetic Alliance. consumer health - Central precocious puberty.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17218731.001).
  • [ISSN] 0804-4643
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ghrelin; 0 / Gonadal Steroid Hormones; 0 / Peptide Hormones; 33515-09-2 / Gonadotropin-Releasing Hormone; 4TI98Z838E / Estradiol; 9002-67-9 / Luteinizing Hormone
  •  go-up   go-down


70. Martín Díaz MJ, Soriano Guillén L, Muñoz Calvo MT, Pozo Román J, Argente Oliver J: [Triptorelin therapy in girls with central precocious puberty increases body mass index]. An Pediatr (Barc); 2006 Nov;65(5):428-33
Genetic Alliance. consumer health - Central precocious puberty.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Triptorelin therapy in girls with central precocious puberty increases body mass index].
  • [Transliterated title] El tratamiento con triptorelina en las niñas con pubertad precoz central provoca incremento del índice de masa corporal.
  • INTRODUCTION: The most important complications of central precocious puberty (CPP) in girls are loss of height and multiple psychosocial problems.
  • OBJECTIVES: To study the effect of triptorelin therapy in a cohort of girls with CPP.
  • PATIENTS AND METHODS: Thirty-four girls diagnosed with organic or idiopathic CPP and treated with monthly triptorelin were studied.
  • Age, height in standard deviation (SD), bone age (Greulich and Pyle), height prediction (Bayle-Pinneau), body mass index (BMI) in SD, uterine size (pelvic ultrasound), target height, cranial magnetic resonance imaging, triptorelin dose, and treatment duration were studied.
  • RESULTS: Triptorelin produced a statistically significant reduction in growth velocity and an increase in BMI after 1 year of therapy and these changes were maintained after discontinuation of therapy.
  • Adult height in patients with organic CPP was significantly lower than that in patients with idiopathic CPP.
  • Triptorelin can increase BMI in girls with CPP.
  • 2. The presence of an organic cause in patients with CPP worsens the prognosis for adult height.
  • 3. The Bayley-Pinneau prediction method for "average" bone age is useful for establishing a prognosis of adult height in girls with CPP treated with triptorelin.
  • [MeSH-major] Body Mass Index. Growth / drug effects. Luteolytic Agents / pharmacology. Puberty, Precocious / drug therapy. Triptorelin Pamoate / pharmacology

  • Genetic Alliance. consumer health - Precocious puberty.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17184602.001).
  • [ISSN] 1695-4033
  • [Journal-full-title] Anales de pediatría (Barcelona, Spain : 2003)
  • [ISO-abbreviation] An Pediatr (Barc)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Luteolytic Agents; 57773-63-4 / Triptorelin Pamoate
  •  go-up   go-down


71. Lamvu G, Williams R, Zolnoun D, Wechter ME, Shortliffe A, Fulton G, Steege JF: Long-term outcomes after surgical and nonsurgical management of chronic pelvic pain: one year after evaluation in a pelvic pain specialty clinic. Am J Obstet Gynecol; 2006 Aug;195(2):591-8; discussion 598-600
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The purpose of this study was to describe long-term outcomes for women with chronic pelvic pain (CPP) after evaluation in a CPP specialty clinic.
  • STUDY DESIGN: This was a prospective observational cohort study of women treated for CPP at the UNC Pelvic Pain clinic between 1993 and 2000.
  • The primary outcome was improvement in pain and the main exposure was treatment group: primarily medical (pharmacotherapy, psychotherapy, physical therapy, or combinations of the 3) or surgical (hysterectomy, resection or ablative procedures, oophrectomy, diagnostic surgery, pain mapping, vulvar or vestibular repair).
  • Univariate, bivariate, and multivariable analyses were performed to look for relationships between background characteristics, treatment group, and improvement in pain.
  • RESULTS: Of 370 participants; 189 had surgical treatment and 181 had medical treatment.
  • Improvement in pain was similar in both treatment groups and odds of improvement were equal even after adjusting for background characteristics, psychosocial comorbidity, and previous treatments.
  • CONCLUSION: One year after evaluation in a CPP specialty clinic, women experienced modest improvements in pain and depression after recommended surgical or nonsurgical treatment.
  • [MeSH-minor] Adolescent. Adult. Aged. Chronic Disease. Comorbidity. Depression / etiology. Female. Follow-Up Studies. Humans. Logistic Models. Middle Aged. Multivariate Analysis. Pain Measurement. Prospective Studies. Sex Offenses. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pelvic Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16729951.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Massart F, Parrino R, Placidi G, Massai G, Federico G, Saggese G: Prolactin secretion before, during, and after chronic gonadotropin-releasing hormone agonist treatments in children. Fertil Steril; 2005 Sep;84(3):719-24
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolactin secretion before, during, and after chronic gonadotropin-releasing hormone agonist treatments in children.
  • OBJECTIVE: To examine the effect of long-term administration of GnRH agonists (GnRHa) on PRL secretion in children affected by central precocious puberty (CPP) and growth hormone deficiency (GHD).
  • DESIGN: Prospective analysis of blood sampling before, during, and after GnRHa treatments.
  • PATIENT(S): One hundred nineteen and 93 children with a diagnosis of CPP and GHD, respectively.
  • INTERVENTION(S): Monthly depot injections of GnRHa drugs (leuprorelin acetate 3.75 mg [LA] and triptorelin 3.75 mg [TR]) administered to CPP and GHD patients for 40 and 24 months, respectively.
  • MAIN OUTCOME MEASURE(S): Serum PRL levels at baseline and after 6, 12, 18, 24, 30, 36, and 40 months of treatment with GnRHa were compared between CPP and GHD groups.
  • RESULT(S): Although serum PRL levels tended to be higher in TR- than in LA-treated patients, no significant difference in circulating PRL in basal condition and during GnRHa treatment was detected between the CPP and GHD groups.
  • However, five children (3.8%) developed hyperprolactinemia during TR treatment.
  • CONCLUSION(S): Although there are no general concerns about GnRHa treatment safety, careful PRL monitoring is required in GnRHa-treated children.
  • [MeSH-minor] Child. Child, Preschool. Female. Human Growth Hormone / blood. Human Growth Hormone / deficiency. Humans. Male. Prospective Studies. Puberty, Precocious / blood. Puberty, Precocious / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16169408.001).
  • [ISSN] 1556-5653
  • [Journal-full-title] Fertility and sterility
  • [ISO-abbreviation] Fertil. Steril.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone; 33515-09-2 / Gonadotropin-Releasing Hormone; 9002-62-4 / Prolactin
  •  go-up   go-down


73. Li Y, Jiang HL, Zhu KJ, Liu JH, Hao YL: Preparation, characterization and nasal delivery of alpha-cobrotoxin-loaded poly(lactide-co-glycolide)/polyanhydride microspheres. J Control Release; 2005 Nov 2;108(1):10-20
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, alpha-cobrotoxin was incorporated into the microspheres composed of poly(lactide-co-glycolide) (PLGA) and poly[1,3-bis(p-carboxy-phenoxy) propane-co-p-(carboxyethylformamido) benzoic anhydride] (P(CPP:CEFB)) and intranasally delivered to model rats in order to improve its analgesic activity.
  • Scanning electron micrograph (SEM) study indicated that P(CPP:CEFB) content played a considerable role on the morphology and degradation of the microspheres.
  • The presence of P(CPP:CEFB) in the microspheres increased their residence time at the surface of the nasal rat mucosa.
  • Compared with the free alpha-cobrotoxin and PLGA microspheres, PLGA/P(CPP:CEFB) microspheres showed an apparent increase in the strength and duration of the antinociceptive effect at the same dose of alpha-cobrotoxin (80 microg/kg body weight).
  • [MeSH-major] Analgesics, Non-Narcotic. Cobra Neurotoxin Proteins. Drug Delivery Systems. Pain / drug therapy. Polyglactin 910 / chemistry
  • [MeSH-minor] Administration, Intranasal. Animals. Drug Compounding. Drug Stability. Male. Microspheres. Nasal Mucosa / drug effects. Nasal Mucosa / metabolism. Nasal Mucosa / pathology. Rats. Rats, Wistar. Solubility. Time Factors

  • MedlinePlus Health Information. consumer health - Pain.
  • MedlinePlus Health Information. consumer health - Pain Relievers.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16125269.001).
  • [ISSN] 0168-3659
  • [Journal-full-title] Journal of controlled release : official journal of the Controlled Release Society
  • [ISO-abbreviation] J Control Release
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Analgesics, Non-Narcotic; 0 / Cobra Neurotoxin Proteins; 34346-01-5 / Polyglactin 910; 69344-74-7 / alpha-cobratoxin
  •  go-up   go-down


74. Okuhara K, Tajima T, Abe S, Satoh K, Nakae J, Shinohara N, Fujieda K: Gonadotropin-releasing hormone analog therapy failed to improve predicted final height in two children with central precocious puberty and microcephalus. Endocr J; 2000 Mar;47 Suppl:S129-32
Genetic Alliance. consumer health - Central precocious puberty.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gonadotropin-releasing hormone analog therapy failed to improve predicted final height in two children with central precocious puberty and microcephalus.
  • Long-acting gonadotropin-releasing hormone (GnRH) analog treatment for central precocious puberty (CPP) suppresses excessive bone maturation by inhibiting the pituitary-gonadal axis, and usually assures favorable results for growth potential.
  • Recently, we encountered two children with CPP and microcephalus in whom GnRH analog therapy arrested pubertal development, but could not suppress bone age maturation effectively.
  • The reason why these two cases did not respond to GnRH analog therapy remains unknown.
  • Our cases suggest that careful evaluation will be required especially for CPP with microcephalus throughout treatment with GnRH analog.
  • [MeSH-major] Body Height / drug effects. Gonadotropin-Releasing Hormone / analogs & derivatives. Microcephaly / complications. Puberty, Precocious / complications. Puberty, Precocious / drug therapy
  • [MeSH-minor] Adolescent. Child, Preschool. Female. Forecasting. Humans. Male. Treatment Failure

  • Genetic Alliance. consumer health - Precocious puberty.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10890201.001).
  • [ISSN] 0918-8959
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 33515-09-2 / Gonadotropin-Releasing Hormone
  •  go-up   go-down


75. Di Gennaro JL, Mack CD, Malakouti A, Zimmerman JJ, Armstead W, Vavilala MS: Use and effect of vasopressors after pediatric traumatic brain injury. Dev Neurosci; 2010;32(5-6):420-30
Hazardous Substances Data Bank. PHENYLEPHRINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use and effect of vasopressors after pediatric traumatic brain injury.
  • BACKGROUND: Vasopressors are commonly used to increase mean arterial blood pressure (MAP) and cerebral perfusion pressure (CPP) after traumatic brain injury (TBI), but there are few data comparing vasopressor effectiveness after pediatric TBI.
  • OBJECTIVE: To determine which vasopressor is most effective at increasing MAP and CPP in children with moderate-to-severe TBI.
  • We evaluated differences in MAP and CPP at 3 h after initiation of therapy between phenylephrine, dopamine and norepinephrine among patients who did not require a second vasopressor during this time.
  • Multivariate linear regression was used to adjust for age, gender, injury severity score and baseline MAP or CPP and to cluster by subject.
  • The most common initial medication was phenylephrine for 47 (57%).
  • Thirteen (16%) of the patients received a second vasopressor during the first 3 h of treatment and were thus not included in the regression analyses; these patients received more fluid resuscitation and exhibited higher in-hospital mortality (77 vs. 32%; p = 0.004) compared to patients receiving a single vasopressor.
  • The norepinephrine group exhibited a 5 mm Hg higher MAP (95% CI: -4 to 13; p = 0.31) and a 12 mm Hg higher CPP (95% CI: -2 to 26; p = 0.10) than the phenylephrine group, and a 5 mm Hg higher MAP (95% CI: -4 to 15; p = 0.27) and a 10 mm Hg higher CPP (95% CI: -5 to 25; p = 0.18) than the dopamine group.
  • However, in post hoc analysis, after adjusting for time to start of vasopressor, hypertonic saline and pentobarbital, the effect on MAP was lost, but the CPP was 8 mm Hg higher (95% CI: -10 to 25; p = 0.39) than in the phenylephrine group, and 5 mm Hg higher (95% CI: -14 to 24; p = 0.59) than in the dopamine group.
  • While there was no statistically significant difference in MAP or CPP between vasopressor groups, norepinephrine was associated with a clinically relevant higher CPP and lower intracranial pressure at 3 h after start of vasopressor therapy compared to the other vasopressors examined.
  • [MeSH-major] Brain / drug effects. Brain Injuries / drug therapy. Vasoconstrictor Agents / therapeutic use
  • [MeSH-minor] Adolescent. Blood Pressure / drug effects. Child. Child, Preschool. Cohort Studies. Dopamine / therapeutic use. Female. Humans. Infant. Infant, Newborn. Male. Norepinephrine / therapeutic use. Phenylephrine / therapeutic use. Retrospective Studies

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Norepinephrine .
  • Hazardous Substances Data Bank. DOPAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 S. Karger AG, Basel.
  • [Cites] Intensive Care Med. 2001 Jan;27(1):101-6 [11280619.001]
  • [Cites] Crit Care Med. 2009 Nov;37(11):2968-72 [19770747.001]
  • [Cites] Crit Care Med. 2002 Apr;30(4):739-45 [11940738.001]
  • [Cites] Crit Care Med. 2002 Jul;30(7):1630-5 [12130990.001]
  • [Cites] Acta Neurochir Suppl. 2002;81:225-7 [12168310.001]
  • [Cites] J Neurosurg. 2002 Aug;97(2):326-36 [12186460.001]
  • [Cites] J Neurotrauma. 2002 Nov;19(11):1421-32 [12490007.001]
  • [Cites] Pediatr Crit Care Med. 2003 Jul;4(3 Suppl):S45-8 [12847348.001]
  • [Cites] J Trauma. 2003 Dec;55(6):1039-44 [14676648.001]
  • [Cites] Crit Care Med. 2004 Apr;32(4):1049-54 [15071400.001]
  • [Cites] Intensive Care Med. 2004 May;30(5):791-7 [15048550.001]
  • [Cites] Neuropediatrics. 1984 May;15(2):68-75 [6738819.001]
  • [Cites] J Trauma. 1987 Sep;27(9):1007-13 [3656462.001]
  • [Cites] Arch Dis Child. 1992 Dec;67(12):1430-5 [1489220.001]
  • [Cites] J Trauma. 1993 Feb;34(2):216-22 [8459458.001]
  • [Cites] Acta Neurochir Suppl (Wien). 1993;59:121-5 [8310858.001]
  • [Cites] J Pediatr Surg. 1998 Feb;33(2):333-8 [9498412.001]
  • [Cites] Acta Neurochir Suppl. 1998;71:19-21 [9779132.001]
  • [Cites] J Appl Physiol (1985). 2005 Oct;99(4):1545-51 [15976364.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2006 Feb;77(2):234-40 [16103043.001]
  • [Cites] J Physiol. 2006 Oct 15;576(Pt 2):569-83 [16873404.001]
  • [Cites] J Head Trauma Rehabil. 2006 Nov-Dec;21(6):544-8 [17122685.001]
  • [Cites] Shock. 2009 Aug;32(2):190-3 [19174739.001]
  • [Cites] Crit Care Med. 2008 Sep;36(9):2641-50 [18679110.001]
  • [Cites] J Neurotrauma. 2009 May;26(5):657-63 [19292656.001]
  • [Cites] J Trauma. 2000 Oct;49(4):654-8; discussion 658-9 [11038082.001]
  • [Cites] Shock. 2007 Apr;27(4):416-21 [17414425.001]
  • [Cites] J Neurotrauma. 2007;24 Suppl 1:S7-13 [17511549.001]
  • [Cites] J Neurosurg. 2007 Jun;106(6 Suppl):463-6 [17566403.001]
  • [Cites] Br J Anaesth. 2007 Jul;99(1):4-9 [17573392.001]
  • [Cites] Childs Nerv Syst. 2008 Feb;24(2):245-51 [17712566.001]
  • [Cites] J Neurotrauma. 2001 Nov;18(11):1247-54 [11721743.001]
  • (PMID = 21124016.001).
  • [ISSN] 1421-9859
  • [Journal-full-title] Developmental neuroscience
  • [ISO-abbreviation] Dev. Neurosci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Vasoconstrictor Agents; 1WS297W6MV / Phenylephrine; VTD58H1Z2X / Dopamine; X4W3ENH1CV / Norepinephrine
  • [Other-IDs] NLM/ PMC3073759
  •  go-up   go-down


76. Powers MS, Barrenha GD, Mlinac NS, Barker EL, Chester JA: Effects of the novel endocannabinoid uptake inhibitor, LY2183240, on fear-potentiated startle and alcohol-seeking behaviors in mice selectively bred for high alcohol preference. Psychopharmacology (Berl); 2010 Dec;212(4):571-83
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Evidence suggests that the endocannabinoid system (ECS) is a promising therapeutic target for the treatment of individuals with anxiety and/or alcohol-use disorders.
  • We examined the effects of LY2183240 on the expression of FPS in HAP and LAP mice and on alcohol-induced conditioned place preference (CPP) and limited-access alcohol drinking behavior in HAP mice.
  • Both the 10 and 30 mg/kg doses of LY2183240 enhanced the expression of alcohol-induced CPP and this effect persisted in the absence of the drug.
  • LY2183240 may be an effective pharmacotherapy for individuals with anxiety disorders, such as post-traumatic stress disorder, but may not be appropriate for individuals with co-morbid anxiety and alcohol-use disorders.

  • MedlinePlus Health Information. consumer health - Alcohol.
  • MedlinePlus Health Information. consumer health - Anxiety.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. UREA .
  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Psychopharmacology (Berl). 2008 Jun;198(3):405-11 [18446325.001]
  • [Cites] Psychopharmacology (Berl). 2008 Jul;198(4):449-60 [18446329.001]
  • [Cites] Neurobiol Learn Mem. 2008 Jul;90(1):290-3 [18486502.001]
  • [Cites] Alcohol Clin Exp Res. 2008 Oct;32(10):1782-94 [18652593.001]
  • [Cites] Eur Neuropsychopharmacol. 2008 Dec;18(12):849-59 [18706790.001]
  • [Cites] Learn Mem. 2008 Nov;15(11):806-9 [18957525.001]
  • [Cites] Physiol Rev. 2009 Jan;89(1):309-80 [19126760.001]
  • [Cites] Psychopharmacology (Berl). 2009 Jun;204(2):203-11 [19148622.001]
  • [Cites] Cell Calcium. 2009 Jun;45(6):611-24 [19356798.001]
  • [Cites] Pharmacol Biochem Behav. 2009 Nov;94(1):154-62 [19698735.001]
  • [Cites] Pharmacol Biochem Behav. 2010 Apr;95(2):258-65 [20138906.001]
  • [Cites] J Neurosci Res. 2000 Apr 1;60(1):122-8 [10723075.001]
  • [Cites] J Clin Psychiatry. 2000;61 Suppl 7:22-32 [10795606.001]
  • [Cites] Alcohol Res Health. 2000;24(2):85-92 [11199282.001]
  • [Cites] Psychopharmacology (Berl). 2002 Jan;159(2):181-7 [11862347.001]
  • [Cites] Nature. 2002 Aug 1;418(6897):530-4 [12152079.001]
  • [Cites] Psychopharmacology (Berl). 2002 Nov;164(3):318-28 [12424556.001]
  • [Cites] Biol Psychiatry. 2002 Nov 15;52(10):958-75 [12437937.001]
  • [Cites] Psychopharmacology (Berl). 2003 Jan;165(3):238-44 [12451436.001]
  • [Cites] J Neurochem. 2003 Feb;84(4):698-704 [12562514.001]
  • [Cites] Neuropsychopharmacology. 2003 Apr;28(4):654-63 [12655310.001]
  • [Cites] Neuron. 2003 Jun 19;38(6):863-9 [12818173.001]
  • [Cites] Learn Behav. 2003 Aug;31(3):273-80 [14577550.001]
  • [Cites] Br J Psychiatry. 2004 Aug;185:116-26 [15286062.001]
  • [Cites] Acta Biol Exp (Warsz). 1967;27(2):147-61 [6080678.001]
  • [Cites] Arch Gen Psychiatry. 1981 Aug;38(8):869-71 [7259423.001]
  • [Cites] Arch Gen Psychiatry. 1985 Apr;42(4):367-72 [3977554.001]
  • [Cites] Pharmacol Biochem Behav. 1987 Jul;27(3):517-9 [3659074.001]
  • [Cites] Pharmacol Biochem Behav. 1988 Mar;29(3):601-7 [3362955.001]
  • [Cites] Am J Psychiatry. 1990 Jun;147(6):685-95 [2188513.001]
  • [Cites] Pharmacol Ther. 1990;47(2):147-65 [2203068.001]
  • [Cites] Psychopharmacology (Berl). 1992;107(2-3):453-6 [1615143.001]
  • [Cites] Pharmacol Biochem Behav. 1992 Sep;43(1):97-102 [1409822.001]
  • [Cites] Eur Arch Psychiatry Clin Neurosci. 1993;243(3-4):205-11 [8117765.001]
  • [Cites] Eur J Pharmacol. 1994 Nov 15;269(3):365-74 [7895775.001]
  • [Cites] Psychopharmacology (Berl). 1995 Mar;118(2):150-4 [7617801.001]
  • [Cites] Arch Gen Psychiatry. 1995 Dec;52(12):1048-60 [7492257.001]
  • [Cites] Am J Orthopsychiatry. 1996 Jan;66(1):17-31 [8720638.001]
  • [Cites] Arch Gen Psychiatry. 1997 Jan;54(1):81-7 [9006404.001]
  • [Cites] Behav Brain Res. 1997 Mar;84(1-2):241-6 [9079788.001]
  • [Cites] Arch Gen Psychiatry. 1997 Apr;54(4):313-21 [9107147.001]
  • [Cites] Alcohol Clin Exp Res. 1997 Sep;21(6):1083-91 [9309321.001]
  • [Cites] Alcohol Clin Exp Res. 1998 Apr;22(2):468-73 [9581655.001]
  • [Cites] Psychol Med. 1998 Jul;28(4):773-88 [9723135.001]
  • [Cites] Eur J Pharmacol. 1999 Apr 16;370(3):233-40 [10334497.001]
  • [Cites] J Occup Environ Med. 1999 May;41(5):384-92 [10337608.001]
  • [Cites] Behav Genet. 1999 Jan;29(1):47-57 [10371758.001]
  • [Cites] Ann N Y Acad Sci. 2004 Oct;1025:515-27 [15542757.001]
  • [Cites] Neuropsychopharmacology. 2005 Feb;30(2):339-49 [15383833.001]
  • [Cites] Neuropsychopharmacology. 2005 Mar;30(3):516-24 [15637635.001]
  • [Cites] Behav Neurosci. 2005 Feb;119(1):213-23 [15727526.001]
  • [Cites] Eur J Neurosci. 2005 Apr;21(8):2243-51 [15869521.001]
  • [Cites] Pharmacol Biochem Behav. 2005 Jun;81(2):331-42 [15927244.001]
  • [Cites] Behav Brain Res. 2005 Nov 7;164(2):206-13 [16140402.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 6;102(49):17852-7 [16314570.001]
  • [Cites] Learn Mem. 2006 Jan-Feb;13(1):1-3 [16452648.001]
  • [Cites] Am J Drug Alcohol Abuse. 2006;32(2):203-24 [16595324.001]
  • [Cites] J Am Chem Soc. 2006 Aug 2;128(30):9699-704 [16866524.001]
  • [Cites] Pharmacol Rev. 2006 Sep;58(3):389-462 [16968947.001]
  • [Cites] Am Psychol. 2006 Nov;61(8):741-56 [17115806.001]
  • [Cites] Neuropsychopharmacology. 2007 Jan;32(1):117-26 [16482090.001]
  • [Cites] Neurobiol Learn Mem. 2007 Feb;87(2):167-73 [17079171.001]
  • [Cites] Psychopharmacology (Berl). 2007 Apr;191(2):223-31 [17211653.001]
  • [Cites] Neuropsychopharmacology. 2007 Jul;32(7):1570-82 [17164820.001]
  • [Cites] Alcohol Clin Exp Res. 2007 Jul;31(7):1081-8 [17451404.001]
  • [Cites] Eur J Neurosci. 2007 Jul;26(2):476-86 [17650118.001]
  • [Cites] Mol Neurobiol. 2007 Aug;36(1):92-101 [17952654.001]
  • [Cites] Mol Neurobiol. 2007 Aug;36(1):102-12 [17952655.001]
  • [Cites] Br J Pharmacol. 2007 Nov;152(5):576-82 [17704824.001]
  • [Cites] Pharmacol Res. 2007 Nov;56(5):367-81 [17951068.001]
  • [Cites] J Neurochem. 2008 Jan;104(1):233-43 [17944864.001]
  • [Cites] J Neurosci. 2008 Jan 30;28(5):1076-84 [18234886.001]
  • [Cites] Alcohol. 2008 Feb;42(1):1-11 [18164576.001]
  • [Cites] Eur J Pharmacol. 2008 May 13;585(2-3):453-7 [18410917.001]
  • [Cites] Addict Biol. 2008 Jun;13(2):160-87 [18422831.001]
  • (PMID = 20838777.001).
  • [ISSN] 1432-2072
  • [Journal-full-title] Psychopharmacology
  • [ISO-abbreviation] Psychopharmacology (Berl.)
  • [Language] ENG
  • [Grant] United States / NIAAA NIH HHS / AA / R01 AA016843; United States / NIAAA NIH HHS / AA / R01 AA016843-04; United States / NIAAA NIH HHS / AA / AA019529-02; United States / NIAAA NIH HHS / AA / R21 AA019529; United States / NIAAA NIH HHS / AA / AA016843; United States / NIAAA NIH HHS / AA / R21 AA019529-02; United States / NIAAA NIH HHS / AA / AA016843-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Anti-Anxiety Agents; 0 / Cannabinoid Receptor Modulators; 0 / Endocannabinoids; 0 / Heterocyclic Compounds, 1-Ring; 0 / LY2183240; 3K9958V90M / Ethanol; 8W8T17847W / Urea
  • [Other-IDs] NLM/ NIHMS233448; NLM/ PMC2982902
  •  go-up   go-down


77. Dalpiaz O, Kerschbaumer A, Mitterberger M, Pinggera G, Bartsch G, Strasser H: Chronic pelvic pain in women: still a challenge. BJU Int; 2008 Nov;102(9):1061-5
MedlinePlus Health Information. consumer health - Pelvic Pain.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chronic pelvic pain (CPP), a common condition particularly in reproductive-aged women, causes disability and distress, and significantly compromises quality of life and affects healthcare costs.
  • The pathogenesis of CPP is still poorly understood and consequently poorly managed.
  • Furthermore, the lack of a consensus on the definition of CPP greatly hinders epidemiological studies.
  • Other conditions, e.g. depression, anxiety and drug addiction, can also coexist.
  • The key to treating CPP is to treat it as the complex disease it is.
  • Treatment options range from conservative medical therapy to surgical intervention, and are primarily directed towards symptom relief.
  • Unsatisfactory results of treatment render this condition a frustrating problem for both patients and physicians.
  • [MeSH-major] Pelvic Pain / therapy. Quality of Life
  • [MeSH-minor] Adolescent. Adult. Chronic Disease. Female. Humans. Middle Aged. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18540938.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 34
  •  go-up   go-down


78. Patel MB, Feinstein AJ, Saenz AD, Majetschak M, Proctor KG: Prehospital HBOC-201 after traumatic brain injury and hemorrhagic shock in swine. J Trauma; 2006 Jul;61(1):46-56
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prehospital HBOC-201 after traumatic brain injury and hemorrhagic shock in swine.
  • BACKGROUND: Data are limited on the actions of hemoglobin based oxygen carriers (HBOCs) after traumatic brain injury (TBI).
  • Supplemental NS was administered to both groups to maintain mean arterial pressure (MAP) >60 mm Hg until 60 minutes, and to maintain cerebral perfusion pressure (CPP) >70 mm Hg from 60 to 300 minutes.
  • The control group received mannitol (1 g/kg) and blood (10 mL/kg) at 90 minutes and half (n = 5) received CPP directed phenylephrine (PE) therapy after 120 minutes.
  • RESULTS: With HBOC administration, MAP, CPP, and brain tissue PO2 were restored within 30 minutes and maintained until 300 minutes.
  • In contrast, with control, MAP and brain tissue PO2 did not correct until 120 minutes, after mannitol, transfusion and 40% more crystalloid.
  • Furthermore, without PE, CPP did not reach target and 0/5 could be extubated.
  • CONCLUSIONS: After TBI, a single HBOC-201 bolus with minimal supplements provided rapid resuscitation, while maintaining CPP and improving brain oxygenation, without causing cardiac dysfunction, coagulopathy, cytokine release, or brain structural changes.
  • [MeSH-major] Blood Substitutes / toxicity. Brain Injuries / therapy. Fluid Therapy / methods. Hemoglobins / toxicity. Shock, Hemorrhagic / therapy
  • [MeSH-minor] Analysis of Variance. Animals. Blood Coagulation / drug effects. Brain / drug effects. Brain / pathology. Cerebrovascular Circulation / drug effects. Cytokines / blood. Drug-Related Side Effects and Adverse Reactions. Female. Hemodynamics / drug effects. Male. Swine

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16832248.001).
  • [ISSN] 0022-5282
  • [Journal-full-title] The Journal of trauma
  • [ISO-abbreviation] J Trauma
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / T32 GM08749-01
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Blood Substitutes; 0 / Cytokines; 0 / HBOC 201; 0 / Hemoglobins
  •  go-up   go-down


79. Peng PW, Castano ED: Survey of chronic pain practice by anesthesiologists in Canada. Can J Anaesth; 2005 Apr;52(4):383-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To describe the pattern of chronic pain practice (CPP) among anesthesiologists in Canada.
  • While 38% of responding anesthesiologists were involved in CPP, in the majority of cases, this accounted for less than 20% of their clinical time.
  • Thirty percent of those involved in CPP had previous training in pain management.
  • The types of CPP included nerve blocks (84%) and pharmacological treatment (60%) in non-cancer pain (85%) and cancer pain (50%) patients.
  • Ten percent and 28% of anesthesiologists were involved in research and teaching respectively while 26% were affiliated with a multidisciplinary clinic.
  • Seventy percent of anesthesiologists prescribed opioids as part of their CPP.
  • [MeSH-minor] Analgesia, Epidural. Analgesics, Opioid / therapeutic use. Autonomic Nerve Block. Chronic Disease. Humans. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15814753.001).
  • [ISSN] 0832-610X
  • [Journal-full-title] Canadian journal of anaesthesia = Journal canadien d'anesthésie
  • [ISO-abbreviation] Can J Anaesth
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Analgesics, Opioid
  •  go-up   go-down


80. Leri F, Franklin KB: Diazepam in the ventral striatum dissociates dopamine-dependent and dopamine-independent place conditioning. Neuroreport; 2000 Aug 3;11(11):2553-7
Hazardous Substances Data Bank. MORPHINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We have previously shown that diazepam blocks both the formation and the expression of amphetamine-induced conditioned place preference (CPP), but has no effect on the CPP induced by morphine.
  • The second and third experiments demonstrated that intra-cranial injections of diazepam in the nucleus accumbens blocked the expression of amphetamine CPP but not of morphine CPP.
  • It is concluded that diazepam interferes with mesolimbic dopamine-dependent motivational effects of drugs.
  • [MeSH-major] Conditioning (Psychology) / drug effects. Diazepam / pharmacology. Dopamine / metabolism. Neural Pathways / drug effects. Neurons / drug effects. Nucleus Accumbens / drug effects. Ventral Tegmental Area / drug effects
  • [MeSH-minor] 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer / pharmacology. Amphetamine / pharmacology. Animals. Drug Interactions / physiology. Male. Morphine / pharmacology. Motor Activity / drug effects. Motor Activity / physiology. Rats. Rats, Long-Evans. Receptors, Opioid, kappa / agonists. Receptors, Opioid, kappa / metabolism. Substance-Related Disorders / drug therapy. Substance-Related Disorders / metabolism. Substance-Related Disorders / physiopathology

  • Hazardous Substances Data Bank. AMPHETAMINE .
  • Hazardous Substances Data Bank. DIAZEPAM .
  • Hazardous Substances Data Bank. DOPAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10943721.001).
  • [ISSN] 0959-4965
  • [Journal-full-title] Neuroreport
  • [ISO-abbreviation] Neuroreport
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Receptors, Opioid, kappa; 67198-13-4 / 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; 76I7G6D29C / Morphine; CK833KGX7E / Amphetamine; Q3JTX2Q7TU / Diazepam; VTD58H1Z2X / Dopamine
  •  go-up   go-down


81. Biala G, Staniak N, Budzynska B: Effects of varenicline and mecamylamine on the acquisition, expression, and reinstatement of nicotine-conditioned place preference by drug priming in rats. Naunyn Schmiedebergs Arch Pharmacol; 2010 Apr;381(4):361-70
Hazardous Substances Data Bank. MORPHINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of varenicline and mecamylamine on the acquisition, expression, and reinstatement of nicotine-conditioned place preference by drug priming in rats.
  • In the present study, we used the conditioned place preference (CPP) paradigm to investigate the establishment, extinction, reinstatement, and cross-reinstatement of nicotine-induced place conditioning in rats.
  • Once established, nicotine CPP was extinguished by repeated testing.
  • These priming injections of both drugs induced a marked preference for the compartment previously paired with nicotine.
  • Furthermore, given the important role of alpha4beta2 (a4b2) nicotinic receptor subtype in the acquisition and maintenance of nicotine dependence, we evaluated and compared the efficacy of varenicline, a partial a4b2 nicotinic receptor agonist (0.5, 1, and 2 mg/kg, subcutaneously (s.c.
  • ), a non-selective nicotinic receptor antagonist, in blocking nicotine-induced CPP as well as reinstatement of nicotine CPP provoked by nicotine and morphine.
  • It was shown that both nicotinic receptor ligands attenuated the acquisition and expression of nicotine CPP as well as the expression of reinstatement of nicotine CPP provoked by both drugs.
  • Our results indicate similar cholinergic mechanisms, probably through the a4b2 receptors involved in the rewarding effects of nicotine and morphine in rats and may suggest that nicotinic receptors could be a potential target for developing pharmacotherapeutic strategies to treat and prevent nicotine and/or opioid addiction and relapse.
  • [MeSH-major] Nicotine / administration & dosage. Nicotinic Agonists / pharmacology. Nicotinic Antagonists / pharmacology. Receptors, Nicotinic / drug effects
  • [MeSH-minor] Animals. Benzazepines / administration & dosage. Benzazepines / pharmacology. Conditioning, Classical / drug effects. Dose-Response Relationship, Drug. Male. Mecamylamine / administration & dosage. Mecamylamine / pharmacology. Morphine / administration & dosage. Morphine / pharmacology. Quinoxalines / administration & dosage. Quinoxalines / pharmacology. Rats. Rats, Wistar. Reward. Tobacco Use Disorder / physiopathology. Varenicline

  • Hazardous Substances Data Bank. VARENICLINE .
  • Hazardous Substances Data Bank. NICOTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Addiction. 2008 Jan;103(1):146-54 [18028247.001]
  • [Cites] Neuropharmacology. 2007 Mar;52(3):985-94 [17157884.001]
  • [Cites] Prog Neurobiol. 1998 Dec;56(6):613-72 [9871940.001]
  • [Cites] Prog Neurobiol. 2004 Dec;74(6):363-96 [15649582.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 1993 Jan;347(1):9-13 [8095326.001]
  • [Cites] Brain Res. 2001 Jun 8;903(1-2):62-5 [11382388.001]
  • [Cites] Nicotine Tob Res. 2007 Mar;9(3):315-27 [17365764.001]
  • [Cites] Neuron. 2002 Mar 14;33(6):905-19 [11906697.001]
  • [Cites] J Med Chem. 2005 May 19;48(10):3474-7 [15887955.001]
  • [Cites] J Neurosci. 2002 Dec 15;22(24):10935-40 [12486188.001]
  • [Cites] J Neurosci. 2003 Apr 15;23(8):3176-85 [12716925.001]
  • [Cites] Neuropharmacology. 2007 Mar;52(3):755-63 [17097117.001]
  • [Cites] Behav Neurosci. 1993 Dec;107(6):1077-87 [8136061.001]
  • [Cites] Curr Drug Targets CNS Neurol Disord. 2002 Aug;1(4):413-21 [12769613.001]
  • [Cites] J Pharmacol Exp Ther. 2009 Apr;329(1):225-30 [19126781.001]
  • [Cites] Psychopharmacology (Berl). 2006 Mar;184(3-4):619-27 [16308727.001]
  • [Cites] Trends Neurosci. 1997 Feb;20(2):92-8 [9023878.001]
  • [Cites] J Neurosci. 1992 Jul;12(7):2765-84 [1613557.001]
  • [Cites] Neuroscience. 2005;136(2):531-8 [16216430.001]
  • [Cites] Eur Neuropsychopharmacol. 1999 Mar;9(3):227-33 [10208292.001]
  • [Cites] Psychopharmacology (Berl). 1999 Nov;147(2):135-42 [10591880.001]
  • [Cites] Neuropharmacology. 2000 Oct;39(13):2740-55 [11044744.001]
  • [Cites] Trends Pharmacol Sci. 2007 Jul;28(7):316-25 [17573127.001]
  • [Cites] Eur J Pharmacol. 2007 May 7;562(1-2):92-102 [17336285.001]
  • [Cites] Nature. 2005 Jul 7;436(7047):103-7 [16001069.001]
  • [Cites] Pharmacol Rep. 2005 Nov-Dec;57(6):755-60 [16382193.001]
  • [Cites] Psychopharmacology (Berl). 1999 Feb;142(1):85-94 [10102787.001]
  • [Cites] JAMA. 2006 Jul 5;296(1):64-71 [16820548.001]
  • [Cites] JAMA. 1994 Feb 23;271(8):589-94 [8301790.001]
  • [Cites] J Pharmacol Exp Ther. 2003 Jul;306(1):407-20 [12682217.001]
  • [Cites] Eur J Pharmacol. 2006 May 10;537(1-3):85-93 [16616917.001]
  • [Cites] Prog Neuropsychopharmacol Biol Psychiatry. 2006 Jan;30(1):15-21 [16202496.001]
  • [Cites] Psychopharmacology (Berl). 2006 Nov;189(1):27-36 [17019569.001]
  • [Cites] Nat Med. 2002 May;8(5):447-9 [11984581.001]
  • [Cites] Nature. 1998 Jan 8;391(6663):173-7 [9428762.001]
  • [Cites] Synapse. 2000 Feb;35(2):129-36 [10611638.001]
  • [Cites] Am J Health Syst Pharm. 2007 Jul 1;64(13):1381-4 [17592002.001]
  • [Cites] Prog Neuropsychopharmacol Biol Psychiatry. 1994 Sep;18(5):925-33 [7972862.001]
  • [Cites] Pharmacol Biochem Behav. 1997 Aug;57(4):915-21 [9259024.001]
  • [Cites] Pharmacol Biochem Behav. 2008 Mar;89(1):116-25 [18178244.001]
  • [Cites] Neuron. 2001 Aug 16;31(3):349-52 [11516393.001]
  • [Cites] Eur J Neurosci. 2003 Apr;17 (7):1329-37 [12713636.001]
  • [Cites] Psychopharmacology (Berl). 2000 Jan;147(4):347-55 [10672627.001]
  • [Cites] Psychopharmacology (Berl). 1992;107(2-3):285-9 [1615127.001]
  • [Cites] Pol J Pharmacol. 2003 May-Jun;55(3):327-35 [14506311.001]
  • [Cites] Curr Opin Pharmacol. 2005 Feb;5(1):53-9 [15661626.001]
  • [Cites] Pharmacol Biochem Behav. 1999 Apr;62(4):743-51 [10208381.001]
  • (PMID = 20217050.001).
  • [ISSN] 1432-1912
  • [Journal-full-title] Naunyn-Schmiedeberg's archives of pharmacology
  • [ISO-abbreviation] Naunyn Schmiedebergs Arch. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Benzazepines; 0 / Nicotinic Agonists; 0 / Nicotinic Antagonists; 0 / Quinoxalines; 0 / Receptors, Nicotinic; 0 / nicotinic receptor alpha4beta2; 6EE945D3OK / Mecamylamine; 6M3C89ZY6R / Nicotine; 76I7G6D29C / Morphine; W6HS99O8ZO / Varenicline
  •  go-up   go-down


82. Sarkissian CN, Scriver CR, Mamer OA: Quantitation of phenylalanine and its trans-cinnamic, benzoic and hippuric acid metabolites in biological fluids in a single GC-MS analysis. J Mass Spectrom; 2007 Jun;42(6):811-7
Hazardous Substances Data Bank. DEUTERIUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We describe a sensitive, simple and convenient stable isotope dilution assay developed to study endogenous metabolism of administered stable isotope-labeled phenylalanine (Phe) in phenylketonuric (PKU) mice treated experimentally with phenylalanine ammonia lyase (PAL).
  • Mouse urine and plasma containing endogenous and administered labeled Phe together with internal standard Phe bearing a different pattern of labeling are converted by in situ diazotization to 2-chloro-3-phenylpropionic acid (CPP).
  • A single solvent extraction is then used to isolate the isotopomers of CPP along with the trans-cinnamic acid (TCA) produced from Phe by PAL, as well as the TCA metabolites benzoic and hippuric acids.
  • This procedure eliminates the need for a separate ion-exchange isolation step for Phe on a second sample aliquot and separate GC-MS analysis.
  • Extracted CPP and the Phe metabolites are then measured by conversion to the pentafluorobenzyl esters and a single analysis by electron capture negative ion GC-MS.
  • [MeSH-minor] Animals. Deuterium. Drug Therapy, Combination. Mice. Mice, Mutant Strains. Phenylalanine Ammonia-Lyase / pharmacokinetics

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. (L)-Phenylalanine .
  • Hazardous Substances Data Bank. BENZOIC ACID .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17511014.001).
  • [ISSN] 1076-5174
  • [Journal-full-title] Journal of mass spectrometry : JMS
  • [ISO-abbreviation] J Mass Spectrom
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cinnamates; 0 / Hippurates; 47E5O17Y3R / Phenylalanine; 8SKN0B0MIM / Benzoic Acid; AR09D82C7G / Deuterium; EC 4.3.1.24 / Phenylalanine Ammonia-Lyase; TE0865N2ET / hippuric acid; U14A832J8D / cinnamic acid
  •  go-up   go-down


83. Belfort MA: Is high cerebral perfusion pressure and cerebral flow predictive of impending seizures in preeclampsia? A case report. Hypertens Pregnancy; 2005;24(1):59-63
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Transcranial Doppler ultrasound was used to demonstrate elevated estimated cerebral perfusion pressure (CPP) and cerebral flow index (CFI) in a preeclamptic patient.
  • She subsequently developed eclampsia.
  • After magnesium sulfate therapy her CPP and CFI were within the normal range and she did not experience further seizures.
  • This finding suggests that cerebral overperfusion may be at least one of the etiologies involved in the pathogenesis of eclampsia.
  • [MeSH-major] Intracranial Hypertension / ultrasonography. Pre-Eclampsia / ultrasonography. Pregnancy Outcome. Seizures / diagnosis. Ultrasonography, Doppler, Transcranial
  • [MeSH-minor] Adult. Blood Flow Velocity. Cerebrovascular Circulation / physiology. Eclampsia / diagnosis. Eclampsia / drug therapy. Female. Humans. Magnesium Sulfate / therapeutic use. Parity. Predictive Value of Tests. Pregnancy. Pregnancy Trimester, Third. Risk Assessment


84. Wang B, Zhang B, Ge X, Luo F, Han J: Inhibition by peripheral electric stimulation of the reinstatement of morphine-induced place preference in rats and drug-craving in heroin addicts. Beijing Da Xue Xue Bao; 2003 Jun 18;35(3):241-7
Hazardous Substances Data Bank. MORPHINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition by peripheral electric stimulation of the reinstatement of morphine-induced place preference in rats and drug-craving in heroin addicts.
  • OBJECTIVE: To test the hypothesis that peripheral electric stimulation (PES) may suppress the reinstatement of morphine-induced conditioned place preference (CPP) in rats as well as the drug craving of detoxified heroin addicts in a frequency-dependent manner.
  • METHODS: CPP model of the rat was constructed with two compartment automatic CPP apparatus, and the craving of the heroin addicts was assessed with a visual analogue scale (VAS). RESULTS:.
  • (1) PES of low frequency could prevent the drug priming- or foot shock-induced reinstatement of morphine CPP;.
  • (2) this effect was naloxone-reversible, suggesting a possible involvement of endogenous opioid mechanisms; and (3) PES of low frequency could also accelerate the rate of natural decay of drug craving in heroin addicts after successful abstinence.
  • CONCLUSION: PES might serve as a therapeutic measure for the treatment of heroin addiction.
  • [MeSH-major] Conditioning (Psychology) / drug effects. Heroin Dependence / therapy. Morphine / pharmacology. Transcutaneous Electric Nerve Stimulation

  • MedlinePlus Health Information. consumer health - Heroin.
  • Hazardous Substances Data Bank. NALOXONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12914237.001).
  • [ISSN] 1671-167X
  • [Journal-full-title] Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences
  • [ISO-abbreviation] Beijing Da Xue Xue Bao
  • [Language] eng
  • [Grant] United States / NIDA NIH HHS / DA / DA 03983
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] China
  • [Chemical-registry-number] 36B82AMQ7N / Naloxone; 76I7G6D29C / Morphine
  •  go-up   go-down


85. Said Hassane F, Saleh AF, Abes R, Gait MJ, Lebleu B: Cell penetrating peptides: overview and applications to the delivery of oligonucleotides. Cell Mol Life Sci; 2010 Mar;67(5):715-26
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cell penetrating peptides (CPP), also named protein transduction domains, comprise short and usually basic amino acids-rich peptides originating from proteins able to cross biological barriers, such as the viral Tat protein, or are rationally designed.
  • They have emerged as a new class of non-viral vectors allowing the delivery of various biomolecules across biological barriers from low molecular weight drugs to nanosized particles.
  • Encouraging data with CPP-conjugated oligonucleotides have been obtained both in vitro and in vivo in animal models of diseases such as Duchenne muscular dystrophy.
  • Whether CPP-cargo conjugates enter cells by direct translocation across the plasma membrane or by endocytosis remains controversial.
  • [MeSH-major] Cells / metabolism. Drug Delivery Systems. Oligonucleotides / administration & dosage. Peptides / pharmacokinetics
  • [MeSH-minor] Animals. Cell Membrane Permeability / drug effects. Gene Transfer Techniques. Humans. Muscular Dystrophy, Duchenne / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Protein Pept Sci. 2003 Apr;4(2):133-40 [12678852.001]
  • [Cites] FEBS Lett. 2007 Feb 20;581(4):702-6 [17274989.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Dec 21;101(51):17867-72 [15601762.001]
  • [Cites] J Biol Chem. 2003 Sep 5;278(36):34141-9 [12773529.001]
  • [Cites] Cardiovasc Res. 2007 Mar 1;73(4):699-709 [17234167.001]
  • [Cites] Org Lett. 2003 Sep 18;5(19):3459-62 [12967299.001]
  • [Cites] Adv Drug Deliv Rev. 2008 Mar 1;60(4-5):452-72 [18164781.001]
  • [Cites] Adv Drug Deliv Rev. 2008 Mar 1;60(4-5):499-516 [18093693.001]
  • [Cites] Biochemistry. 1998 May 5;37(18):6235-9 [9572837.001]
  • [Cites] Biochim Biophys Acta. 2004 Oct 11;1665(1-2):48-56 [15471570.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 30;105(39):14814-9 [18806224.001]
  • [Cites] J Biol Chem. 1994 Apr 8;269(14):10444-50 [8144628.001]
  • [Cites] Eur J Biochem. 2001 Mar;268(5):1304-14 [11231282.001]
  • [Cites] J Control Release. 2005 Jan 20;102(1):247-53 [15653149.001]
  • [Cites] J Biol Chem. 2005 Apr 15;280(15):15300-6 [15687490.001]
  • [Cites] Bioconjug Chem. 2000 May-Jun;11(3):301-5 [10821645.001]
  • [Cites] Bioconjug Chem. 1999 Mar-Apr;10(2):186-91 [10077466.001]
  • [Cites] Biochem Soc Trans. 2007 Aug;35(Pt 4):821-5 [17635156.001]
  • [Cites] FASEB J. 1998 Jan;12(1):67-77 [9438412.001]
  • [Cites] J Biol Chem. 2001 Jul 13;276(28):26204-10 [11346640.001]
  • [Cites] Biochim Biophys Acta. 2001 Dec 1;1515(2):101-9 [11718666.001]
  • [Cites] Hum Mol Genet. 2009 Nov 15;18(22):4405-14 [19692354.001]
  • [Cites] Nucleic Acids Res. 2001 Oct 1;29(19):3965-74 [11574678.001]
  • [Cites] J Pharm Sci. 2008 Jan;97(1):144-62 [17763452.001]
  • [Cites] J Control Release. 2008 Nov 24;132(1):21-5 [18727945.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):42-7 [11120883.001]
  • [Cites] Biochem J. 2002 Nov 1;367(Pt 3):761-9 [12137567.001]
  • [Cites] J Biol Chem. 2003 Dec 12;278(50):50188-94 [14517218.001]
  • [Cites] Nucleic Acids Res. 1997 Jul 15;25(14):2730-6 [9207018.001]
  • [Cites] J Virol. 2007 Jun;81(11):5637-48 [17344287.001]
  • [Cites] Nat Med. 2004 Mar;10(3):310-5 [14770178.001]
  • [Cites] Lancet Neurol. 2009 Oct;8(10):918-28 [19713152.001]
  • [Cites] Curr Opin Mol Ther. 2001 Apr;3(2):147-52 [11338927.001]
  • [Cites] Nucleic Acids Res. 2008 Nov;36(20):6343-54 [18796528.001]
  • [Cites] J Biol Chem. 2003 Sep 12;278(37):35109-14 [12837762.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Jan 18;91(2):664-8 [8290579.001]
  • [Cites] Oligonucleotides. 2006 Summer;16(2):145-57 [16764538.001]
  • [Cites] Adv Drug Deliv Rev. 2008 Mar 1;60(4-5):608-13 [18037528.001]
  • [Cites] J Biol Chem. 1997 Jun 20;272(25):16010-7 [9188504.001]
  • [Cites] Trends Neurosci. 2007 Jun;30(6):260-7 [17418905.001]
  • [Cites] Science. 1999 Sep 3;285(5433):1569-72 [10477521.001]
  • [Cites] Adv Drug Deliv Rev. 2008 Aug 17;60(11):1241-51 [18508157.001]
  • [Cites] Nat Med. 2006 Feb;12(2):175-7 [16444267.001]
  • [Cites] Nat Biotechnol. 2009 Jun;27(6):567-71 [19448630.001]
  • [Cites] Bioconjug Chem. 2000 Nov-Dec;11(6):762-71 [11087323.001]
  • [Cites] J Control Release. 2009 Mar 19;134(3):221-7 [19105971.001]
  • [Cites] Adv Drug Deliv Rev. 2005 Feb 28;57(4):579-96 [15722165.001]
  • [Cites] Nucleic Acids Res. 2007;35(13):4495-502 [17584792.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Feb 22;291(2):367-71 [11846414.001]
  • [Cites] J Pept Res. 2000 Nov;56(5):318-25 [11095185.001]
  • [Cites] Mol Biol Cell. 2004 May;15(5):2347-60 [15020715.001]
  • [Cites] Traffic. 2007 Jul;8(7):848-66 [17587406.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Aug 26;105(34):12128-33 [18713866.001]
  • [Cites] Nat Biotechnol. 1998 Sep;16(9):857-61 [9743120.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jul 17;98(15):8786-91 [11438707.001]
  • [Cites] J Biol Chem. 2009 Feb 6;284(6):3370-8 [19047062.001]
  • [Cites] Biol Cell. 2008 Apr;100(4):201-17 [18341479.001]
  • [Cites] Mol Pharmacol. 2002 Oct;62(4):864-72 [12237333.001]
  • [Cites] Mol Pharm. 2009 May-Jun;6(3):686-95 [19397332.001]
  • [Cites] N Engl J Med. 2007 Dec 27;357(26):2677-86 [18160687.001]
  • [Cites] J Control Release. 2006 Feb 21;110(3):595-604 [16377019.001]
  • [Cites] Hum Mol Genet. 2008 Dec 15;17(24):3909-18 [18784278.001]
  • [Cites] Mol Ther. 2007 Sep;15(9):1587-92 [17579573.001]
  • [Cites] Nucleic Acids Res. 2005 Nov 30;33(21):6837-49 [16321967.001]
  • [Cites] Int J Mol Sci. 2008 Jun;9(7):1276-320 [19325804.001]
  • [Cites] Eur J Cardiothorac Surg. 2005 Jan;27(1):117-21 [15621482.001]
  • [Cites] Chembiochem. 2006 Oct;7(10):1497-515 [16972294.001]
  • [Cites] RNA. 2007 Oct;13(10):1609-24 [17684229.001]
  • [Cites] Nucleic Acids Res. 2008 Nov;36(20):6418-28 [18842625.001]
  • [Cites] FEBS Lett. 2006 Feb 20;580(5):1451-6 [16460737.001]
  • [Cites] J Biol Chem. 2003 Jan 3;278(1):585-90 [12411431.001]
  • [Cites] New Biol. 1991 Nov;3(11):1121-34 [1777485.001]
  • [Cites] Adv Drug Deliv Rev. 2008 Mar 1;60(4-5):517-29 [18037527.001]
  • [Cites] J Neurosci. 2004 Aug 4;24(31):6880-8 [15295022.001]
  • [Cites] J Control Release. 2006 Dec 1;116(3):304-13 [17097177.001]
  • [Cites] Nucleic Acids Res. 2009 Aug;37(14):4559-69 [19483097.001]
  • [Cites] Biochemistry. 2001 Feb 13;40(6):1824-34 [11327845.001]
  • [Cites] Adv Drug Deliv Rev. 2008 Mar 1;60(4-5):548-58 [18053612.001]
  • [Cites] Curr Pharm Des. 2008;14(24):2415-47 [18781991.001]
  • [Cites] J Med Chem. 2002 Aug 15;45(17):3612-8 [12166934.001]
  • [Cites] J Pept Sci. 2008 Apr;14(4):455-60 [18236382.001]
  • [Cites] Bioconjug Chem. 2005 Sep-Oct;16(5):1176-80 [16173795.001]
  • [Cites] Hum Mol Genet. 1998 Jul;7(7):1083-90 [9618164.001]
  • [Cites] Curr Pharm Des. 2008;14(34):3628-36 [19075739.001]
  • [Cites] J Gene Med. 2006 Feb;8(2):207-16 [16285002.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):1768-75 [11280720.001]
  • [Cites] Cell. 1988 Dec 23;55(6):1189-93 [2849510.001]
  • [Cites] Mol Ther. 2008 Sep;16(9):1624-9 [18545222.001]
  • [Cites] Biochim Biophys Acta. 1998 Nov 11;1414(1-2):127-39 [9804921.001]
  • [Cites] Expert Opin Drug Deliv. 2006 Nov;3(6):739-46 [17076596.001]
  • [Cites] Nat Med. 2000 Nov;6(11):1253-7 [11062537.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Jan 4;102(1):198-203 [15608067.001]
  • [Cites] J Control Release. 2007 Apr 2;118(2):216-24 [17239466.001]
  • [Cites] Chem Biol. 2005 Aug;12(8):923-9 [16125104.001]
  • [Cites] Biopolymers. 2008;90(5):604-10 [18381624.001]
  • [Cites] J Biol Chem. 2001 Feb 23;276(8):5836-40 [11084031.001]
  • [Cites] Pharm Res. 2004 Sep;21(9):1662-9 [15497694.001]
  • (PMID = 19898741.001).
  • [ISSN] 1420-9071
  • [Journal-full-title] Cellular and molecular life sciences : CMLS
  • [ISO-abbreviation] Cell. Mol. Life Sci.
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U105178803
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Oligonucleotides; 0 / Peptides
  • [Number-of-references] 99
  •  go-up   go-down


86. Herrold AA, Shen F, Graham MP, Harper LK, Specio SE, Tedford CE, Napier TC: Mirtazapine treatment after conditioning with methamphetamine alters subsequent expression of place preference. Drug Alcohol Depend; 2009 Jan 1;99(1-3):231-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mirtazapine treatment after conditioning with methamphetamine alters subsequent expression of place preference.
  • There are currently no FDA approved pharmacotherapies for the MP addict.
  • This study evaluated the potential of Mirt as a therapeutic agent for MP addiction and described associated changes in neuronal signaling.
  • A single pairing conditioned place preference (CPP) paradigm was utilized as a behavioral measure of MP-induced effects.
  • Mirt (5.0 mg/kg i.p.) was given in the home cage on day 3 and CPP was assessed on day 4.
  • To evaluate signaling events that correlate with this behavior, brain tissue of these rats were dissected for immunoblot assays of extracellular signal-regulated kinase (ERK) and a transcriptional regulator, cAMP response element-binding protein (CREB) after the CPP test.
  • During the CPP test, rats conditioned with MP spent more time in the environment associated with MP.
  • Importantly, rats given Mirt did not express CPP.
  • MP-induced CPP was associated with a decrease in phosphorylated CREB (pCREB) in the ventral tegmental area, and decreased phosphorylated ERK and pCREB in the nucleus accumbens and treatment with Mirt did not reverse these changes.
  • Overall, a post-conditioning treatment with Mirt can nullify MP-induced associative learning.
  • [MeSH-major] Adrenergic alpha-Antagonists / pharmacology. Central Nervous System Stimulants / pharmacology. Conditioning, Operant / drug effects. Methamphetamine / pharmacology. Mianserin / analogs & derivatives
  • [MeSH-minor] Animals. Blotting, Western. Cues. Cyclic AMP Response Element-Binding Protein / metabolism. Extracellular Signal-Regulated MAP Kinases / metabolism. Male. Memory / drug effects. Phosphorylation. Rats. Rats, Sprague-Dawley. Receptors, Serotonin / drug effects. Signal Transduction / drug effects. Taste / drug effects

  • MedlinePlus Health Information. consumer health - Methamphetamine.
  • Hazardous Substances Data Bank. MIANSERIN .
  • Hazardous Substances Data Bank. d-METHAMPHETAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18945553.001).
  • [ISSN] 1879-0046
  • [Journal-full-title] Drug and alcohol dependence
  • [ISO-abbreviation] Drug Alcohol Depend
  • [Language] eng
  • [Grant] United States / NIDA NIH HHS / DA / DA015760; United States / NIDA NIH HHS / DA / DA016496; United States / NIDA NIH HHS / DA / DA019763; United States / NIDA NIH HHS / DA / DA023306
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Adrenergic alpha-Antagonists; 0 / Central Nervous System Stimulants; 0 / Cyclic AMP Response Element-Binding Protein; 0 / Receptors, Serotonin; 250PJI13LM / Mianserin; 44RAL3456C / Methamphetamine; A051Q2099Q / mirtazapine; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases
  •  go-up   go-down


87. Concolino D, Muzzi G, Pisaturo L, Piccirillo A, Di Natale P, Strisciuglio P: Precocious puberty in Sanfilippo IIIA disease: diagnosis and follow-up of two new cases. Eur J Med Genet; 2008 Sep-Oct;51(5):466-71
Genetic Alliance. consumer health - Precocious puberty.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Precocious puberty in Sanfilippo IIIA disease: diagnosis and follow-up of two new cases.
  • We observed two children affected by MPS IIIA with central precocious puberty (CPP) both treated with GnRH agonists.
  • The occurrence of CPP in both patients with MPS IIIA suggests that it is necessary to look for an association between the two conditions.
  • The follow-up of our two patients leads us to believe also that GnRH agonist treatment can have a beneficial effect on final height and probably on the improvement of behavioural problems.
  • [MeSH-major] Mucopolysaccharidosis III / complications. Mucopolysaccharidosis III / diagnosis. Mutation. Puberty, Precocious / complications
  • [MeSH-minor] Adolescent. Body Height / drug effects. Brain / pathology. Child. Child Behavior Disorders / complications. Child Behavior Disorders / drug therapy. DNA Mutational Analysis. Gonadotropin-Releasing Hormone / agonists. Humans. Luteolytic Agents / therapeutic use. Magnetic Resonance Imaging / methods. Male. Triptorelin Pamoate / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18586597.001).
  • [ISSN] 1769-7212
  • [Journal-full-title] European journal of medical genetics
  • [ISO-abbreviation] Eur J Med Genet
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Luteolytic Agents; 33515-09-2 / Gonadotropin-Releasing Hormone; 57773-63-4 / Triptorelin Pamoate
  •  go-up   go-down


88. Moulton HM, Fletcher S, Neuman BW, McClorey G, Stein DA, Abes S, Wilton SD, Buchmeier MJ, Lebleu B, Iversen PL: Cell-penetrating peptide-morpholino conjugates alter pre-mRNA splicing of DMD (Duchenne muscular dystrophy) and inhibit murine coronavirus replication in vivo. Biochem Soc Trans; 2007 Aug;35(Pt 4):826-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we discuss our recent findings regarding (R-Ahx-R)(4)AhxB (Ahx is 6-aminohexanoic acid and B is beta-alanine) CPP-PMO conjugates in DMD (Duchenne muscular dystrophy) and murine coronavirus research.
  • An (R-Ahx-R)(4)AhxB-PMO conjugate was the most effective compound in inducing the correction of mutant dystrophin transcripts in myoblasts derived from a canine model of DMD.
  • Similarly, normal levels of dystrophin expression were restored in the diaphragms of mdx mice, with treatment starting at the neonatal stage, and protein was still detecTable 22 weeks after the last dose of an (R-Ahx-R)(4)AhxB-PMO conjugate.
  • Effects of length, linkage and carbohydrate modification of this CPP on the delivery of a PMO were investigated in a coronavirus mouse model.
  • Shortening the CPP length, modifying it with a mannosylated serine moiety or replacing it with the R(9)F(2) CPP significantly decreased the efficacy of the resulting PPMO (CPP-PMO conjugate).
  • We attribute the success of this CPP to its stability in serum and its capacity to transport PMO to RNA targets in a manner superior to that of poly-arginine CPPs.
  • [MeSH-major] Antiviral Agents / pharmacology. Coronavirus / drug effects. Morpholines / pharmacology. Muscular Dystrophy, Duchenne / drug therapy. Peptides / therapeutic use. RNA Splicing / drug effects. Virus Replication / drug effects
  • [MeSH-minor] Animals. Drug Delivery Systems. Dystrophin / biosynthesis. Dystrophin / genetics. Humans. Mice. Protein Sorting Signals / physiology. Protein Transport / physiology. RNA Precursors / metabolism

  • Genetic Alliance. consumer health - Duchenne Muscular Dystrophy.
  • Genetic Alliance. consumer health - Muscular dystrophy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17635157.001).
  • [ISSN] 0300-5127
  • [Journal-full-title] Biochemical Society transactions
  • [ISO-abbreviation] Biochem. Soc. Trans.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Dystrophin; 0 / Morpholines; 0 / Peptides; 0 / Protein Sorting Signals; 0 / RNA Precursors
  • [Number-of-references] 11
  •  go-up   go-down


89. Suge T, Kawasaki A, Ishikawa K, Matsuo T, Ebisu S: Comparison of the occluding ability of dentinal tubules with different morphology between calcium phosphate precipitation method and potassium oxalate treatment. Dent Mater J; 2005 Dec;24(4):522-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of the occluding ability of dentinal tubules with different morphology between calcium phosphate precipitation method and potassium oxalate treatment.
  • The aim of this study was to evaluate the occluding ability of calcium phosphate precipitation (CPP) method and potassium oxalate treatment when each method was applied to dentin disks with different surface morphology.
  • Irrespective of the diameter of the dentinal tubules, the CPP method showed a consistent occluding ability for dentinal tubules at the dentin surface, and that the depths of the precipitate formed in the dentinal tubules by CPP method were not significantly different.
  • In contrast, the occluding ability of potassium oxalate treatment was reduced with increasing diameter of the dentinal tubules.
  • However, the reduction of the occluding ability of potassium oxalate treatment was more markedly affected by the demineralization of dentin surface.
  • Since the CPP method showed a consistent occluding ability irrespective of the diameter of the dentinal tubules, it is suggested that the CPP method would be a useful means for treating dentin hypersensitivity.
  • [MeSH-major] Calcium Phosphates / pharmacology. Dentin / drug effects. Dentin / ultrastructure. Dentin Sensitivity / drug therapy. Oxalates / pharmacology
  • [MeSH-minor] Adult. Dentin Permeability / drug effects. Humans. Microscopy, Electron, Scanning. Surface Properties

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445013.001).
  • [ISSN] 0287-4547
  • [Journal-full-title] Dental materials journal
  • [ISO-abbreviation] Dent Mater J
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Calcium Phosphates; 0 / Oxalates; 97Z1WI3NDX / calcium phosphate
  •  go-up   go-down


90. Klouche K, Weil MH, Sun S, Tang W, Zhao DH: A comparison of alpha-methylnorepinephrine, vasopressin and epinephrine for cardiac resuscitation. Resuscitation; 2003 Apr;57(1):93-100
Hazardous Substances Data Bank. VASOPRESSIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We had previously observed significantly better outcomes with a selective alpha(2)-adrenergic agonist when compared with epinephrine.
  • The present study was, therefore, undertaken to compare a selective alpha(2)-adrenergic vasopressor drug with vasopressin, epinephrine, and saline placebo.
  • Left ventricular pressure, dP/dt(40), -dP/dt, and cardiac index were measured for an interval of 240 min after resuscitation.
  • Except for saline controls, comparable increases in coronary perfusion pressure (CPP) were observed after each drug intervention.
  • [MeSH-major] Cardiopulmonary Resuscitation / methods. Nordefrin / pharmacology. Vasoconstrictor Agents / pharmacology. Vasopressins / pharmacology. Ventricular Fibrillation / therapy
  • [MeSH-minor] Analysis of Variance. Animals. Cardiac Output / physiology. Disease Models, Animal. Dose-Response Relationship, Drug. Drug Administration Schedule. Electrocardiography. Hemodynamics / physiology. Male. Probability. Rats. Rats, Sprague-Dawley. Sensitivity and Specificity. Survival Rate

  • MedlinePlus Health Information. consumer health - CPR.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12668305.001).
  • [ISSN] 0300-9572
  • [Journal-full-title] Resuscitation
  • [ISO-abbreviation] Resuscitation
  • [Language] eng
  • [Grant] United States / NHLBI NIH HHS / HL / HL-54322
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Vasoconstrictor Agents; 11000-17-2 / Vasopressins; R81X549E70 / Nordefrin
  •  go-up   go-down


91. Suge T, Ishikawa K, Kawasaki A, Suzuki K, Matsuo T, Noiri Y, Imazato S, Ebisu S: Calcium phosphate precipitation method for the treatment of dentin hypersensitivity. Am J Dent; 2002 Aug;15(4):220-6
Hazardous Substances Data Bank. CALCIUM HYDROGEN PHOSPHATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Calcium phosphate precipitation method for the treatment of dentin hypersensitivity.
  • PURPOSE: To evaluate the feasibility of the calcium phosphate precipitation (CPP) method as a treatment for dentin hypersensitivity using vital teeth of beagle dogs.
  • Also, gingival tissue response to two types of CPP methods was examined histologically.
  • MATERIALS AND METHODS: Dentin tubules of the dogs' vital teeth were exposed by shallow cavity preparation followed by etching with 50% citric acid to simulate the condition of hypersensitive dentin.
  • After CPP treatment was applied to the vital tooth, the dentin surface and longitudinal sections were observed by SEM to evaluate the occluding ability of the CPP method.
  • The gingival tissue before and after CPP method was examined histologically with light microscopy.
  • RESULTS: Dentin tubules were occluded homogeneously and completely with an apatitic mineral after application of the CPP treatment in vital teeth.
  • However, the depth of the precipitate in dentin tubules from the dentin surface was approximately half that seen in extracted teeth.
  • No histological change was observed in gingival tissues when NaHCO3 was used as a post-treatment solution of the CPP method, whereas another CPP method using NaOH solution resulted in atrophy and degeneration of the epithelium of gingival tissue.
  • [MeSH-major] Calcium Phosphates / administration & dosage. Dentin Permeability / drug effects. Dentin Sensitivity / drug therapy
  • [MeSH-minor] Analysis of Variance. Animals. Chemical Precipitation. Dentin / ultrastructure. Dogs. Electron Probe Microanalysis. Feasibility Studies. Gingiva / drug effects. Microscopy, Electron, Scanning

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12572638.001).
  • [ISSN] 0894-8275
  • [Journal-full-title] American journal of dentistry
  • [ISO-abbreviation] Am J Dent
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Calcium Phosphates; 0 / alpha-tricalcium phosphate; 0 / tetracalcium phosphate; 701EKV9RMN / calcium phosphate, monobasic, anhydrous; 97Z1WI3NDX / calcium phosphate; L11K75P92J / calcium phosphate, dibasic, anhydrous
  •  go-up   go-down


92. Municchi G, Marconcini S, D'Ambrosio A, Berardi R, Acquaviva A: Central precocious puberty in multisystem Langerhans cell histiocytosis: a case report. Pediatr Hematol Oncol; 2002 Jun;19(4):273-8
MedlinePlus Health Information. consumer health - Diabetes Insipidus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The authors describe a girl with multisystem Langerhans cell histiocytosis (LCH) who developed central precocious puberty (CPP).
  • She subsequently developed diabetes insipidus with a documented lesion of the pituitary stalk; she received chemotherapy and began therapy with l-desamino-8-D-argininevasopressin.
  • Growth hormone deficiency was diagnosed at the age of 4.4 years and GH replacement therapy started.
  • The patient has been off therapy for LCH since the age of 6.
  • Signs of pubertal development appeared at 7.5 years (bone age 8 years) and gonadotropin-releasing hormone analog (GnRHa) treatment was started.
  • During the observation period she developed central hypothyroidism.
  • Development of CPP during LCH is extremely rare; to the authors 'knowledge, no patient has been described so far.
  • The authors believe that CPP was secondary to LCH and did not represent a casual finding, even in the absence of hypothalamic-pituitary axis involvement.
  • The possibility of CPP development should be considered during the follow-up of these patients.


93. Carlotti CG Jr, Salhia B, Weitzman S, Greenberg M, Dirks PB, Mason W, Becker LE, Rutka JT: Evaluation of proliferative index and cell cycle protein expression in choroid plexus tumors in children. Acta Neuropathol; 2002 Jan;103(1):1-10
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of proliferative index and cell cycle protein expression in choroid plexus tumors in children.
  • Choroid plexus tumors are papillary neoplasms originating from the epithelium of the choroid plexus within the cerebral ventricles.
  • Accordingly, we performed a clinicopathological correlation study of neoplasms arising from the choroid plexus in children using immunohistochemistry to characterize both their proliferative potential and their degree of cell cycle dysregulation when compared to non-neoplastic choroid epithelium.
  • Twelve children with choroid plexus papillomas (CPPs) and 11 with choroid plexus carcinomas (CPCs) were identified from the time period 1982-1997.
  • The outcome and survival of these children following treatment was determined from the medical record.
  • Immunohistochemical studies were performed on CPPs and CPCs in this patient population and on non-neoplastic choroid epithelium using antibodies to MIB-1, p53, cyclin E, retinoblastoma protein (pRB), p107, and E2F-1.
  • In 5 children with CPCs, tumor tissue was available for immunohistochemistry at a second surgery after cycles of chemotherapy had been given.
  • The mean survival for patients with CPPs was 8.5 years, and with CPCs 5.2 years with a minimum follow-up of 4 years for the group.
  • The expression of cell cycle markers and MIB-1 was greater in CPCs than in CPPs or normal choroid plexus.
  • The expression of MIB-1, p53, pRB, and E2F-1 was significantly lower in patients with CPCs after chemotherapy than before.
  • The MIB-1 labeling index for CPC patients who are alive and well after treatments was 15.19+/-3.2 compared to 22.63+/-3.04 for patients who have died from their disease (P<0.05).
  • Chemotherapy may work in part on CPCs to decrease their proliferative potential and expression of cell cycle regulatory proteins.
  • [MeSH-major] Cell Cycle Proteins / analysis. Choroid Plexus Neoplasms / chemistry. Choroid Plexus Neoplasms / pathology. DNA-Binding Proteins. Papilloma, Choroid Plexus / chemistry. Papilloma, Choroid Plexus / pathology
  • [MeSH-minor] Adolescent. Antigens, Nuclear. Cell Division. Child. Child, Preschool. Cyclin E / analysis. E2F Transcription Factors. E2F1 Transcription Factor. Female. Glial Fibrillary Acidic Protein / analysis. Humans. Immunohistochemistry. Infant. Ki-67 Antigen. Male. Nuclear Proteins / analysis. Retinoblastoma Protein / analysis. Retinoblastoma-Like Protein p107. Survival Analysis. Synaptophysin / analysis. Transcription Factors / analysis. Tumor Suppressor Protein p53 / analysis

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11837741.001).
  • [ISSN] 0001-6322
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, Nuclear; 0 / Cell Cycle Proteins; 0 / Cyclin E; 0 / DNA-Binding Proteins; 0 / E2F Transcription Factors; 0 / E2F1 Transcription Factor; 0 / E2F1 protein, human; 0 / Glial Fibrillary Acidic Protein; 0 / Ki-67 Antigen; 0 / Nuclear Proteins; 0 / RBL1 protein, human; 0 / Retinoblastoma Protein; 0 / Retinoblastoma-Like Protein p107; 0 / Synaptophysin; 0 / Transcription Factors; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


94. Follis F, Blisard K, Varvitsiotis PS, Pett SB Jr, Temes T, Wernly JA: Competitive NMDA receptor antagonists and spinal-cord ischemia. J Invest Surg; 2000 Mar-Apr;13(2):117-21; discussion 123-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Accordingly, we investigated the protective effect during spinal cord ischemia of two competitive antagonists, 4-(3-phosphonopropyl)-2-piperazine-carboxylic acid (CPP) and cis-4-(phosphonomethyl)-2-piperidine-carboxylic acid (CGS).
  • Male Sprague-Dawley rats underwent intrathecal administration of 10 microL saline, CGS, and CPP 10 mM solutions, in a randomized blinded fashion, and were subjected to balloon occlusion of the thoracic aorta.
  • In the acute protocol, 21 rats divided in 3 groups of 7 (saline, CPP, and CGS) were used to calculate the aortic occlusion time (AOT) resulting in paraplegia in 50% of animals (P50).
  • In the chronic study, 24 rats divided in 4 groups of 6 (saline, CPP, CGS, sham) underwent 12-min occlusion.
  • In the acute study, the P50 of CGS (10 min 48 s) and CPP (11 min 11 s) was longer than saline (10 min 27 s).
  • In the chronic groups, analysis of variance of neurologic (p = .66) and histologic (p = .66) scores did not disclose differences between CGS, CPP, and saline.
  • In conclusion, blockade of NMDA receptors with CPP or CGS may afford some protection for durations of occlusion around the P50, but it is not beneficial when ischemic injury is more protracted.
  • [MeSH-major] Excitatory Amino Acid Antagonists / pharmacology. Pipecolic Acids / pharmacology. Piperazines / pharmacology. Receptors, N-Methyl-D-Aspartate / antagonists & inhibitors. Spinal Cord Ischemia / drug therapy
  • [MeSH-minor] Acute Disease. Animals. Arterial Occlusive Diseases / drug therapy. Chronic Disease. Disease Models, Animal. Male. Paraplegia / drug therapy. Rats. Rats, Sprague-Dawley. Spinal Cord / blood supply. Spinal Cord / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10801049.001).
  • [ISSN] 0894-1939
  • [Journal-full-title] Journal of investigative surgery : the official journal of the Academy of Surgical Research
  • [ISO-abbreviation] J Invest Surg
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Excitatory Amino Acid Antagonists; 0 / Pipecolic Acids; 0 / Piperazines; 0 / Receptors, N-Methyl-D-Aspartate; 100828-16-8 / 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid; 4VGJ4A41L2 / selfotel
  •  go-up   go-down


95. Brooks NA, Pouniotis DS, Tang CK, Apostolopoulos V, Pietersz GA: Cell-penetrating peptides: application in vaccine delivery. Biochim Biophys Acta; 2010 Jan;1805(1):25-34
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recent years have seen a surge in interest in cell-penetrating peptides (CPP) as an efficient means for delivering therapeutic targets into cellular compartments.
  • The cell membrane is impermeable to hydrophilic substances yet linking to CPP can facilitate delivery into cells.
  • Thus the unique translocatory property of CPP ensures they remain an attractive carrier, with the capacity to deliver cargoes in an efficient manner having applications in drug delivery, gene transfer and DNA vaccination.
  • Linking of antigens to CPP overcomes such obstacles by facilitating cellular uptake, processing and presentation of exogenous antigen for the induction of potent immune responses.
  • This review will encompass the various strategies for the delivery of whole proteins, T cell epitopes and preclinical studies utilizing CPP for cancer vaccines.
  • [MeSH-major] Cancer Vaccines / administration & dosage. Carrier Proteins / administration & dosage. Drug Delivery Systems. Neoplasms / drug therapy. Peptide Fragments / administration & dosage

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier B.V. All rights reserved.
  • (PMID = 19782720.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cancer Vaccines; 0 / Carrier Proteins; 0 / Peptide Fragments; 0 / penetratin
  • [Number-of-references] 110
  •  go-up   go-down


96. Gong F, Li F, Zhang L, Li J, Zhang Z, Wang G: Hypoglycemic effects of crude polysaccharide from Purslane. Int J Mol Sci; 2009 Mar;10(3):880-8
Hazardous Substances Data Bank. CHOLESTEROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The effects of crude polysaccharide from Purslane (CPP) on body weight (bw), blood glucose, total cholesterol (TC), high-density lipoprotein cholesterol (HDL-c), triglyceride (TG) and serum insulin levels were studied in diabetes mellitus mice.
  • CPP treatment (200, 400 mg/kg bw) for 28 days resulted in a significant decrease in the concentrations of fasting blood glucose (FBG), TC and TG.
  • Furthermore, CPP significantly increased the concentration of HDL-c, body weight and serum insulin level in the mice.
  • In addition, according to acute toxicity studies and single cell gel electrophoresis analysis, CPP did not produce any physical or behavioral signs of toxicity.
  • More significantly, our data demonstrated CPP exhibited the best effects at the dose of 400 mg/kg bw.
  • The above results suggest that CPP can control blood glucose and modulate the metabolism of glucose and blood lipids in diabetes mellitus mice, so we conclude that CPP should be evaluated as a candidate for future studies on diabetes mellitus.
  • [MeSH-major] Diabetes Mellitus, Experimental / drug therapy. Hypoglycemic Agents / therapeutic use. Plant Extracts / therapeutic use. Portulaca / metabolism
  • [MeSH-minor] Animals. Behavior, Animal / drug effects. Blood Glucose / analysis. Body Weight. Cholesterol / blood. Cholesterol, HDL / blood. Insulin / blood. Mice. Single-Cell Analysis. Triglycerides / blood

  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Fitoterapia. 2008 Jan;79(1):21-3 [17855019.001]
  • [Cites] J Ethnopharmacol. 2003 Apr;85(2-3):201-6 [12639741.001]
  • [Cites] J Herb Pharmacother. 2004;4(1):35-40 [15273075.001]
  • [Cites] J Clin Invest. 1969 Nov;48(11):2129-39 [4241908.001]
  • [Cites] Life Sci. 1984 Feb 6;34(6):591-5 [6363864.001]
  • [Cites] J Ethnopharmacol. 2007 Jun 13;112(2):305-11 [17467937.001]
  • [Cites] Diabetes Res Clin Pract. 1995 May;28(2):103-17 [7587918.001]
  • [Cites] J Ethnopharmacol. 2005 Apr 26;98(3):245-50 [15814255.001]
  • [Cites] J Ethnopharmacol. 2006 Sep 19;107(2):285-90 [16644162.001]
  • [Cites] J Trace Elem Med Biol. 2006;20(3):191-6 [16959596.001]
  • [Cites] Diabetes Care. 1995 Aug;18(8):1113-23 [7587846.001]
  • (PMID = 19399226.001).
  • [ISSN] 1422-0067
  • [Journal-full-title] International journal of molecular sciences
  • [ISO-abbreviation] Int J Mol Sci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Blood Glucose; 0 / Cholesterol, HDL; 0 / Hypoglycemic Agents; 0 / Insulin; 0 / Plant Extracts; 0 / Triglycerides; 97C5T2UQ7J / Cholesterol
  • [Other-IDs] NLM/ PMC2672007
  • [Keywords] NOTNLM ; Diabetes / Purslane / hypoglycemia / polysaccharide
  • [General-notes] NLM/ Original DateCompleted: 20100624
  •  go-up   go-down


97. Baviera M, Invernizzi RW, Carli M: Haloperidol and clozapine have dissociable effects in a model of attentional performance deficits induced by blockade of NMDA receptors in the mPFC. Psychopharmacology (Berl); 2008 Feb;196(2):269-80
Hazardous Substances Data Bank. CLOZAPINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: Attentional performance was assessed using the five-choice serial reaction time task.
  • The task provides indices of attentional functioning (% correct responses), executive control (measured by anticipatory and perseverative responding), decision time (measured by correct response latency), and omissions.
  • Haloperidol and clozapine were given intraperitoneally (IP) to animals that had received vehicle or a competitive NMDA receptor antagonist, 3-(R)-2-carboxypiperazin-4-propyl-1-phosphonic acid (CPP), directly into the medial prefrontal cortex.
  • RESULTS: Fifty nanograms/side of CPP reduced accuracy (% correct responses) and increased anticipatory and perseverative responding.
  • Haloperidol (0.03 mg/kg IP) reduced the CPP-induced anticipatory and perseverative overresponding but not the impairment in accuracy.
  • CPP increased decision time and omissions, but these effects were not affected by either haloperidol or clozapine.
  • [MeSH-major] Attention / drug effects. Clozapine / pharmacology. Haloperidol / pharmacology. Prefrontal Cortex / drug effects. Schizophrenia / physiopathology
  • [MeSH-minor] Analysis of Variance. Animals. Antipsychotic Agents / administration & dosage. Antipsychotic Agents / pharmacology. Behavior, Animal / drug effects. Dopamine Antagonists / administration & dosage. Dopamine Antagonists / pharmacology. Dose-Response Relationship, Drug. Injections, Intraperitoneal. Male. Microinjections. Piperazines / administration & dosage. Piperazines / toxicity. Rats. Reaction Time / drug effects. Receptors, N-Methyl-D-Aspartate / antagonists & inhibitors. Serial Learning / drug effects. Serotonin Antagonists / administration & dosage. Serotonin Antagonists / pharmacology

  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • Hazardous Substances Data Bank. HALOPERIDOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neuron. 2006 Feb 16;49(4):603-15 [16476668.001]
  • [Cites] Neuropharmacology. 1999 Aug;38(8):1185-94 [10462131.001]
  • [Cites] Behav Neurosci. 2001 Aug;115(4):812-25 [11508720.001]
  • [Cites] J Neurosci. 1997 Dec 1;17(23):9285-97 [9364074.001]
  • [Cites] Psychopharmacology (Berl). 2006 Jul;187(1):73-85 [16767417.001]
  • [Cites] Synapse. 2005 Apr;56(1):12-20 [15700289.001]
  • [Cites] Schizophr Bull. 1999;25(2):201-22 [10416727.001]
  • [Cites] Neuropsychopharmacology. 2001 Oct;25(4):476-88 [11557161.001]
  • [Cites] Behav Brain Res. 1999 Apr;100(1-2):99-112 [10212057.001]
  • [Cites] Eur J Pharmacol. 2005 Sep 5;519(1-2):114-7 [16099452.001]
  • [Cites] Behav Neurosci. 2001 Aug;115(4):799-811 [11508719.001]
  • [Cites] Psychopharmacology (Berl). 1998 May;137(1):33-42 [9631954.001]
  • [Cites] Psychopharmacology (Berl). 2002 Oct;163(3-4):362-80 [12373437.001]
  • [Cites] Behav Brain Res. 1983 Sep;9(3):361-80 [6639741.001]
  • [Cites] Psychopharmacology (Berl). 1999 Oct;146(4):348-61 [10550486.001]
  • [Cites] J Pharmacol Exp Ther. 1997 Nov;283(2):666-74 [9353384.001]
  • [Cites] Psychopharmacology (Berl). 1992;106(2):228-34 [1532259.001]
  • [Cites] Psychopharmacology (Berl). 2003 May;167(3):304-14 [12677356.001]
  • [Cites] Neuropsychopharmacology. 2006 Sep;31(9):1854-63 [16319908.001]
  • [Cites] Neuron. 2004 May 27;42(4):653-63 [15157425.001]
  • [Cites] Neuropsychopharmacology. 2002 Jun;26(6):716-28 [12007742.001]
  • [Cites] Am J Psychiatry. 1996 Mar;153(3):321-30 [8610818.001]
  • [Cites] J Pharmacol Exp Ther. 1998 Dec;287(3):839-46 [9864262.001]
  • [Cites] Neuroscience. 1993 Feb;52(3):595-604 [8450961.001]
  • [Cites] Behav Brain Res. 1997 Dec;89(1-2):135-49 [9475622.001]
  • [Cites] Brain Res. 1995 Jan 23;670(1):165-8 [7719718.001]
  • [Cites] J Pharmacol Exp Ther. 1997 Oct;283(1):226-34 [9336328.001]
  • [Cites] J Pharmacol Exp Ther. 1993 Sep;266(3):1374-84 [8103793.001]
  • [Cites] Neuropsychopharmacology. 2006 Sep;31(9):1900-9 [16421514.001]
  • [Cites] Psychopharmacology (Berl). 1987;91(4):458-66 [3108926.001]
  • [Cites] J Neurosci. 2000 Feb 1;20(3):1208-15 [10648725.001]
  • [Cites] Neuropsychopharmacology. 1998 Feb;18(2):63-101 [9430133.001]
  • [Cites] Prog Neuropsychopharmacol Biol Psychiatry. 2003 Oct;27(7):1159-72 [14642974.001]
  • [Cites] Psychopharmacology (Berl). 1999 Jul;145(2):193-204 [10463321.001]
  • [Cites] Am J Psychiatry. 2004 Jun;161(6):985-95 [15169686.001]
  • [Cites] J Neurosci. 1999 Jun 1;19(11):4585-94 [10341256.001]
  • [Cites] Psychopharmacology (Berl). 1998 Jan;135(2):194-200 [9497025.001]
  • [Cites] Neuropsychopharmacology. 2006 Apr;31(4):757-67 [16192987.001]
  • [Cites] Cereb Cortex. 1996 May-Jun;6(3):470-81 [8670672.001]
  • [Cites] J Clin Psychiatry. 1994 Sep;55 Suppl B:8-14 [7961581.001]
  • [Cites] J Comp Neurol. 2002 Jan 21;442(4):392-404 [11793342.001]
  • [Cites] Behav Brain Res. 2003 Jan 6;138(1):59-69 [12493630.001]
  • [Cites] J Neural Transm Gen Sect. 1995;101(1-3):127-48 [8695043.001]
  • [Cites] J Neurochem. 2001 Mar;76(5):1521-31 [11238736.001]
  • [Cites] Psychopharmacology (Berl). 1993;111(3):339-44 [7870972.001]
  • [Cites] Psychopharmacology (Berl). 2003 Nov;170(3):309-19 [12904968.001]
  • [Cites] Psychopharmacology (Berl). 2004 Nov;176(3-4):376-85 [15232674.001]
  • [Cites] J Pharmacol Exp Ther. 1994 Nov;271(2):787-94 [7965797.001]
  • [Cites] Neuropsychopharmacology. 2007 Feb;32(2):273-83 [16641946.001]
  • [Cites] Eur Neuropsychopharmacol. 1996 Nov;6(4):305-10 [8985714.001]
  • [Cites] J Neurosci. 1996 Jan;16(1):373-9 [8613804.001]
  • [Cites] Am J Psychiatry. 1991 Oct;148(10):1301-8 [1654746.001]
  • [Cites] Neuropsychopharmacology. 2004 Sep;29(9):1637-47 [15127084.001]
  • [Cites] Neuropsychopharmacology. 1996 Feb;14 (2):87-96 [8822531.001]
  • [Cites] Schizophr Bull. 1999;25(2):233-55 [10416729.001]
  • [Cites] Brain Res. 2002 Aug 30;947(2):157-65 [12176156.001]
  • [Cites] Br J Psychiatry. 1993 Oct;163:451-5 [7902766.001]
  • [Cites] Biol Psychiatry. 2001 Nov 15;50(10 ):750-7 [11720693.001]
  • [Cites] Neuroscience. 1998 Mar;83(2):489-99 [9460757.001]
  • [Cites] Neuropsychopharmacology. 1995 Feb;12(1):57-64 [7766287.001]
  • [Cites] Psychopharmacology (Berl). 2005 Apr;179(1):99-107 [15678364.001]
  • [Cites] Neuropsychopharmacology. 1994 Nov;11(3):167-77 [7865098.001]
  • [Cites] Neurosci Lett. 1993 Apr 2;152(1-2):61-4 [8100055.001]
  • [Cites] Cereb Cortex. 2003 Apr;13(4):400-8 [12631569.001]
  • [Cites] Eur J Pharmacol. 1996 Aug 1;309(1):1-11 [8864686.001]
  • [Cites] Am J Psychiatry. 2001 Feb;158(2):176-84 [11156796.001]
  • [Cites] Psychopharmacology (Berl). 2003 Sep;169(3-4):404-11 [12590356.001]
  • [Cites] Biol Psychiatry. 2002 Jun 15;51(12):972-8 [12062881.001]
  • [Cites] J Neurophysiol. 2001 Feb;85(2):659-70 [11160501.001]
  • [Cites] Schizophr Bull. 2000;26(1):119-36 [10755673.001]
  • [Cites] J Neurosci. 2004 Jan 28;24(4):773-80 [14749421.001]
  • [Cites] Arch Gen Psychiatry. 2000 Mar;57(3):249-58 [10711911.001]
  • [Cites] Brain. 1993 Oct;116 ( Pt 5):1159-75 [8221053.001]
  • (PMID = 17940750.001).
  • [ISSN] 0033-3158
  • [Journal-full-title] Psychopharmacology
  • [ISO-abbreviation] Psychopharmacology (Berl.)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antipsychotic Agents; 0 / Dopamine Antagonists; 0 / Piperazines; 0 / Receptors, N-Methyl-D-Aspartate; 0 / Serotonin Antagonists; 98Y1I8ZD4M / 3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid; J60AR2IKIC / Clozapine; J6292F8L3D / Haloperidol
  •  go-up   go-down


98. Gupta N: Choroid plexus tumors in children. Neurosurg Clin N Am; 2003 Oct;14(4):621-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Choroid plexus tumors in children.
  • Choroid plexus tumors represent a well-defined subset of brain tumors that occur mainly in young children.
  • Surgical resection for papilloma is usually curative, although careful surgical planning is required to minimize the potential risks.
  • Although adjunctive therapy for carcinoma includes chemotherapy or radiation, the long-term survival for carcinoma remains poor.
  • [MeSH-major] Choroid Plexus Neoplasms / pathology. Choroid Plexus Neoplasms / surgery. Nuclear Proteins

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15024805.001).
  • [ISSN] 1042-3680
  • [Journal-full-title] Neurosurgery clinics of North America
  • [ISO-abbreviation] Neurosurg. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / SMARCA1 protein, human; 0 / SMARCA2 protein, human; 0 / Transcription Factors; EC 3.6.1.- / SMARCA4 protein, human; EC 3.6.4.- / DNA Helicases
  • [Number-of-references] 53
  •  go-up   go-down


99. Koos B, Paulsson J, Jarvius M, Sanchez BC, Wrede B, Mertsch S, Jeibmann A, Kruse A, Peters O, Wolff JE, Galla HJ, Söderberg O, Paulus W, Ostman A, Hasselblatt M: Platelet-derived growth factor receptor expression and activation in choroid plexus tumors. Am J Pathol; 2009 Oct;175(4):1631-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Platelet-derived growth factor receptor expression and activation in choroid plexus tumors.
  • Choroid plexus tumors are intraventricular neoplasms predominantly affecting young children.
  • In contrast to choroid plexus papillomas, choroid plexus carcinomas progress frequently, necessitating the development of adjuvant treatment concepts.
  • The finding of PDGF receptor expression in choroid plexus tumors prompted us to elucidate PDGF receptor activation state using a novel method, in situ proximity ligation assay, on formalin-fixed, paraffin-embedded, archival samples of 19 choroid plexus tumors.
  • As assessed by in situ proximity ligation assay, the proportion of phosphorylated PDGF receptor alpha was low in choroid plexus papillomas and choroid plexus carcinomas, whereas phosphorylated PDGF receptor beta was found to be significantly higher in choroid plexus carcinomas.
  • In the immortalized choroid plexus epithelial cell line Z310 expressing PDGF receptor beta, PDGF-BB exhibited a time- and dose-dependent proliferative response, which was significantly attenuated by imatinib (gleevec).
  • In conclusion, our findings suggest that PDGF receptor beta is functionally involved in the biology of choroid plexus tumors and may represent a molecular target for therapy.
  • In addition, this study demonstrates the feasibility and usefulness of in situ proximity ligation assay for monitoring receptor tyrosine kinase activation in formalin-fixed, paraffin-embedded, archival tissues.
  • [MeSH-major] Choroid Plexus Neoplasms / metabolism. Receptor, Platelet-Derived Growth Factor alpha / metabolism. Receptor, Platelet-Derived Growth Factor beta / metabolism
  • [MeSH-minor] Animals. Cell Line. Cell Line, Transformed. Cell Proliferation / drug effects. Epithelial Cells / drug effects. Epithelial Cells / metabolism. Epithelial Cells / pathology. Female. Humans. Immunohistochemistry. Infant. Male. Papilloma / metabolism. Papilloma / pathology. Phosphorylation / drug effects. Platelet-Derived Growth Factor / pharmacology. Rats

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Genet. 2001 Oct;29(2):143-52 [11544480.001]
  • [Cites] Comput Methods Programs Biomed. 2009 Apr;94(1):58-65 [18950895.001]
  • [Cites] Brain Res. 2002 Dec 27;958(2):371-80 [12470873.001]
  • [Cites] Cytokine Growth Factor Rev. 2004 Aug;15(4):197-204 [15207811.001]
  • [Cites] Mol Cancer. 2003 Jan 3;2:1 [12537587.001]
  • [Cites] Blood. 2004 Nov 1;104(9):2655-60 [15231574.001]
  • [Cites] EMBO J. 1992 Feb;11(2):543-50 [1311251.001]
  • [Cites] J Neuropathol Exp Neurol. 2005 May;64(5):391-7 [15892296.001]
  • [Cites] Am J Surg Pathol. 2006 Jan;30(1):66-74 [16330944.001]
  • [Cites] J Neurooncol. 2006 Jan;76(2):105-9 [16205964.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 Nov;65(11):1069-73 [17086103.001]
  • [Cites] Adv Cancer Res. 2007;97:247-74 [17419949.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Mol Cell Proteomics. 2007 Sep;6(9):1500-9 [17565975.001]
  • [Cites] Mod Pathol. 2008 Mar;21(3):265-70 [18157090.001]
  • [Cites] Genes Dev. 2008 May 15;22(10):1276-312 [18483217.001]
  • [Cites] Nat Rev Drug Discov. 2002 Jul;1(7):493-502 [12120256.001]
  • (PMID = 19717644.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Platelet-Derived Growth Factor; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta
  • [Other-IDs] NLM/ PMC2751559
  •  go-up   go-down


100. Forrest JB, Mishell DR Jr: Breaking the cycle of pain in interstitial cystitis/painful bladder syndrome: toward standardization of early diagnosis and treatment: consensus panel recommendations. J Reprod Med; 2009 Jan;54(1):3-14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breaking the cycle of pain in interstitial cystitis/painful bladder syndrome: toward standardization of early diagnosis and treatment: consensus panel recommendations.
  • Chronic pelvic pain (CPP) affects about 15% of female adults in the United States.
  • Despite the frequent occurrence of IC/PBS as a cause of CPP, there currently are no universally accepted guidelines for diagnosis and treatment of this disorder, and, consequently, many patients do not receive appropriate treatment in a timely manner.
  • In an effort to develop a rational way to diagnose and treat patients with CPP, a panel of leaders in urology, gynecology, urogynecology and general women's health met to review recent literature, reach consensus and formulate 2 algorithms, one for diagnosing and the other for managing IC/PBS.
  • [MeSH-major] Analgesics / therapeutic use. Cystitis, Interstitial / diagnosis. Cystitis, Interstitial / therapy. Pelvic Pain / drug therapy
  • [MeSH-minor] Algorithms. Diet Therapy. Female. Humans

  • Genetic Alliance. consumer health - Interstitial cystitis.
  • MedlinePlus Health Information. consumer health - Interstitial Cystitis.
  • MedlinePlus Health Information. consumer health - Pelvic Pain.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19263874.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Consensus Development Conference; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics
  • [Number-of-references] 70
  •  go-up   go-down






Advertisement